

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C12N 15/57, 9/64, 9/48, 1/19, 5/10, 1/21, A61K 38/48, C07K 16/40		A2	(11) International Publication Number: <b>WO 99/36550</b> (43) International Publication Date: 22 July 1999 (22.07.99)
(21) International Application Number: PCT/US99/00655 (22) International Filing Date: 12 January 1999 (12.01.99) (30) Priority Data: 09/008,271 16 January 1998 (16.01.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/008,271 (CIP) Filed on 16 January 1998 (16.01.98) (71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive, #12, Mountain View, CA 94040 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, Ca 94025 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US).			TANG, Y., Tom [CN/US]; 110 East Remington Drive #14, Sunnyvale, CA 94087 (US). SHAH, Purvi [IN/US]; 1608 Queen Charlotte Drive #5, Sunnyvale, CA 94087 (US). (74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>

(54) Title: HUMAN PROTEASE MOLECULES

## (57) Abstract

The invention provides human protease molecules (HUPM) and polynucleotides which identify and encode HUPM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HUPM.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## HUMAN PROTEASE MOLECULES

### TECHNICAL FIELD

5 This invention relates to nucleic acid and amino acid sequences of human protease molecules and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative and immune disorders.

### BACKGROUND OF THE INVENTION

10 Proteolytic processing is an essential component of normal cell growth, differentiation, remodeling, and homeostasis. The cleavage of peptide bonds within cells is necessary for the maturation of precursor proteins to their active form, the removal of signal sequences from targeted proteins, the degradation of incorrectly folded proteins, and the controlled turnover of peptides within the cell. Proteases participate in apoptosis,  
15 inflammation, and in tissue remodeling during embryonic development, wound healing, and normal growth. They are necessary components of bacterial, parasitic, and viral invasion and replication within a host. Four principal categories of mammalian proteases have been identified based on active site structure, mechanism of action, and overall three-dimensional structure. (Beynon, R.J. and J.S. Bond (1994) Proteolytic Enzymes: A  
20 Practical Approach, Oxford University Press, New York, NY, pp. 1-5.)

The serine proteases (SPs) are a large family of proteolytic enzymes that include the digestive enzymes, trypsin and chymotrypsin; components of the complement cascade and of the blood-clotting cascade; and enzymes that control the degradation and turnover of macromolecules of the extracellular matrix. SPs are so named because of the presence  
25 of a serine residue found in the active catalytic site for protein cleavage and usually within the sequence GDSGGP. The active site of all SP is composed of a triad of residues including the aforementioned serine, an aspartate, and a histidine residue. SPs have a wide range of substrate specificities and can be subdivided into subfamilies on the basis of these specificities. The main sub-families are tryptases which cleave after arginine or  
30 lysine; aspartases which cleave after aspartate; chymases which cleave after phenylalanine or leucine; metases which cleavage after methionine; and serases which cleave after serine.

The SPs are secretory proteins containing N-terminal signal peptides which export the immature protein across the endoplasmic reticulum prior to cleavage. (von Heijne, G. (1986) *Nuc. Acid. Res.* 14:5683-5690). Differences in these signal sequences provide one means of distinguishing individual SPs. Some SPs, particularly the digestive enzymes, exist as inactive precursors or preproenzymes and contain a leader or activation peptide on the C-terminal side of the signal peptide. This activation peptide may be 2-12 amino acids in length, and extend from the cleavage site of the signal peptide to the N-terminus of the active, mature protein. Cleavage of this sequence activates the enzyme. This sequence varies in different SPs according to the biochemical pathway and/or its substrate. (Zunino, S.J. et al. (1990) *J. Immunol.* 144:2001-2009; and Sayers, T.J. et al. (1994) *J. Immunol.* 152:2289-2297.)

Cysteine proteases are involved in diverse cellular processes ranging from the processing of precursor proteins to intracellular degradation. Mammalian cysteine proteases include lysosomal cathepsins and cytosolic calcium activated proteases, calpains. Cysteine proteases are produced by monocytes, macrophages and other cells of the immune system which migrate to sites of inflammation and in their protective role secrete various molecules to repair damaged tissue. These cells may overproduce the same molecules and cause tissue destruction in certain disorders. In autoimmune diseases such as rheumatoid arthritis, the secretion of the cysteine protease, cathepsin C, degrades collagen, laminin, elastin and other structural proteins found in the extracellular matrix of bones. The cathepsin family of lysosomal proteases includes the cysteine proteases; cathepsins B, H, K, L, O2, and S; and the aspartyl proteases; cathepsins D and G. Various members of this endosomal protease family are differentially expressed. Some, such as cathepsin D, have a ubiquitous tissue distribution while others, such as cathepsin L, are found only in monocytes, macrophages, and other cells of the immune system.

Abnormal regulation and expression of cathepsins is evident in various inflammatory disease states. In cells isolated from inflamed synovia, the mRNA for stromelysin, cytokines, TIMP-1, cathepsin, gelatinase, and other molecules is preferentially expressed. Expression of cathepsins L and D is elevated in synovial tissues from patients with rheumatoid arthritis and osteoarthritis. Cathepsin L expression may also contribute to the influx of mononuclear cells which exacerbates the destruction of the rheumatoid synovium. (Keyszer, G.M. (1995) *Arthritis Rheum.* 38:976-984.) The

increased expression and differential regulation of the cathepsins is linked to the metastatic potential of a variety of cancers and as such is of therapeutic and prognostic interest.

(Chambers, A.F. et al. (1993) Crit. Rev. Oncog. 4:95-114.)

Cysteine proteases are characterized by a catalytic domain containing a triad of  
5 amino acid residues similar to that found in serine proteases. A cysteine replaces the active serine residue. Catalysis proceeds via a thiol ester intermediate and is facilitated by the side chains of the adjacent histidine and aspartate residues.

Aspartic proteases include bacterial penicillopepsin, mammalian pepsin, renin, chymosin, and certain fungal proteases. The characteristic active site residues of aspartic  
10 proteases are a pair of aspartic acid residues, e.g., asp33 and asp213 in penicillopepsin. Aspartic proteases are also called acid proteases because the optimum pH for activity is between 2 and 3. In this pH range, one of the aspartate residues is ionized, the other un-ionized. A potent inhibitor of aspartic proteases is the hexapeptide, pepstatin, which in the transition state resembles normal substrates.

15 Carboxypeptidases A and B are the principal mammalian representatives of the metallo-protease family. Both are exopeptidases of similar structure and active sites. Carboxypeptidase A, like chymotrypsin, prefers C-terminal aromatic and aliphatic side chains of hydrophobic nature, whereas carboxypeptidase B is directed toward basic arginine and lysine residues. Active site components include zinc, with its three ligands of  
20 two glutamic acid and one histidine residues.

Many other proteolytic enzymes do not fit any of the major categories discussed above because their mechanisms of action and/or active sites have not been elucidated. These include the aminopeptidases and signal peptidases.

Aminopeptidases catalyze the hydrolysis of amino acid residues from the amino  
25 terminus of peptide substrates. Bovine leucine aminopeptidase is a zinc metallo-enzyme that utilizes the sulfhydryl groups from at least three reactive cysteine residues at its active site in the binding of metal ions. (Cuypers, H.T. et al. (1982) J. Biol. Chem. 257:7086-7091.)

Signal peptidases are a specialized class of proteases found in all prokaryotic and  
30 eukaryotic cell types that serve in the processing of signal peptides from certain proteins. Signal peptides are amino-terminal sequences on a protein which directs the protein from its ribosomal assembly site to a particular cellular or extracellular location. Once the

protein has been exported, removal of the signal sequence by a signal peptidase and posttranslational processing, e.g., glycosylation or phosphorylation, activate the protein.

Signal peptidases exist as multi-subunit complexes in both yeast and mammals. The canine signal peptidase complex is composed of five subunits; all associate with the  
5 mitochondrial membrane, and containing hydrophobic regions that span the membrane one or more times. (Shelness, G.S. and Blobel, G. (1990) J. Biol. Chem. 265:9512-9519.) Some of these subunits serve to fix the complex in its proper position on the membrane while others contain the actual catalytic activity. The catalytic activity appears to involve a serine residue in its active site.

10 Proteasome is an intracellular protease complex which is found in some bacteria and in all eukaryotic cells and plays an important role in cellular physiology. Proteasomes are responsible for the timely degradation of cellular proteins of all types and control proteins that function to activate or repress cellular processes such as transcription and cell cycle progression. (Ciechanover, A. (1994) Cell 79:13-21.) Proteasomes act on proteins  
15 which have been targeted for hydrolysis by the covalent attachment of a small protein called ubiquitin to lysine side chains of the protein. Ubiquitin-proteasome systems are implicated in the degradation of mitotic cyclic kinases, oncoproteins, tumor suppressor genes (p53), cell surface receptors associated with signal transduction, transcriptional regulators, and mutated or damaged proteins. (Ciechanover, supra.) Proteasomes are large  
20 (~ 2000 kDa), multisubunit complexes composed of a central catalytic core containing a variety of proteases and terminal subunits that serve in substrate recognition and regulation of proteasome activity.

Protease inhibitors play a major role in the regulation of the activity and effect of proteases. They have been shown to control pathogenesis in animal models of proteolytic  
25 disorders. (Murphy, G. (1991) Agents Actions Suppl 35:69-76.) In particular, low levels of the cystatins, low molecular weight inhibitors of the cysteine proteases, seem to be correlated with malignant progression of tumors. (Calkins, C. et al (1995) Biol Biochem Hoppe Seyler 376:71-80.) The balance between levels of cysteine proteases and their  
inhibitors is also significant in the development of disorders. Specifically, increases in  
30 cysteine protease levels, when accompanied by reductions in inhibitor activity, are correlated with increased malignant properties of tumor cells and the pathology of arthritis and immunological diseases in humans.

The serpins are high molecular weight, e.g., 370-420 amino acid residues, inhibitors of mammalian plasma serine proteases. Many of these inhibitors serve to regulate the blood clotting cascade and/or the complement cascade in mammals.

Prominent among these inhibitors are  $\alpha$ -1 protease inhibitor,  $\alpha$ -1-antichymotrypsin, antithrombin III, and the "universal protease inhibitor"  $\alpha$ -2 macroglobulin.  $\alpha$ -1 protease inhibitor is primarily effective against the neutrophil elastase but combines with other serine proteases as well.  $\alpha$ -1 protease inhibitor,  $\alpha$ -1-antichymotrypsin, and antithrombin III all show striking sequence homology, suggesting that specialization of these inhibitors has occurred in response to specialization of the corresponding proteases themselves.

The discovery of new human protease molecules and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, treatment, and prevention of cell proliferative and immune disorders.

## SUMMARY OF THE INVENTION

The invention features substantially purified polypeptides, human protease molecules, referred to collectively as "HUPM" and individually as "HUPM-1", "HUPM-2", "HUPM-3", "HUPM-4", "HUPM-5", "HUPM-6", "HUPM-7", "HUPM-8", "HUPM-9", "HUPM-10", "HUPM-11", and "HUPM-12". In one aspect, the invention provides a substantially purified polypeptide, HUPM, comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12, and fragments thereof.

The invention further provides a substantially purified variant of HUPM having at least 90% amino acid identity to the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12, or to a fragment of any of these sequences. The invention also provides an isolated and purified polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12, and fragments thereof. The invention also includes an isolated and purified polynucleotide variant having at least 90%



polynucleotide identity to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12, and fragments thereof.

Additionally, the invention provides a composition comprising a polynucleotide encoding the polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12, and fragments thereof. The invention further provides an isolated and purified polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12, and fragments thereof, as well as an isolated and purified polynucleotide sequence which is complementary to the polynucleotide encoding the polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12, and fragments thereof.

The invention also provides an isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24. The invention further provides an isolated and purified polynucleotide variant having at least 90% polynucleotide identity to the polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24, and fragments thereof, as well as an isolated and purified polynucleotide which is complementary to the polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ

ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24, and fragments thereof.

The invention further provides an expression vector containing at least a fragment of the polynucleotide encoding the polypeptide comprising an amino acid sequence  
5 selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12, and fragments thereof. In another aspect, the expression vector is contained within a host cell.

The invention also provides a method for producing a polypeptide comprising the  
10 amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:12, or fragments thereof, the method comprising the steps of: (a) culturing the host cell containing an expression vector containing at least a fragment of a polynucleotide sequence encoding HUPM under conditions suitable for the expression  
15 of the polypeptide; and (b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified HUPM having the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:12, or fragments  
20 thereof, in conjunction with a suitable pharmaceutical carrier.

The invention further includes a purified antibody which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:12, or fragments thereof, as well as a  
25 purified agonist and a purified antagonist to the polypeptide.

The invention also provides a method for treating or preventing a cell proliferative disorder associated with increased expression or activity of HUPM, the method comprising administering to a subject in need of such treatment an effective amount of an antagonist of HUPM.

30 The invention also provides a method for treating or preventing an immune disorder associated with increased expression or activity of HUPM, the method comprising administering to a subject in need of such treatment an effective amount of an

antagonist of HUPM.

The invention also provides a method for treating or preventing a cell proliferative disorder associated with decreased expression or activity of HUPM, the method comprising administering to a subject in need of such treatment an effective amount of a  
5 pharmaceutical composition comprising HUPM in conjunction with a suitable pharmaceutical carrier.

The invention also provides a method for treating or preventing an immune disorder associated with decreased expression or activity of HUPM, the method comprising administering to a subject in need of such treatment an effective amount of a  
10 pharmaceutical composition comprising HUPM in conjunction with a suitable pharmaceutical carrier.

The invention also provides a method for detecting a polynucleotide encoding HUPM in a biological sample containing nucleic acids, the method comprising the steps of: (a) hybridizing the complement of the polynucleotide sequence encoding the  
15 polypeptide comprising SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:12, or fragments thereof to at least one of the nucleic acids of the biological sample, thereby forming a hybridization complex; and (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with  
20 the presence of a polynucleotide encoding HUPM in the biological sample. In one aspect, the nucleic acids of the biological sample are amplified by the polymerase chain reaction prior to the hybridizing step.

25

## DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors, and reagents described, as these may vary. It is also to be understood that  
30 the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof  
5 known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the  
10 preferred methods, devices, and materials are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, vectors, and methodologies which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

15

#### DEFINITIONS

"HUPM," as used herein, refers to the amino acid sequences of substantially purified HUPM obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and preferably the human species, from any  
20 source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist," as used herein, refers to a molecule which, when bound to HUPM, increases or prolongs the duration of the effect of HUPM. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to and modulate the effect of HUPM.

25 An "allele" or an "allelic sequence," as these terms are used herein, is an alternative form of the gene encoding HUPM. Alleles may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes which give  
30 rise to alleles are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding HUPM, as described herein, include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polynucleotide the same HUPM or a polypeptide with at least one functional characteristic of HUPM. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding HUPM, and improper or unexpected hybridization to alleles, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding HUPM. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent HUPM. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of HUPM is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, positively charged amino acids may include lysine and arginine, and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine; glycine and alanine; asparagine and glutamine; serine and threonine; and phenylalanine and tyrosine.

The terms "amino acid" or "amino acid sequence," as used herein, refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. In this context, "fragments", "immunogenic fragments", or "antigenic fragments" refer to fragments of HUPM which are preferably about 5 to about 15 amino acids in length and which retain some biological activity or immunological activity of HUPM. Where "amino acid sequence" is recited herein to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification," as used herein, relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art. (See, e.g., Dieffenbach, C.W. and G.S. Dveksler (1995) PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview, NY, pp.1-5.)

The term "antagonist," as it is used herein, refers to a molecule which, when bound

to HUPM, decreases the amount or the duration of the effect of the biological or immunological activity of HUPM. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies, or any other molecules which decrease the effect of HUPM.

As used herein, the term "antibody" refers to intact molecules as well as to  
5 fragments thereof, such as Fa, F(ab')<sub>2</sub>, and Fv fragments, which are capable of binding the epitopic determinant. Antibodies that bind HUPM polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized  
10 chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant," as used herein, refers to that fragment of a  
15 molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (given regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the  
20 immune response) for binding to an antibody.

The term "antisense," as used herein, refers to any composition containing a nucleic acid sequence which is complementary to a specific nucleic acid sequence. The term "antisense strand" is used in reference to a nucleic acid strand that is complementary to the "sense" strand. Antisense molecules may be produced by any method including  
25 synthesis or transcription. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form duplexes and to block either transcription or translation. The designation "negative" can refer to the antisense strand, and the designation "positive" can refer to the sense strand.

As used herein, the term "biologically active," refers to a protein having structural,  
30 regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic HUPM, or of any oligopeptide thereof, to induce a specific immune response in

appropriate animals or cells and to bind with specific antibodies.

The terms "complementary" or "complementarity," as used herein, refer to the natural binding of polynucleotides under permissive salt and temperature conditions by base pairing. For example, the sequence "A-G-T" binds to the complementary sequence  
5 "T-C-A." Complementarity between two single-stranded molecules may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. This is of particular  
10 importance in amplification reactions, which depend upon binding between nucleic acids strands, and in the design and use of peptide nucleic acid (PNA) molecules.

A "composition comprising a given polynucleotide sequence" or a "composition comprising a given amino acid sequence," as these terms are used herein, refer broadly to any composition containing the given polynucleotide or amino acid sequence. The  
15 composition may comprise a dry formulation, an aqueous solution, or a sterile composition. Compositions comprising polynucleotide sequences encoding HUPM or fragments of HUPM may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g.,  
20 NaCl), detergents (e.g., SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

The phrase "consensus sequence," as used herein, refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, extended using XL-PCR™ (Perkin Elmer, Norwalk, CT) in the 5' and/or the 3' direction, and resequenced, or which has been  
25 assembled from the overlapping sequences of more than one Incyte Clone using a computer program for fragment assembly, such as the GELVIEW™ Fragment Assembly system (GCG, Madison, WI). Some sequences have been both extended and assembled to produce the consensus sequence .

As used herein, the term "correlates with expression of a polynucleotide" indicates  
30 that the detection of the presence of nucleic acids, the same or related to a nucleic acid sequence encoding HUPM, by northern analysis is indicative of the presence of nucleic acids encoding HUPM in a sample, and thereby correlates with expression of the transcript

from the polynucleotide encoding HUPM.

A "deletion," as the term is used herein, refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

5       The term "derivative," as used herein, refers to the chemical modification of HUPM, of a polynucleotide sequence encoding HUPM, or of a polynucleotide sequence complementary to a polynucleotide sequence encoding HUPM. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at  
10 least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains a at least one biological or immunological function of the polypeptide from which it was derived.

      The term "homology," as used herein, refers to a degree of complementarity.  
15 There may be partial homology or complete homology. The word "identity" may substitute for the word "homology." A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as "substantially homologous." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization  
20 assay (Southern or northern blot, solution hybridization, and the like) under conditions of reduced stringency. A substantially homologous sequence or hybridization probe will compete for and inhibit the binding of a completely homologous sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced stringency are such that non-specific binding is permitted, as reduced stringency  
25 conditions require that the binding of two sequences to one another be a specific (i.e., a selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% homology or identity). In the absence of non-specific binding, the substantially homologous sequence or probe will not hybridize to the second non-  
30 complementary target sequence.

      The phrases "percent identity" or "% identity" refer to the percentage of sequence similarity found in a comparison of two or more amino acid or nucleic acid sequences.



Percent identity can be determined electronically, e.g., by using the MegAlign program (DNASTAR, Inc., Madison WI). This program can create alignments between two or more sequences according to different methods, e.g., the clustal method. (Higgins, D.G. and P. M. Sharp (1988) *Gene* 73:237-244.) The clustal algorithm groups sequences into  
5 clusters by examining the distances between all pairs. The clusters are aligned pairwise and then in groups. The percentage similarity between two amino acid sequences, e.g., sequence A and sequence B, is calculated by dividing the length of sequence A, minus the number of gap residues in sequence A, minus the number of gap residues in sequence B, into the sum of the residue matches between sequence A and sequence B, times one  
10 hundred. Gaps of low or of no homology between the two amino acid sequences are not included in determining percentage similarity. Percent identity between nucleic acid sequences can also be counted or calculated by other methods known in the art, such as the Jotun Hein method. (See, e.g., Hein, J. (1990) *Methods Enzymol.* 183:626-645.) Identity between sequences can also be determined by other methods known in the art, e.g., by  
15 varying hybridization conditions.

"Human artificial chromosomes" (HACs), as described herein, are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for stable mitotic chromosome segregation and maintenance. (See, e.g., Harrington, J.J. et al. (1997) *Nat Genet.* 15:345-355.)

20 The term "humanized antibody," as used herein, refers to antibody molecules in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization," as the term is used herein, refers to any process by which a strand  
25 of nucleic acid binds with a complementary strand through base pairing.

As used herein, the term "hybridization complex" as used herein, refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g.,  $C_0t$  or  $R_0t$  analysis) or formed between one nucleic acid sequence present  
30 in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" or "addition," as used herein, refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively, to the sequence found in the naturally occurring molecule.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

The term "microarray," as used herein, refers to an arrangement of distinct polynucleotides or oligonucleotides on a substrate, such as paper, nylon or any other type of membrane, filter, chip, glass slide, or any other suitable solid support.

The term "modulate," as it appears herein, refers to a change in the activity of HUPM. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of HUPM.

The phrases "nucleic acid" or "nucleic acid sequence," as used herein, refer to an oligonucleotide, nucleotide, polynucleotide, or any fragment thereof, to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material. In this context, "fragments" refers to those nucleic acid sequences which are greater than about 60 nucleotides in length, and most preferably are at least about 100 nucleotides, at least about 1000 nucleotides, or at least about 10,000 nucleotides in length.

The terms "operably associated" or "operably linked," as used herein, refer to functionally related nucleic acid sequences. A promoter is operably associated or operably linked with a coding sequence if the promoter controls the transcription of the encoded polypeptide. While operably associated or operably linked nucleic acid sequences can be contiguous and in reading frame, certain genetic elements, e.g., repressor genes, are not contiguously linked to the encoded polypeptide but still bind to operator sequences that control expression of the polypeptide.

The term "oligonucleotide," as used herein, refers to a nucleic acid sequence of at least about 6 nucleotides to 60 nucleotides, preferably about 15 to 30 nucleotides, and most preferably about 20 to 25 nucleotides, which can be used in PCR amplification or in

a hybridization assay or microarray. As used herein, the term "oligonucleotide" is substantially equivalent to the terms "amplimer," "primer," "oligomer," and "probe," as these terms are commonly defined in the art.

"Peptide nucleic acid" (PNA), as used herein, refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA and RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell. (See, e.g., Nielsen, P.E. et al. (1993) Anticancer Drug Des. 8:53-63.)

The term "sample," as used herein, is used in its broadest sense. A biological sample suspected of containing nucleic acids encoding HUPM, or fragments thereof, or HUPM itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a solid support; a tissue; a tissue print; etc.

As used herein, the terms "specific binding" or "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, or an antagonist. The interaction is dependent upon the presence of a particular structure of the protein, the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

As used herein, the term "stringent conditions" refers to conditions which permit hybridization between polynucleotide sequences and the claimed polynucleotide sequences. Suitably stringent conditions can be defined by, for example, the concentrations of salt or formamide in the prehybridization and hybridization solutions, or by the hybridization temperature, and are well known in the art. In particular, stringency can be increased by reducing the concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature.

For example, hybridization under high stringency conditions could occur in about 50% formamide at about 37°C to 42°C. Hybridization could occur under reduced stringency conditions in about 35% to 25% formamide at about 30°C to 35°C. In

particular, hybridization could occur under high stringency conditions at 42°C in 50% formamide, 5X SSPE, 0.3% SDS, and 200 µg/ml sheared and denatured salmon sperm DNA. Hybridization could occur under reduced stringency conditions as described above, but in 35% formamide at a reduced temperature of 35°C. The temperature range

5 corresponding to a particular level of stringency can be further narrowed by calculating the purine to pyrimidine ratio of the nucleic acid of interest and adjusting the temperature accordingly. Variations on the above ranges and conditions are well known in the art.

The term "substantially purified," as used herein, refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or  
10 separated, and are at least about 60% free, preferably about 75% free, and most preferably about 90% free from other components with which they are naturally associated.

A "substitution," as used herein, refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

"Transformation," as defined herein, describes a process by which exogenous DNA  
15 enters and changes a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection,  
20 electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, and transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

25 A "variant" of HUPM, as used herein, refers to an amino acid sequence that is altered by one or more amino acids. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine). More rarely, a variant may have "nonconservative" changes (e.g., replacement of glycine with tryptophan). Analogous  
30 minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs

well known in the art, for example, DNASTAR software.

# THE INVENTION

The invention is based on the discovery of new human protease molecules (HUPM), the polynucleotides encoding HUPM, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative and immune disorders. Table 1 shows the sequence identification numbers, Incyte Clone identification number, and cDNA library for each of the human protease molecules disclosed herein.

Table 1

PROTEIN	NUCLEOTIDE	CLONE ID	LIBRARY
SEQ ID NO:1	SEQ ID NO:13	135360	BMARNOT02
SEQ ID NO:2	SEQ ID NO:14	447484	TLYMNOT02
SEQ ID NO:3	SEQ ID NO:15	789927	PROSTUT03
SEQ ID NO:4	SEQ ID NO:16	877617	LUNGAST01
SEQ ID NO:5	SEQ ID NO:17	999322	KIDNTUT01
SEQ ID NO:6	SEQ ID NO:18	1337018	COLNNOT13
SEQ ID NO:7	SEQ ID NO:19	1798496	COLNNOT27
SEQ ID NO:8	SEQ ID NO:20	2082147	UTRSNOT08
SEQ ID NO:9	SEQ ID NO:21	2170967	ENDCNOT03
SEQ ID NO:10	SEQ ID NO:22	2484218	SMCANOT01
SEQ ID NO:11	SEQ ID NO:23	2680548	SINIUCT01
SEQ ID NO:12	SEQ ID NO:24	2957969	KIDNFET01

Nucleic acids encoding the HUPM-1 of the present invention were first identified

in Incyte Clone 135360 from the bone marrow cDNA library (BMARNOT02) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:13, was derived from the following overlapping and/or extended nucleic acid sequences: Incyte Clones 135360 (BMARNOT02), 1440654 (THYRNOT03), 1985677  
5 (LUNGAST01), 2016316 (ENDCNOT03), 2309369 (NGANNOT01), 3003105 (TLYMNOT06), and 3604791 (LUNGNOT30).

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:1. HUPM-1 is 63 amino acids in length and, as shown in Figures 1A and 1B, has chemical and structural homology with rat proteasome  
10 subunit, C8 (GI 203207). In particular, HUPM-1 and rat C8 share 54% identity. The fragment of SEQ ID NO:13 from about nucleotide 688 to about nucleotide 744 is useful for hybridization. Northern analysis shows the expression of this sequence in cardiovascular, male and female reproductive, and gastrointestinal cDNA libraries. Approximately 25% of these libraries are associated with neoplastic disorders and 33%  
15 with inflammation and the immune response.

Nucleic acids encoding the HUPM-2 of the present invention were first identified in Incyte Clone 447484 from the T-lymphocyte cDNA library (TLYMNOT02) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:14, was derived from the following overlapping and/or extended nucleic acid  
20 sequences: Incyte Clones 007562 (HMC1NOT01), 288369 (EOSIHET02), 447484 (TLYMNOT02), 1357876 (LUNGNOT09), 1688150 (PROSTUT10), 2506075 (CONUTUT01), 2748364 (LUNGTUT11), and shotgun sequences SAJA02963, SAJA00487, and SAJA00384.

In another embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:2. HUPM-2 is 262 amino acids in length and has a  
25 potential N-glycosylation site at N91, and potential phosphorylation sites for casein kinase II at S55, S63, S97, and T168, and for protein kinase C at S97, S186, and T246. A potential catalytic active site triad for cysteine proteases is found in amino acid residues C36, D176, and H177. The fragment of SEQ ID NO:14 from about nucleotide 2242 to  
30 2292 encompasses the active site cysteine encoding region of the molecule and is useful for hybridization. Northern analysis shows the expression of this sequence in cardiovascular, male and female reproductive, and hematopoietic cDNA libraries.

Approximately 48% of these libraries are associated with neoplastic disorders and 24% with inflammation and the immune response.

Nucleic acids encoding the HUPM-3 of the present invention were first identified in Incyte Clone 789927 from the prostate tumor cDNA library (PROSTUT03) using a  
5 computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:15, was derived from the following overlapping and/or extended nucleic acid sequences: Incyte Clones 789927 (PROSTUT03), 1646976 (PROSTUT09), and 1979791 (LUNGTUT03).

In another embodiment, the invention encompasses a polypeptide comprising the  
10 amino acid sequence of SEQ ID NO:3. HUPM-3 is 314 amino acids in length and has a potential signal peptide sequence between amino acid residues M1 and R19. Potential N-glycosylation sites are found at residues N167, N200, and N273, and potential phosphorylation sites are found for casein kinase II at T86, S134, S161, T190, and S291, and for protein kinase C at T39, S58, S73, S127, and S212. Sequences containing  
15 potential active site histidine and serine residues, characteristic of serine proteases, are found at LTAAH82 and GDS238GGP in HUPM-3. The fragment of SEQ ID NO:15 between about nucleotide 271 to about nucleotide 330 which encompasses the active site histidine is useful for hybridization. Northern analysis shows the expression of this sequence in cardiovascular, hematopoietic, and male reproductive cDNA libraries.  
20 Approximately 86% of these libraries are associated with neoplastic disorders.

Nucleic acids encoding the HUPM-4 of the present invention were first identified in Incyte Clone 877617 from the lung cDNA library (LUNGAST01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:16, was derived from the following overlapping and/or extended nucleic acid sequences: Incyte  
25 Clones 372314 (LUNGNOT02), 698335 (SYNORAT03), 692718 (LUNGTUT02), 877617 (LUNGAST01), and 1399470 (BRAITUT08).

In another embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:4. HUPM-4 is 420 amino acids in length and has a potential signal peptide sequence extending from residues M1 to P21. Potential N-  
30 glycosylation sites are found at residues N90, N133, and N336. Potential phosphorylation sites are found for casein kinase II at S60 and T338, and for protein kinase C at S106, T143, T346, and S393. Two potential leucine zipper patterns are found beginning at

L309 and L316, and a potential cell attachment site is found in the sequence R387GD.

Two potential active site aspartate residues, characteristic of aspartic proteases, are found at residues D96 and D283. The fragment of SEQ ID NO:16 from about nucleotide 1609 to about nucleotide 1692, encompassing a leucine zipper domain, is useful for hybridization.

- 5 Northern analysis shows the expression of this sequence in cardiovascular, hematopoietic, and male and female reproductive cDNA libraries. Approximately 56% of these libraries are associated with neoplastic disorders, 18% with inflammation and the immune response, and 18% with trauma.

- Nucleic acids encoding the HUPM-5 of the present invention were first identified  
10 in Incyte Clone 999322 from the kidney tumor cDNA library (KIDNTUT01) using a computer search for amino acid sequence alignments, and a consensus sequence, SEQ ID NO:17, was derived from this clone.

- In another embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:5. HUPM-5 is 200 amino acids in length and has a  
15 potential N-glycosylation site at N121, and potential phosphorylation sites for cAMP- and cGMP-dependent protein kinase at S35, for casein kinase II at S150 and T158, and for protein kinase C at T180. A potential active site serine for serine protease is found in the sequence GDS112GGP. The fragment of SEQ ID NO:17 from about nucleotide 775 to about nucleotide 838 from the active site serine domain is useful for hybridization.

- 20 Northern analysis shows the expression of this sequence exclusively in kidney tumor (KIDNTUT01):

- Nucleic acids encoding the HUPM-6 of the present invention were first identified in Incyte Clone 1337018 from the colon cDNA library (COLNNOT13) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:18, was  
25 derived from the following overlapping and/or extended nucleic acid sequences: Incyte Clones 1271725 (TESTTUT02), 1337018 (COLNNOT13), 586982 and 588598 (UTRSNOT01).

- In another embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:6. HUPM-6 is 435 amino acids in length and has  
30 potential N-glycosylation sites at residues N128 and N176, potential phosphorylation sites for cAMP- and cGMP-dependent protein kinase T249, for casein kinase II at S93 and S231, for protein kinase C at T26, S144, T148, S197, T200, S260, T303, S351, and T365,



and for tyrosine kinase at Y59 and Y360. Sequences containing potential active site histidine and serine residues for serine proteases are found at LTAAH243C and GDS385GGP, respectively. The fragment of SEQ ID NO:18 from about nucleotide 900 to about nucleotide 949 encompassing the active site histidine residue is useful for

5 hybridization. Northern analysis shows the expression of this sequence in gastrointestinal and male and female reproductive cDNA libraries. Approximately 65% of these libraries are associated with neoplastic disorders and 22% with the immune response.

Nucleic acids encoding the HUPM-7 of the present invention were first identified in Incyte Clone 1798496 from the colon cDNA library (COLNNOT27) using a computer

10 search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:19, was derived from the following overlapping and/or extended nucleic acid sequences: Incyte Clones 819896 (KERANOT02), 1798496 (COLNNOT27), and shotgun sequence SAGA00119.

In another embodiment, the invention encompasses a polypeptide comprising the

15 amino acid sequence of SEQ ID NO:7. HUPM-7 is 260 amino acids in length and has a potential signal peptide sequence extending from residues M1 to A28. Potential N-myristoylation sites are found in the vicinity of the signal peptide cleavage site at G19, G20, and G35. A potential N-glycosylation site is found at N110, and potential phosphorylation sites are found for casein kinase II at S112, S140, and S162, for protein

20 kinase C at T80, S162, S201, and S236, and for tyrosine kinase at Y188. A potential glycosaminoglycan attachment site is found at S155, and sequences containing potential active site histidine and serine residues for serine proteases are found at LTAAH73C and GDS212GGP, respectively. The fragment of SEQ ID NO:19 from about nucleotide 517 to about nucleotide 574, located between the active site histidine and serine residues, is

25 useful for hybridization. Northern analysis shows the expression of this sequence in female reproductive, neural, lung, and colon cDNA libraries. Approximately 83% of these libraries are associated with neoplastic disorders.

Nucleic acids encoding the HUPM-8 of the present invention were first identified in Incyte Clone 2082147 from the uterine tissue cDNA library (UTRSNOT08) using a

30 computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:20, was derived from the following overlapping and/or extended nucleic acid sequences: Incyte Clones 586776 (UTRSNOT01), 1719194 (BLADNOT06), 2082147 and

2082170 (UTRSNOT08), 3359814 (PROSTUT16), and shotgun sequences SAGA01368 and SAGA01895.

In another embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:8. HUPM-8 is 175 amino acids in length and has a potential signal peptide sequence extending between residues M1 and L30, potential phosphorylation sites for casein kinase II at T28, and for protein kinase C at S81. A potential cell attachment site sequence is found at R73DG, and a potential signal peptidase signature sequence containing an active site serine residue is found in the sequence GDHHGHS128FD. The fragment of SEQ ID NO:20 from about nucleotide 757 to about nucleotide 789 from the catalytic active site is useful for hybridization. Northern analysis shows the expression of this sequence in fetal, gastrointestinal, male and female reproductive, and neuronal cDNA libraries. Approximately 38% of these libraries are associated with neoplastic disorders, 24% with the immune response, and 14% with fetal development.

Nucleic acids encoding the HUPM-9 of the present invention were first identified in Incyte Clone 2170967 from the endothelial cell cDNA library (ENDCN0T03) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:21, was derived from the following overlapping and/or extended nucleic acid sequences: Incyte Clones 1667462 (BMARN0T03), 1830465 (THP1AZT01), 1888989 (BLADTUT07), 1928627 (BRSTN0T02), 2170967 (ENDCN0T03), 3125590 (LUNGTUT12), and 3456567 (293TF1T01).

In another embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:9. HUPM-9 is 519 amino acids in length and has a potential aminopeptidase signature sequence at N362TDAEGRL in which D364 and E366 represent the zinc binding ligands at the active site. HUPM-9 also has two potential N-glycosylation sites at N72 and N410, and potential phosphorylation sites for casein kinase II at S28, S54, S138, S228, S238, T363, T487, and T506, and for protein kinase C at S174, S227, S292, S340, T487, and T500. The fragment of SEQ ID NO:21 from about nucleotide 688 to about nucleotide 747 is useful for hybridization. Northern analysis shows the expression of this sequence in cardiovascular, male and female reproductive, hematopoietic, and nervous system cDNA libraries. Approximately 46% of these libraries are associated with neoplastic disorders and 31% with the immune response.

Nucleic acids encoding the HUPM-10 of the present invention were first identified in Incyte Clone 2484218 from the aortic smooth muscle cell cDNA library (SMCANOT01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:22, was derived from the following overlapping and/or  
5 extended nucleic acid sequences: Incyte Clones 1351043 (LATRTUT02), 1381980 (BRAITUT08), 1432027 (BEPINON01), 1457881 (COLNFET02), and 2484218 (SMCANOT01).

In another embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:10. HUPM-10 is 327 amino acids in length and has  
10 three potential N-glycosylation sites at N12, N50, and N214, and potential phosphorylation sites for casein kinase II at S18, T93, T107, S166, S170, and T216, for protein kinase C at T272, and for tyrosine kinase at Y104. HUPM-10 has chemical and structural homology with human proteasome subunit p40 (GI 971270). In particular, HUPM-10 and human p40 share 23% homology. The fragment of SEQ ID NO:22 from  
15 about nucleotide 136 to about nucleotide 211 is useful for hybridization. Northern analysis shows the expression of this sequence in cardiovascular, male and female reproductive, nervous system, and hematopoietic cDNA libraries. Approximately 40% of these libraries are associated with neoplastic disorders, 24% with the immune response, and 22% with fetal development.

20 Nucleic acids encoding the HUPM-11 of the present invention were first identified in Incyte Clone 2680548 from the ileum tissue cDNA library (SINIUCT01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:23, was derived from the following overlapping and/or extended nucleic acid sequences: Incyte Clones 725100 (SYNOOAT01), 779975 (MYOMNOT01), 1528274  
25 (UCMCL5T01), 1658964 (URETTUT01), 1781933 (PGANNON02), 2618786 (GBLANOT01), and 2680548 (SINIUCT01).

In another embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:11. HUPM-11 is 458 amino acids in length and has two sequences containing potential active site histidine and serine residues for serine  
30 proteases at VTNAH198V and GNS306GGP, respectively. Two potential N-glycosylation sites are found at N181 and N349, and potential phosphorylation sites are found for cAMP- and cGMP-dependent protein kinase at S350, for casein kinase II at

T221, T290, and S383, and for protein kinase C at S13, S142, T231, T322, S335, and S357. The fragment of SEQ ID NO:23 from about nucleotide 694 to about nucleotide 756, located between the potential histidine and serine active site residues, is useful for hybridization. Northern analysis shows the expression of this sequence in gastrointestinal, male and female reproductive, and nervous system cDNA libraries. Approximately 43% of these libraries are associated with neoplastic disorders and 25% with the immune response.

Nucleic acids encoding the HUPM-12 of the present invention were first identified in Incyte Clone 2957969 from the fetal kidney cDNA library (KIDNFET01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:24, was derived from the following overlapping and/or extended nucleic acid sequences: Incyte Clones 875973 (LUNGAST01), 978220 (BRSTNOT02), 1362955 (LUNGNOT12), 1511581 (LUNGNOT14), 2354566 (LUNGNOT20), 2957969 (KIDNFET01), and 3676880 (PLACNOT07).

In another embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:12. HUPM-12 is 532 amino acids in length and has three potential N-glycosylation sites at N182, N329, and N348, potential phosphorylation sites for casein kinase II at S20, T205, T331, T350, and S441, and for protein kinase C at T144, S150, S279, S341, T388, and S526. A potential aminopeptidase signature sequence is found at N349TDAEGRL in which D351 and E353 represent the zinc binding ligands at the active site. A potential ATP/GTP-binding site (P-loop) is also found in the sequence G277LSIKGKT. The fragment of SEQ ID NO:24 from about nucleotide 709 to about nucleotide 781 is useful for hybridization. Northern analysis shows the expression of this sequence in cardiovascular, male and female reproductive, and nervous system cDNA libraries. Approximately 55% of these libraries are associated with neoplastic disorders, 12% with the immune response, and 14% with fetal tissues and proliferative cell lines.

The invention also encompasses HUPM variants. A preferred HUPM variant is one which has at least about 80%, more preferably at least about 90%, and most preferably at least about 95% amino acid sequence identity to the HUPM amino acid sequence, and which contains at least one functional or structural characteristic of HUPM.

The invention also encompasses polynucleotides which encode HUPM. In a particular embodiment, the invention encompasses a polynucleotide consisting of a

nucleic acid sequence selected from the group consisting of SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24.

The invention also encompasses a variant of a polynucleotide sequence encoding  
5 HUPM. In particular, such a variant polynucleotide sequence will have at least about 80%, more preferably at least about 90%, and most preferably at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding HUPM. A particular aspect of the invention encompasses a variant of a polynucleotide sequence selected from the group consisting of SEQ ID NO:13 SEQ ID NO:14, SEQ ID NO:15,  
10 SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24 which has at least about 80%, more preferably at least about 90%, and most preferably at least about 95% polynucleotide sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:13 SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID  
15 NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of HUPM.

It will be appreciated by those skilled in the art that as a result of the degeneracy of  
20 the genetic code, a multitude of polynucleotide sequences encoding HUPM, some bearing minimal homology to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard  
25 triplet genetic code as applied to the polynucleotide sequence of naturally occurring HUPM, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode HUPM and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring HUPM under appropriately selected conditions of stringency, it may be advantageous to  
30 produce nucleotide sequences encoding HUPM or its derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the

frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding HUPM and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced  
5 from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode HUPM and HUPM derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents that are well known in the art.  
10 Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding HUPM or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ  
15 ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:24, or fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; and Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.)

Methods for DNA sequencing are well known and generally available in the art  
20 and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase® (US Biochemical Corp., Cleveland, OH), Taq polymerase (Perkin Elmer), thermostable T7 polymerase (Amersham, Chicago, IL), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE Amplification System (GIBCO/BRL,  
25 Gaithersburg, MD). Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno, NV), Peltier Thermal Cycler (PTC200; MJ Research, Watertown, MA) and the ABI Catalyst and 373 and 377 DNA Sequencers (Perkin Elmer).

The nucleic acid sequences encoding HUPM may be extended utilizing a partial  
30 nucleotide sequence and employing various methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal primers to retrieve unknown

sequence adjacent to a known locus. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) In particular, genomic DNA is first amplified in the presence of a primer complementary to a linker sequence within the vector and a primer specific to a region of the nucleotide sequence. The amplified sequences are then subjected to a second round of  
5 PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR may also be used to amplify or extend sequences using divergent primers based on a known region. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) The primers may be designed using commercially available software such as  
10 OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, MN) or another appropriate program to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to 72°C. The method uses several restriction enzymes to generate a suitable  
15 fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

Another method which may be used is capture PCR, which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods  
20 Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060.) Additionally, one may use PCR, nested primers, and  
25 PromoterFinder™ libraries to walk genomic DNA (Clontech, Palo Alto, CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable in that they will include more sequences which contain the 5' regions of genes. Use of a  
30 randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser  
5 activated, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., Genotyper™ and Sequence Navigator™, Perkin Elmer), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small  
10 pieces of DNA which might be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode HUPM may be used in recombinant DNA molecules to direct expression of HUPM, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which  
15 encode substantially the same or a functionally equivalent amino acid sequence may be produced, and these sequences may be used to clone and express HUPM.

As will be understood by those of skill in the art, it may be advantageous to produce HUPM-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can  
20 be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter HUPM-encoding sequences for a  
25 variety of reasons including, but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon  
30 preference, produce splice variants, introduce mutations, and so forth.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding HUPM may be ligated to a heterologous sequence to encode a



fusion protein. For example, to screen peptide libraries for inhibitors of HUPM activity, it may be useful to encode a chimeric HUPM protein that can be recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between the HUPM encoding sequence and the heterologous protein sequence, so that HUPM may be cleaved and purified away from the heterologous moiety.

In another embodiment, sequences encoding HUPM may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucl. Acids Res. Symp. Ser. 215-223, and Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 225-232.) Alternatively, the protein itself may be produced using chemical methods to synthesize the amino acid sequence of HUPM, or a fragment thereof. For example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g., Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A Peptide Synthesizer (Perkin Elmer). Additionally, the amino acid sequence of HUPM, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, T. (1983) Proteins, Structures and Molecular Properties, WH Freeman and Co., New York, NY.)

In order to express a biologically active HUPM, the nucleotide sequences encoding HUPM or derivatives thereof may be inserted into appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding HUPM and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning. A Laboratory Manual, Cold Spring Harbor Press, Plainview, NY, ch. 4, 8, and 16-17; and Ausubel, F.M. et al. (1995, and periodic supplements) Current Protocols in Molecular Biology, John Wiley & Sons, New York,

NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding HUPM. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression  
5 vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus (CaMV) or tobacco mosaic virus (TMV)) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems.

10 The invention is not limited by the host cell employed.

The "control elements" or "regulatory sequences" are those non-translated regions, e.g., enhancers, promoters, and 5' and 3' untranslated regions, of the vector and polynucleotide sequences encoding HUPM which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and  
15 specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters, e.g., hybrid lacZ promoter of the Bluescript® phagemid (Stratagene, La Jolla, CA) or pSport1™ plasmid (GIBCO/BRL), may be used. The baculovirus polyhedrin promoter may be used  
20 in insect cells. Promoters or enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO, and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding  
25 HUPM, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for HUPM. For example, when large quantities of HUPM are needed for the induction of antibodies, vectors which direct high level expression of fusion  
30 proteins that are readily purified may be used. Such vectors include, but are not limited to, multifunctional E. coli cloning and expression vectors such as Bluescript® (Stratagene), in which the sequence encoding HUPM may be ligated into the vector in frame with

sequences for the amino-terminal Met and the subsequent 7 residues of  $\beta$ -galactosidase so that a hybrid protein is produced, and pSPORT vectors. (Gibco/BRL, Gaithersburg, MD.) pGEX vectors (Pharmacia Biotech, Uppsala, Sweden) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

10 In the yeast Saccharomyces cerevisiae, a number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH, may be used. (See, e.g., Ausubel, supra; and Grant et al. (1987) *Methods Enzymol.* 153:516-544.)

In cases where plant expression vectors are used, the expression of sequences encoding HUPM may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV. (Takamatsu, N. (1987) *EMBO J.* 6:307-311.) Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews. (See, e.g., Hobbs, S. or Murry, L.E. in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, NY; pp. 191-196.)

25 An insect system may also be used to express HUPM. For example, in one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. The sequences encoding HUPM may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of sequences encoding HUPM will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, S. frugiperda cells or Trichoplusia larvae in which HUPM may

be expressed. (See, e.g., Engelhard, E.K. et al. (1994) Proc. Nat. Acad. Sci. 91:3224-3227.)

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding HUPM may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing HUPM in infected host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained and expressed in a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes.

Specific initiation signals may also be used to achieve more efficient translation of sequences encoding HUPM. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding HUPM and its initiation codon and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.)

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to facilitate correct

insertion, folding, and/or function. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC, Bethesda, MD) and may be chosen to ensure the correct modification  
5 and processing of the foreign protein.

For long term, high yield production of recombinant proteins, stable expression is preferred. For example, cell lines capable of stably expressing HUPM can be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector.  
10 Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to  
15 the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase genes and adenine phosphoribosyltransferase genes, which can be employed in *tk* or *apr* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; and Lowy, I. et al.  
20 (1980) Cell 22:817-823) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *npf* confers resistance to the aminoglycosides neomycin and G-418; and *als* or *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-3570; Colbere-Garapin, F. et al  
25 (1981) J. Mol. Biol. 150:1-14; and Murry, *supra*.) Additional selectable genes have been described, e.g., *trpB*, which allows cells to utilize indole in place of tryptophan, or *hisD*, which allows cells to utilize histinol in place of histidine. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-8051.) Recently, the use of visible markers, such as anthocyanins, green fluorescent proteins,  $\beta$  glucuronidase and its  
30 substrate GUS, luciferase and its substrate luciferin, has increased. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A.

et al. (1995) *Methods Mol. Biol.* 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding HUPM is inserted within a marker gene sequence,  
5 transformed cells containing sequences encoding HUPM can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding HUPM under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

10 Alternatively, host cells which contain the nucleic acid sequence encoding HUPM and express HUPM may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid  
15 or protein sequences.

The presence of polynucleotide sequences encoding HUPM can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding HUPM. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the sequences encoding HUPM  
20 to detect transformants containing DNA or RNA encoding HUPM.

A variety of protocols for detecting and measuring the expression of HUPM, using either polyclonal or monoclonal antibodies specific for the protein, are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site,  
25 monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on HUPM is preferred, but a competitive binding assay may be employed. These and other assays are well described in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St Paul, MN, Section IV; and Maddox, D.E. et al. (1983) *J. Exp. Med.* 158:1211-1216).

30 A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to

polynucleotides encoding HUPM include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding HUPM, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Pharmacia & Upjohn (Kalamazoo, MI), Promega (Madison, WI), and U.S. Biochemical Corp. (Cleveland, OH). Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding HUPM may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode HUPM may be designed to contain signal sequences which direct secretion of HUPM through a prokaryotic or eukaryotic cell membrane. Other constructions may be used to join sequences encoding HUPM to nucleotide sequences encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, WA). The inclusion of cleavable linker sequences, such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, CA), between the purification domain and the HUPM encoding sequence may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing HUPM and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on immobilized metal ion affinity chromatography. (IMAC) (See, e.g., Porath, J. et al. (1992) Prot. Exp. Purif. 3: 263-281.) The enterokinase cleavage site provides a means for purifying HUPM from the fusion

protein. (See, e.g., Kroll, D.J. et al. (1993) DNA Cell Biol. 12:441-453.)

Fragments of HUPM may be produced not only by recombinant production, but also by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, T.E. (1984) Protein: Structures and Molecular Properties, pp. 55-60, W.H. Freeman and Co., New York, NY.) Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be achieved, for example, using the Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Various fragments of HUPM may be synthesized separately and then combined to produce the full length molecule.

## 10 THERAPEUTICS

Chemical and structural homology exists among the human protease molecules of the invention. In addition, HUPM is expressed in proliferating cell types associated with cancer, and the immune response. Therefore, HUPM appears to play a role in cell proliferative disorders and immune disorders. Therefore, in cell proliferative or immune disorders where HUPM is being expressed or is promoting cell proliferation it is desirable to decrease the expression of HUPM. In cell proliferative or immune disorders where expression of HUPM is decreased, it is desirable to provide the protein or increase expression.

Therefore, in one embodiment, an antagonist of HUPM may be administered to a subject to treat or prevent a cell proliferative disorder associated with increased expression or activity of HUPM. Such a disorder may include, but is not limited to, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus. In one aspect, an antibody which specifically binds HUPM may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express HUPM.

In another additional embodiment, a vector expressing the complement of the



polynucleotide encoding HUPM may be administered to a subject to treat or prevent a cell proliferative disorder including, but not limited to, those described above.

In another embodiment, an antagonist of HUPM may be administered to a subject to treat or prevent an immune disorder associated with increased expression or activity of HUPM. Such a disorder may include, but is not limited to AIDS, Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, ulcerative colitis, Werner syndrome, and complications of cancer, hemodialysis, and extracorporeal circulation; viral, bacterial, fungal, parasitic, protozoal, and helminthic infections; and trauma.

In still another embodiment, a vector expressing the complement of the polynucleotide encoding HUPM may be administered to a subject to treat or prevent an immune disorder including, but not limited to, those described above.

In another embodiment, HUPM or a fragment or derivative thereof may be administered to a subject to treat or prevent a cell proliferative disorder associated with decreased expression or activity of HUPM. Such disorders can include, but are not limited to, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus.

In another embodiment, a vector capable of expressing HUPM or a fragment or

derivative thereof may be administered to a subject to treat or prevent a cell proliferative disorder including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified HUPM in conjunction with a suitable pharmaceutical carrier may be administered  
5 to a subject to treat or prevent a cell proliferative disorder including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of HUPM may be administered to a subject to treat or prevent a cell proliferative disorder including, but not limited to, those listed above.

10 In another embodiment, HUPM or a fragment or derivative thereof may be administered to a subject to treat or prevent an immune disorder associated with decreased expression or activity of HUPM. Such disorders can include, but are not limited to, AIDS, Addison's disease, adult respiratory distress syndrome, allergies, ankylosing  
spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia,  
15 autoimmune thyroiditis, bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, lupus  
erythematosus, multiple sclerosis, myasthenia gravis, myocardial or pericardial  
20 inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, ulcerative colitis, Werner syndrome, and complications of cancer, hemodialysis, and extracorporeal circulation; viral, bacterial, fungal, parasitic, protozoal, and helminthic infections; and trauma.

25 In another embodiment, a vector capable of expressing HUPM or a fragment or derivative thereof may be administered to a subject to treat or prevent an immune disorder including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified HUPM in conjunction with a suitable pharmaceutical carrier may be administered  
30 to a subject to treat or prevent an immune disorder including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of HUPM

may be administered to a subject to treat or prevent an immune disorder including, but not limited to, those listed above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination  
5 with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower  
10 dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of HUPM may be produced using methods which are generally known in the art. In particular, purified HUPM may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind HUPM. Antibodies to HUPM may also be generated using methods that are well known in the art.  
15 Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice,  
20 humans, and others may be immunized by injection with HUPM or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil  
25 emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to HUPM have an amino acid sequence consisting of at least about 5 amino acids, and, more preferably, of at least about 10 amino acids. It is also preferable that  
30 these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of HUPM amino acids may be fused with

those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to HUPM may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture.

5 These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R.J. et al. (1983) *Proc. Natl. Acad. Sci.* 80:2026-2030; and Cole, S.P. et al. (1984) *Mol. Cell Biol.* 62:109-120.)

10 In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) *Proc. Natl. Acad. Sci.* 81:6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312:604-608; and Takeda, S. et al. (1985) *Nature* 314:452-454.)

15 Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce HUPM-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton D.R. (1991) *Proc. Natl. Acad. Sci.* 88:10134-10137.)

20 Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) *Proc. Natl. Acad. Sci.* 86: 3833-3837; and Winter, G. et al. (1991) *Nature* 349:293-299.)

Antibody fragments which contain specific binding sites for HUPM may also be  
25 generated. For example, such fragments include, but are not limited to, F(ab')<sub>2</sub> fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) *Science*  
30 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric

assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between HUPM and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering HUPM epitopes is preferred, but a competitive binding assay may also be employed. (Maddox, supra.)

In another embodiment of the invention, the polynucleotides encoding HUPM, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding HUPM may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding HUPM. Thus, complementary molecules or fragments may be used to modulate HUPM activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding HUPM.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors which will express nucleic acid sequences complementary to the polynucleotides of the gene encoding HUPM. (See, e.g., Sambrook, supra; and Ausubel, supra.)

Genes encoding HUPM can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide, or fragment thereof, encoding HUPM. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding HUPM. Oligonucleotides derived

from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

10 Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences  
15 encoding HUPM.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene  
20 containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be  
25 prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding HUPM. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA  
30 polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is  
5 inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and  
10 equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nature Biotechnology 15:462-466.)

15 Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable  
20 carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of HUPM, antibodies to HUPM, and mimetics, agonists, antagonists, or inhibitors of HUPM. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited  
25 to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous,  
30 intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries

which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).

5        Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

10        Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice,  
15    potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

20        Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the  
25    quantity of active compound, i.e., dosage.

      Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and,  
30    optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.



Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of HUPM, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those

skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate  
5 concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example HUPM or fragments thereof, antibodies of HUPM, and agonists, antagonists or inhibitors of HUPM, which ameliorates the symptoms or condition. Therapeutic efficacy  
10 and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED50 (the dose therapeutically effective in 50% of the population) or LD50 (the dose lethal to 50% of the population) statistics. The dose ratio of therapeutic to toxic effects is the therapeutic index, and it can be expressed as the ED50/LD50 ratio. Pharmaceutical compositions which exhibit large  
15 therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

20 The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration,  
25 drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1  $\mu\text{g}$  to 100,000  $\mu\text{g}$ , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to  
30 particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of

polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc..

#### DIAGNOSTICS

5 In another embodiment, antibodies which specifically bind HUPM may be used for the diagnosis of disorders characterized by expression of HUPM, or in assays to monitor patients being treated with HUPM or agonists, antagonists, or inhibitors of HUPM.

Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for HUPM include methods which  
10 utilize the antibody and a label to detect HUPM in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

15 A variety of protocols for measuring HUPM, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of HUPM expression. Normal or standard values for HUPM expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to HUPM under conditions suitable for complex formation. The  
20 amount of standard complex formation may be quantitated by various methods, preferably by photometric means. Quantities of HUPM expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding HUPM may  
25 be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of HUPM may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of HUPM, and to monitor  
30 regulation of HUPM levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding HUPM or closely

related molecules may be used to identify nucleic acid sequences which encode HUPM. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low), will  
5 determine whether the probe identifies only naturally occurring sequences encoding HUPM, alleles, or related sequences.

Probes may also be used for the detection of related sequences, and should preferably contain at least 50% identity to the nucleotides from any of the HUPM encoding sequences. The hybridization probes of the subject invention may be DNA or  
10 RNA and may be derived from the sequence of SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:24 or from genomic sequences including promoters, enhancers, and introns of the HUPM gene.

Means for producing specific hybridization probes for DNAs encoding HUPM  
15 include the cloning of polynucleotide sequences encoding HUPM or HUPM derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by  
20 radionuclides such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding HUPM may be used for the diagnosis of a disorder associated with expression of HUPM. Examples of such a disorder include, but are not limited to, cell proliferative disorders such as arteriosclerosis, atherosclerosis,  
25 bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia,  
30 gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and immune disorders such as AIDS, Addison's disease, adult respiratory distress syndrome,

allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, ulcerative colitis, Werner syndrome, and complications of cancer, hemodialysis, and extracorporeal circulation; viral, bacterial, fungal, parasitic, protozoal, and helminthic infections; and trauma. The polynucleotide sequences encoding HUPM may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and ELISA assays; and in microarrays utilizing fluids or tissues from patients to detect altered HUPM expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding HUPM may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding HUPM may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding HUPM in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of HUPM, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding HUPM, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an

experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

5        Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

10        With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby  
15 preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding HUPM may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced *in vitro*. Oligomers will preferably contain a fragment of a polynucleotide encoding HUPM, or a fragment of a polynucleotide  
20 complementary to the polynucleotide encoding HUPM, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of HUPM include  
25 radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; and Duplaa, C. et al. (1993) Anal. Biochem. 229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a  
30 spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as targets in a microarray. The

microarray can be used to monitor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

In one embodiment, the microarray is prepared and used according to methods known in the art. (See, e.g., Chee et al. (1995) PCT application WO95/11995; Lockhart, D. J. et al. (1996) Nat. Biotech. 14:1675-1680; and Schena, M. et al. (1996) Proc. Natl. Acad. Sci. 93:10614-10619.)

The microarray is preferably composed of a large number of unique single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs. The oligonucleotides are preferably about 6 to 60 nucleotides in length, more preferably about 15 to 30 nucleotides in length, and most preferably about 20 to 25 nucleotides in length. It may be preferable to use oligonucleotides which are about 7 to 10 nucleotides in length. The microarray may contain oligonucleotides which cover the known 5' or 3' sequence, sequential oligonucleotides which cover the full length sequence, or unique oligonucleotides selected from particular areas along the length of the sequence. Polynucleotides used in the microarray may be oligonucleotides specific to a gene or genes of interest. Oligonucleotides can also be specific to one or more unidentified cDNAs associated with a particular cell type or tissue type. It may be appropriate to use pairs of oligonucleotides on a microarray. The first oligonucleotide in each pair differs from the second oligonucleotide by one nucleotide. This nucleotide is preferably located in the center of the sequence. The second oligonucleotide serves as a control. The number of oligonucleotide pairs may range from about 2 to 1,000,000.

In order to produce oligonucleotides for use on a microarray, the gene of interest is examined using a computer algorithm which starts at the 5' end, or, more preferably, at the 3' end of the nucleotide sequence. The algorithm identifies oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack secondary structure that may interfere with hybridization. In one aspect, the oligomers may be synthesized on a substrate using a light-directed chemical process. (See, e.g., Chee et al., *supra*.) The substrate may be any suitable solid support, e.g., paper, nylon, any other type of membrane, or a filter, chip, or glass slide.

In another aspect, the oligonucleotides may be synthesized on the surface of the substrate using a chemical coupling procedure and an ink jet application apparatus. (See, e.g., Baldeschweiler et al. (1995) PCT application WO95/251116.) An array analogous to a dot or slot blot (HYBRIDOT® apparatus, GIBCO/BRL) may be used to arrange and link  
5 cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system or thermal, UV, mechanical, or chemical bonding procedures. An array may also be produced by hand or by using available devices, materials, and machines, e.g. Brinkmann® multichannel pipettors or robotic instruments. The array may contain from 2 to 1,000,000 or any other feasible number of oligonucleotides.

10 In order to conduct sample analysis using the microarrays, polynucleotides are extracted from a sample. The sample may be obtained from any bodily fluid, e.g., blood, urine, saliva, phlegm, gastric juices, cultured cells, biopsies, or other tissue preparations. To produce probes, the polynucleotides extracted from the sample are used to produce nucleic acid sequences complementary to the nucleic acids on the microarray. If the  
15 microarray contains cDNAs, antisense RNAs (aRNAs) are appropriate probes. Therefore, in one aspect, mRNA is reverse-transcribed to cDNA. The cDNA, in the presence of fluorescent label, is used to produce fragment or oligonucleotide aRNA probes. The fluorescently labeled probes are incubated with the microarray so that the probes hybridize to the microarray oligonucleotides. Nucleic acid sequences used as probes can include  
20 polynucleotides, fragments, and complementary or antisense sequences produced using restriction enzymes, PCR, or other methods known in the art.

Hybridization conditions can be adjusted so that hybridization occurs with varying degrees of complementarity. A scanner can be used to determine the levels and patterns of fluorescence after removal of any nonhybridized probes. The degree of complementarity  
25 and the relative abundance of each oligonucleotide sequence on the microarray can be assessed through analysis of the scanned images. A detection system may be used to measure the absence, presence, or level of hybridization for any of the sequences. (See, e.g., Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. 94:2150-2155.)

In another embodiment of the invention, nucleic acid sequences encoding HUPM  
30 may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human



artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Price, C.M. (1993) *Blood Rev.* 7:127-134; and Trask, B.J. (1991) *Trends Genet.* 7:149-154.)

5       Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, R.A. (ed.) Molecular Biology and Biotechnology, VCH Publishers New York, NY, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) site. Correlation between  
10 the location of the gene encoding HUPM on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The nucleotide sequences of the invention may be used to detect differences in gene sequences among normal, carrier, and affected individuals.

In situ hybridization of chromosomal preparations and physical mapping  
15 techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms by physical mapping. This provides valuable information to  
20 investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, e.g., AT to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) *Nature* 336:577-580.) The nucleotide sequence of the subject invention  
25 may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

      In another embodiment of the invention, HUPM, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening  
30 may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between HUPM and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with HUPM, or fragments thereof, and washed. Bound HUPM is then detected by methods well known in the art. Purified HUPM can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

10 In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding HUPM specifically compete with a test compound for binding HUPM. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with HUPM.

In additional embodiments, the nucleotide sequences which encode HUPM may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention.

## EXAMPLES

For purposes of example, the preparation and sequencing of the PROSTUT03 cDNA library, from which Incyte Clone 789927 was isolated, is described. Preparation and sequencing of cDNAs in libraries in the LIFESEQ™ database have varied over time, and the gradual changes involved use of kits, plasmids, and machinery available at the particular time the library was made and analyzed.

### I. PROSTUT03 cDNA Library Construction

30 The PROSTUT03 cDNA library was constructed from prostate tumor tissue removed from a 76-year-old Caucasian male by radical prostatectomy. The pathology report indicated grade 3 (of 4) adenocarcinoma (Gleason grade 3+3) in the periphery of the

prostate. Perineural invasion was present as was involvement of periprostatic tissue. Non-tumorous portions of the prostate exhibited adenofibromatous hyperplasia. The patient had elevated levels of prostate specific antigen (PSA). Pelvic lymph nodes were negative for tumor. A prior stomach ulcer and atherosclerosis were reported in the patient history.

5 The frozen tissue was homogenized and lysed using a Brinkmann Homogenizer Polytron-PT 3000 (Brinkmann Instruments, Inc. Westbury NY) in guanidinium isothiocyanate solution. The lysate was extracted once with acid phenol at pH 4.0 per Stratagene's RNA isolation protocol (Stratagene Inc.) and once with phenol chloroform at pH 4.0. The RNA was precipitated using 0.3 M sodium acetate and 2.5 volumes of  
10 ethanol, resuspended in RNase-free water, and treated with DNase at 37°C. RNA extraction and precipitation were repeated as before. The mRNA was isolated with the Qiagen Oligotex kit (QIAGEN, Inc., Chatsworth, CA) and used to construct the cDNA library.

The RNA was handled according to the recommended protocols in the SuperScript  
15 Plasmid System (catalog #18248-013; Gibco/BRL). PROSTUT03 cDNAs were fractionated on a Sepharose CL4B column (catalog #275105, Pharmacia), and those cDNAs exceeding 400 bp were ligated into pSport I. The plasmid pSport I was subsequently transformed into DH5a™ competent cells (Cat. #18258-012, Gibco/BRL).

## 20 II. Isolation and Sequencing of cDNA Clones

Plasmid DNA was released from the cells and purified using the REAL Prep 96 plasmid kit (Catalog #26173; QIAGEN, Inc.). The recommended protocol was employed except for the following changes: 1) the bacteria were cultured in 1 ml of sterile Terrific Broth (Catalog #22711, Gibco/BRL) with carbenicillin at 25 mg/L and glycerol at 0.4%;  
25 2) after inoculation, the cultures were incubated for 19 hours and at the end of incubation, the cells were lysed with 0.3 ml of lysis buffer; and 3) following isopropanol precipitation, the plasmid DNA pellet was resuspended in 0.1 ml of distilled water. After the last step in the protocol, samples were transferred to a 96-well block for storage at 4° C.

The cDNAs were sequenced by the method of Sanger, et al. (1975, J. Mol. Biol.  
30 94:441f), using a Hamilton Micro Lab 2200 (Hamilton, Reno, NV) in combination with Peltier Thermal Cyclers (PTC200 from MJ Research, Watertown, MA) and Applied Biosystems 377 DNA Sequencing Systems.

### III. Homology Searching of cDNA Clones and Their Deduced Proteins

The nucleotide sequences and/or amino acid sequences of the Sequence Listing were used to query sequences in the GenBank, SwissProt, BLOCKS, and Pima II databases. These databases, which contain previously identified and annotated sequences, were searched for regions of homology using BLAST, which stands for Basic Local Alignment Search Tool. (Altschul, S.F. (1993) J. Mol. Evol 36:290-300; and Altschul, et al. (1990) J. Mol. Biol. 215:403-410.)

BLAST produced alignments of both nucleotide and amino acid sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST was especially useful in determining exact matches or in identifying homologs which may be of prokaryotic (bacterial) or eukaryotic (animal, fungal, or plant) origin. Other algorithms could have been used when dealing with primary sequence patterns and secondary structure gap penalties. (See, e.g., Smith, T. et al. (1992) Protein Engineering 5:35-51.) The sequences disclosed in this application have lengths of at least 49 nucleotides, and no more than 12% uncalled bases (where N can be A, C, G, or T).

The BLAST approach searched for matches between a query sequence and a database sequence. BLAST evaluated the statistical significance of any matches found, and reported only those matches that satisfy the user-selected threshold of significance. In this application, threshold was set at  $10^{-25}$  for nucleotides and  $10^{-10}$  for peptides.

Incyte nucleotide sequences were searched against the GenBank databases for primate (pri), rodent (rod), and other mammalian sequences (mam); and deduced amino acid sequences from the same clones were then searched against GenBank functional protein databases, mammalian (mamp), vertebrate (vrtp), and eukaryote (eukp) for homology.

The nucleotide sequences and/or amino acid sequences of the Sequence Listing were used to query sequences in the GenBank, SwissProt, BLOCKS, and Pima II databases. These databases, which contain previously identified and annotated sequences, were searched for regions of homology using BLAST (Basic Local Alignment Search Tool). (See, e.g., Altschul, S.F. (1993) J. Mol. Evol 36:290-300; and Altschul et al. (1990) J. Mol. Biol. 215:403-410.)

BLAST produced alignments of both nucleotide and amino acid sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST was

especially useful in determining exact matches or in identifying homologs which may be of prokaryotic (bacterial) or eukaryotic (animal, fungal, or plant) origin. Other algorithms could have been used when dealing with primary sequence patterns and secondary structure gap penalties. (See, e.g., Smith, T. et al. (1992) Protein Engineering 5:35-51.)

5 The sequences disclosed in this application have lengths of at least 49 nucleotides and have no more than 12% uncalled bases (where N is recorded rather than A, C, G, or T).

The BLAST approach searched for matches between a query sequence and a database sequence. BLAST evaluated the statistical significance of any matches found, and reported only those matches that satisfy the user-selected threshold of significance. In  
10 this application, threshold was set at  $10^{-25}$  for nucleotides and  $10^{-8}$  for peptides.

Incyte nucleotide sequences were searched against the GenBank databases for primate (pri), rodent (rod), and other mammalian sequences (mam), and deduced amino acid sequences from the same clones were then searched against GenBank functional protein databases, mammalian (mamp), vertebrate (vrtp), and eukaryote (eukp), for  
15 homology.

#### IV. Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See,  
20 e.g., Sambrook, *supra*, ch. 7; and Ausubel, F.M. et al. *supra*, ch. 4 and 16.)

Analogous computer techniques applying BLAST are used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ™ database (Incyte Pharmaceuticals). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to  
25 determine whether any particular match is categorized as exact or homologous.

The basis of the search is the product score, which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

30 The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1% to 2% error, and, with a product score of 70, the match will be

exact. Homologous molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analysis are reported as a list of libraries in which the transcript encoding HUPM occurs. Abundance and percent abundance are also reported.

- 5 Abundance directly reflects the number of times a particular transcript is represented in a cDNA library, and percent abundance is abundance divided by the total number of sequences examined in the cDNA library.

#### V. Extension of HUPM Encoding Polynucleotides

- The sequence of one of the polynucleotides of the present invention was used to  
10 design oligonucleotide primers for extending a partial nucleotide sequence to full length. One primer was synthesized to initiate extension of an antisense polynucleotide, and the other was synthesized to initiate extension of a sense polynucleotide. Primers were used to facilitate the extension of the known sequence "outward" generating amplicons containing new unknown nucleotide sequence for the region of interest. The initial primers were  
15 designed from the cDNA using OLIGO 4.06 (National Biosciences, Plymouth, MN), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

- 20 Selected human cDNA libraries (GIBCO/BRL) were used to extend the sequence. If more than one extension is necessary or desired, additional sets of primers are designed to further extend the known region.

- High fidelity amplification was obtained by following the instructions for the XL-PCR kit (Perkin Elmer) and thoroughly mixing the enzyme and reaction mix. PCR was  
25 performed using the Peltier Thermal Cycler (PTC200; M.J. Research, Watertown, MA), beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, with the following parameters:

- |           |  |
|-----------|--|
| Step 1    | 94° C for 1 min (initial denaturation)               |
| Step 2    | 65° C for 1 min                                      |
| 30 Step 3 | 68° C for 6 min                                      |
| Step 4    | 94° C for 15 sec                                     |
| Step 5    | 65° C for 1 min                                      |
| Step 6    | 68° C for 7 min                                      |
| Step 7    | Repeat steps 4 through 6 for an additional 15 cycles |

- |   |         |   |
|---|---------|---|
|   | Step 8  | 94° C for 15 sec                                      |
|   | Step 9  | 65° C for 1 min                                       |
|   | Step 10 | 68° C for 7:15 min                                    |
|   | Step 11 | Repeat steps 8 through 10 for an additional 12 cycles |
| 5 | Step 12 | 72° C for 8 min                                       |
|   | Step 13 | 4° C (and holding)                                    |

A 5  $\mu$ l to 10  $\mu$ l aliquot of the reaction mixture was analyzed by electrophoresis on a low concentration (about 0.6% to 0.8%) agarose mini-gel to determine which reactions  
 10 were successful in extending the sequence. Bands thought to contain the largest products were excised from the gel, purified using QIAQuick™ (QIAGEN Inc., Chatsworth, CA), and trimmed of overhangs using Klenow enzyme to facilitate religation and cloning.

After ethanol precipitation, the products were redissolved in 13  $\mu$ l of ligation buffer, 1  $\mu$ l T4-DNA ligase (15 units) and 1  $\mu$ l T4 polynucleotide kinase were added, and  
 15 the mixture was incubated at room temperature for 2 to 3 hours, or overnight at 16° C. Competent *E. coli* cells (in 40  $\mu$ l of appropriate media) were transformed with 3  $\mu$ l of ligation mixture and cultured in 80  $\mu$ l of SOC medium. (See, e.g., Sambrook, *supra*, Appendix A, p. 2.) After incubation for one hour at 37° C, the *E. coli* mixture was plated on Luria Bertani (LB) agar (See, e.g., Sambrook, *supra*, Appendix A, p. 1) containing 2x  
 20 Carb. The following day, several colonies were randomly picked from each plate and cultured in 150  $\mu$ l of liquid LB/2x Carb medium placed in an individual well of an appropriate commercially-available sterile 96-well microtiter plate. The following day, 5  $\mu$ l of each overnight culture was transferred into a non-sterile 96-well plate and, after dilution 1:10 with water, 5  $\mu$ l from each sample was transferred into a PCR array.

25 For PCR amplification, 18  $\mu$ l of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer, and one or both of the gene specific primers used for the extension reaction were added to each well. Amplification was performed using the following conditions:

- |    |        |  |
|----|--------|--|
|    | Step 1 | 94° C for 60 sec                                     |
| 30 | Step 2 | 94° C for 20 sec                                     |
|    | Step 3 | 55° C for 30 sec                                     |
|    | Step 4 | 72° C for 90 sec                                     |
|    | Step 5 | Repeat steps 2 through 4 for an additional 29 cycles |
|    | Step 6 | 72° C for 180 sec                                    |
| 35 | Step 7 | 4° C (and holding)                                   |

Aliquots of the PCR reactions were run on agarose gels together with molecular

weight markers. The sizes of the PCR products were compared to the original partial cDNAs, and appropriate clones were selected, ligated into plasmid, and sequenced.

The nucleotide sequences of SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24 are used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for 5' extension, and an appropriate genomic library.

#### **VI. Labeling and Use of Individual Hybridization Probes**

Hybridization probes derived from SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250  $\mu$ Ci of [ $\gamma$ - $^{32}$ P] adenosine triphosphate (Amersham, Chicago, IL), and T4 polynucleotide kinase (DuPont NEN<sup>®</sup>, Boston, MA). The labeled oligonucleotides are substantially purified using a Sephadex G-25 superfine resin column (Pharmacia & Upjohn, Kalamazoo, MI). An aliquot containing  $10^7$  counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN, Boston, MA).

The DNA from each digest is fractionated on a 0.7 percent agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham, NH).

Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT AR<sup>™</sup> film (Kodak, Rochester, NY) is exposed to the blots to film for several hours, hybridization patterns are compared visually.

#### **VII. Microarrays**

To produce oligonucleotides for a microarray, one of the nucleotide sequences of the present invention is examined using a computer algorithm which starts at the 3' end of



the nucleotide sequence. For each, the algorithm identifies oligomers of defined length that are unique to the nucleic acid sequence, have a GC content within a range suitable for hybridization, and lack secondary structure that would interfere with hybridization. The algorithm identifies approximately 20 oligonucleotides corresponding to each nucleic acid sequence. For each sequence-specific oligonucleotide, a pair of oligonucleotides is synthesized in which the first oligonucleotide differs from the second oligonucleotide by one nucleotide in the center of the sequence. The oligonucleotide pairs can be arranged on a substrate, e.g. a silicon chip, using a light-directed chemical process. (See, e.g., Chee, supra.)

In the alternative, a chemical coupling procedure and an ink jet device can be used to synthesize oligomers on the surface of a substrate. (See, e.g., Baldeschweiler, supra.) An array analogous to a dot or slot blot may also be used to arrange and link fragments or oligonucleotides to the surface of a substrate using or thermal, UV, mechanical, or chemical bonding procedures, or a vacuum system. A typical array may be produced by hand or using available methods and machines and contain any appropriate number of elements. After hybridization, nonhybridized probes are removed and a scanner used to determine the levels and patterns of fluorescence. The degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray may be assessed through analysis of the scanned images.

## **VIII. Complementary Polynucleotides**

Sequences complementary to the HUPM-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring HUPM. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using Oligo 4.06 software and the coding sequence of HUPM. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the HUPM-encoding transcript.

## **IX. Expression of HUPM**

Expression of HUPM is accomplished by subcloning the cDNA into an appropriate vector and transforming the vector into host cells. This vector contains an

appropriate promoter, e.g.,  $\beta$ -galactosidase upstream of the cloning site, operably associated with the cDNA of interest. (See, e.g., Sambrook, *supra*, pp. 404-433; and Rosenberg, M. et al. (1983) *Methods Enzymol.* 101:123-138.)

Induction of an isolated, transformed bacterial strain with isopropyl beta-D-thiogalactopyranoside (IPTG) using standard methods produces a fusion protein which  
5 consists of the first 8 residues of  $\beta$ -galactosidase, about 5 to 15 residues of linker, and the full length protein. The signal residues direct the secretion of HUPM into bacterial growth media which can be used directly in the following assay for activity.

#### **X. Demonstration of HUPM Activity**

10 Serine protease activity of HUPM is measured by the hydrolysis of various peptide thiobenzyl ester substrates. The substrates are chosen to represent the different SP types (chymase, trypase, aspase, etc.). Assays are performed at room temperature ( $\sim 25^{\circ}\text{C}$ ) and contain an aliquot of HUPM and the appropriate substrate in HEPES buffer, pH 7.5 containing 0.01M  $\text{CaCl}_2$  and 8% dimethylsulfoxide. The reaction also contains 0.34 mM  
15 dithiopyridine which reacts with the thiobenzyl group that is released during hydrolysis and converts it to thiopyridone. The reaction is carried out in an optical cuvette, and the generation of thiopyridone is measured in a spectrophotometer by the absorption produced at 324 nm. The amount of thiopyridone produced in the reaction is proportional to the activity of HUPM.

#### **20 XI. Production of HUPM Specific Antibodies**

HUPM substantially purified using PAGE electrophoresis (see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols. The HUPM amino acid sequence is analyzed using DNASTAR software (DNASTAR Inc) to determine  
25 regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel et al. *supra*, ch. 11.)

Typically, the oligopeptides are 15 residues in length, and are synthesized using  
30 an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry and coupled to KLH (Sigma, St. Louis, MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester to increase immunogenicity. (See, e.g., Ausubel et al. *supra*.)

Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

5 **XII. Purification of Naturally Occurring HUPM Using Specific Antibodies**

Naturally occurring or recombinant HUPM is substantially purified by immunoaffinity chromatography using antibodies specific for HUPM. An immunoaffinity column is constructed by covalently coupling anti-HUPM antibody to an activated chromatographic resin, such as CNBr-activated Sepharose (Pharmacia & Upjohn). After  
10 the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing HUPM are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of HUPM (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/HUPM binding (e.g., a buffer of pH 2 to pH 3, or a high  
15 concentration of a chaotrope, such as urea or thiocyanate ion), and HUPM is collected.

**XIII. Identification of Molecules Which Interact with HUPM**

HUPM, or biologically active fragments thereof, are labeled with <sup>125</sup>I Bolton-Hunter reagent. (See, e.g., Bolton et al. (1973) Biochem. J. 133:529.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the  
20 labeled HUPM, washed, and any wells with labeled HUPM complex are assayed. Data obtained using different concentrations of HUPM are used to calculate values for the number, affinity, and association of HUPM with the candidate molecules.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and  
25 spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following  
30 claims.

What is claimed is:

1. A substantially purified human protease molecule (HUPM) comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2,  
5 SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12, and fragments thereof.
2. A substantially purified variant of HUPM having at least 90% amino acid  
10 identity to the amino acid sequence of claim 1.
3. An isolated and purified polynucleotide sequence encoding the HUPM of claim 1.
- 15 4. An isolated and purified polynucleotide variant having at least 90% polynucleotide identity to the polynucleotide sequence of claim 3.
5. A composition comprising the polynucleotide sequence of claim 3.
- 20 6. An isolated and purified polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence of claim 3.
7. An isolated and purified polynucleotide sequence which is complementary to the polynucleotide sequence of claim 3.  
25
8. An isolated and purified polynucleotide sequence comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24,  
30 and fragments thereof.
9. An isolated and purified polynucleotide variant having at least 90%

polynucleotide identity to the polynucleotide sequence of claim 8.

10. An isolated and purified polynucleotide sequence which is complementary to the polynucleotide sequence of claim 8.

5

11. An expression vector containing at least a fragment of the polynucleotide sequence of claim 3.

12. A host cell containing the expression vector of claim 11.

10

13. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, or fragments thereof, the method comprising the steps of:

- 15
- a) culturing the host cell of claim 12 under conditions suitable for the expression of the polypeptide; and
  - b) recovering the polypeptide from the host cell culture.

14. A pharmaceutical composition comprising the HUPM of claim 1 in  
20 conjunction with a suitable pharmaceutical carrier.

15. A purified antibody which specifically binds to the HUPM of claim 1.

16. A purified agonist of the HUPM of claim 1.

25

17. A purified antagonist of the HUPM of claim 1.

18. A method for treating or preventing a cell proliferative disorder, the method comprising administering to a subject in need of such treatment an effective amount of the  
30 pharmaceutical composition of claim 14.

19. A method for treating or preventing an immune disorder, the method

comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 14.

20. A method for treating or preventing a cell proliferative disorder, the method  
5 comprising administering to a subject in need of such treatment an effective amount of the purified antagonist of claim 17.

21. A method for treating or preventing an immune disorder, the method  
comprising administering to a subject in need of such treatment an effective amount of the  
10 purified antagonist of claim 17.

22. A method for detecting a polynucleotide encoding HUPM in a biological sample containing nucleic acids, the method comprising the steps of:

(a) hybridizing the polynucleotide of claim 7 to at least one of the  
15 nucleic acids in the biological sample, thereby forming a hybridization complex;  
and

(b) detecting the hybridization complex, wherein the presence of the  
hybridization complex correlates with the presence of a polynucleotide encoding  
HUPM in the biological sample.

20

23. The method of claim 22 wherein the nucleic acids of the biological sample are amplified by the polymerase chain reaction prior to hybridization.

## SEQUENCE LISTING

&lt;110&gt; INCYTE PHARMACEUTICALS, INC.

BANDMAN, Olga

HILLMAN, Jennifer L.

YUE, Henry

GUEGLER, Karl J.

CORLEY, Neil C.

TANG, Y. Tom

SHAH, Purvi

&lt;120&gt; HUMAN PROTEASE MOLECULES

&lt;130&gt; PF-0458 PCT

&lt;140&gt; To Be Assigned

&lt;141&gt; Herewith

&lt;150&gt; 09/008,271

&lt;151&gt; 1998-01-16

&lt;160&gt; 24

&lt;170&gt; PERL PROGRAM

&lt;210&gt; 1

&lt;211&gt; 63

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 135360

&lt;400&gt; 1

Met	Asp	Ile	Leu	Ile	Cys	Thr	Asp	Phe	Gly	Ser	Val	Asn	Tyr	Phe
1				5					10					15
Asn	Val	Trp	Arg	Leu	Pro	Lys	Ser	Tyr	Leu	Ser	Leu	Phe	Tyr	Ser
			20						25					30
Arg	Ile	Tyr	Ile	Val	His	Asp	Glu	Val	Lys	Asp	Lys	Ala	Phe	Glu
			35						40					45
Leu	Glu	Leu	Ser	Trp	Val	Gly	Glu	Cys	Lys	Leu	Phe	Leu	Tyr	Ile
			50						55					60
Tyr	Leu	Pro												

&lt;210&gt; 2

&lt;211&gt; 262

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 447484

```

<400> 2
Met Gly Arg Glu Ile Arg Ser Glu Glu Pro Glu Glu Ser Val Pro
 1          5          10          15
Phe Ser Cys Asp Trp Arg Lys Val Ala Gly Ala Ile Ser Pro Ile
          20          25          30
Lys Asp Gln Lys Asn Cys Asn Cys Cys Trp Ala Met Ala Ala Ala
          35          40          45
Gly Asn Ile Glu Thr Leu Trp Arg Ile Ser Phe Trp Asp Phe Val
          50          55          60
Asp Val Ser Val Gln Glu Leu Leu Asp Cys Gly Arg Cys Gly Asp
          65          70          75
Gly Cys His Gly Gly Phe Val Trp Asp Ala Phe Ile Thr Val Leu
          80          85          90
Asn Asn Ser Gly Leu Ala Ser Glu Lys Asp Tyr Pro Phe Gln Gly
          95          100          105
Lys Val Arg Ala His Arg Cys His Pro Lys Lys Tyr Gln Lys Val
          110          115          120
Ala Trp Ile Gln Asp Phe Ile Met Leu Gln Asn Asn Glu His Arg
          125          130          135
Ile Ala Gln Tyr Leu Ala Thr Tyr Gly Pro Ile Thr Val Thr Ile
          140          145          150
Asn Met Lys Pro Leu Gln Leu Tyr Arg Lys Gly Val Ile Lys Ala
          155          160          165
Thr Pro Thr Thr Cys Asp Pro Gln Leu Val Asp His Ser Val Leu
          170          175          180
Leu Val Gly Phe Gly Ser Val Lys Ser Glu Glu Gly Ile Trp Ala
          185          190          195
Glu Thr Val Ser Ser Gln Ser Gln Pro Gln Pro Pro His Pro Thr
          200          205          210
Pro Tyr Trp Ile Leu Lys Asn Ser Trp Gly Ala Gln Trp Gly Glu
          215          220          225
Lys Gly Tyr Phe Arg Leu His Arg Gly Ser Asn Thr Cys Gly Ile
          230          235          240
Thr Lys Phe Pro Leu Thr Ala Arg Val Gln Lys Pro Asp Met Lys
          245          250          255
Pro Arg Val Ser Cys Pro Pro
          260

```

```

<210> 3
<211> 314
<212> PRT
<213> Homo sapiens

```

```

<220> -
<223> 789927

```

```

<400> 3
Met Gly Ala Arg Gly Ala Leu Leu Leu Ala Leu Leu Leu Ala Arg
 1          5          10          15
Ala Gly Leu Arg Lys Pro Glu Ser Gln Glu Ala Ala Pro Leu Ser
          20          25          30
Gly Pro Cys Gly Arg Arg Val Ile Thr Ser Arg Ile Val Gly Gly
          35          40          45

```



Glu	Asp	Ala	Glu	Leu	Gly	Arg	Trp	Pro	Trp	Gln	Gly	Ser	Leu	Arg	50	55	60
Leu	Trp	Asp	Ser	His	Val	Cys	Gly	Val	Ser	Leu	Leu	Ser	His	Arg	65	70	75
Trp	Ala	Leu	Thr	Ala	Ala	His	Cys	Phe	Glu	Thr	Tyr	Ser	Asp	Leu	80	85	90
Ser	Asp	Pro	Ser	Gly	Trp	Met	Val	Gln	Phe	Gly	Gln	Leu	Thr	Ser	95	100	105
Met	Pro	Ser	Phe	Trp	Ser	Leu	Gln	Ala	Tyr	Tyr	Thr	Arg	Tyr	Phe	110	115	120
Val	Ser	Asn	Ile	Tyr	Leu	Ser	Pro	Arg	Tyr	Leu	Gly	Asn	Ser	Pro	125	130	135
Tyr	Asp	Ile	Ala	Leu	Val	Lys	Leu	Ser	Ala	Pro	Val	Thr	Tyr	Thr	140	145	150
Lys	His	Ile	Gln	Pro	Ile	Cys	Leu	Gln	Ala	Ser	Thr	Phe	Glu	Phe	155	160	165
Glu	Asn	Arg	Thr	Asp	Cys	Trp	Val	Thr	Gly	Trp	Gly	Tyr	Ile	Lys	170	175	180
Glu	Asp	Glu	Ala	Leu	Pro	Ser	Pro	His	Thr	Leu	Gln	Glu	Val	Gln	185	190	195
Val	Ala	Ile	Ile	Asn	Asn	Ser	Met	Cys	Asn	His	Leu	Phe	Leu	Lys	200	205	210
Tyr	Ser	Phe	Arg	Lys	Asp	Ile	Phe	Gly	Asp	Met	Val	Cys	Ala	Gly	215	220	225
Asn	Ala	Gln	Gly	Gly	Lys	Asp	Ala	Cys	Phe	Gly	Asp	Ser	Gly	Gly	230	235	240
Pro	Leu	Ala	Cys	Asn	Lys	Asn	Gly	Leu	Trp	Tyr	Gln	Ile	Gly	Val	245	250	255
Val	Ser	Trp	Gly	Val	Gly	Cys	Gly	Arg	Pro	Asn	Arg	Pro	Gly	Val	260	265	270
Tyr	Thr	Asn	Ile	Ser	His	His	Phe	Glu	Trp	Ile	Gln	Lys	Leu	Met	275	280	285
Ala	Gln	Ser	Gly	Met	Ser	Gln	Pro	Asp	Pro	Ser	Trp	Pro	Leu	Leu	290	295	300
Phe	Phe	Pro	Leu	Leu	Trp	Ala	Leu	Pro	Leu	Leu	Gly	Pro	Val		305	310	

&lt;210&gt; 4

&lt;211&gt; 420

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 877617

&lt;400&gt; 4

Met	Ser	Pro	Pro	Pro	Leu	Leu	Gln	Pro	Leu	Leu	Leu	Leu	Leu	Pro	1	5	10	15
Leu	Leu	Asn	Val	Glu	Pro	Ser	Gly	Ala	Thr	Leu	Ile	Arg	Ile	Pro	20	25	30	
Leu	His	Arg	Val	Gln	Pro	Gly	Arg	Arg	Thr	Leu	Asn	Leu	Leu	Arg	35	40	45	
Gly	Trp	Arg	Glu	Pro	Ala	Glu	Leu	Pro	Lys	Leu	Gly	Ala	Pro	Ser				

Pro Gly Asp Lys	50	Pro Ile Phe Val	55	Ser Asn Tyr Arg	60
	65-		70		75
Val Gln Tyr Phe	80	Gly Glu Ile Gly	85	Thr Pro Pro Gln	90
	95		100		105
Phe Thr Val Ala	110	Phe Asp Thr Gly	115	Ser Asn Leu Trp	120
	125		130		135
Ser Arg Arg Cys	140	His Phe Phe Ser	145	Val Pro Cys Trp	150
	155		160		165
Arg Phe Asp Pro	170	Lys Ala Ser Ser	175	Ser Phe Gln Ala	180
	185		190		195
Lys Phe Ala Ile	200	Gln Tyr Gly Thr	205	Gly Arg Val Asp	210
	215		220		225
Ser Glu Asp Lys	230	Leu Thr Ile Gly	235	Gly Ile Leu	240
	245		250		255
Ile Phe Gly Glu	260	Ala Leu Trp Glu	265	Pro Ser Leu Val	270
	275		280		285
Ala His Phe Asp	290	Gly Ile Leu Gly	295	Leu Phe Pro Ile	300
	305		310		315
Val Glu Gly Val	320	Arg Pro Pro Met	325	Asp Val Leu Val	330
	335		340		345
Leu Leu Asp Lys	350	Pro Val Phe Ser	355	Phe Tyr Leu Asn	360
	365		370		375
Glu Glu Pro Asp	380	Gly Gly Glu Leu	385	Val Leu Gly Gly	390
	395		400		405
Ala His Tyr Ile	410	Pro Pro Leu Thr	415	Phe Val Pro Val	420
Ala Tyr Trp Gln		Ile His Met Glu		Arg Val Lys Val	
Leu Thr Leu Cys		Ala Lys Gly Cys		Ala Ile Leu Asp	
Thr Ser Leu Ile		Thr Gly Pro Thr		Glu Glu Ile Arg	
Ala Ala Ile Gly		Gly Ile Pro Leu		Leu Ala Gly Glu	
Leu Cys Ser Glu		Ile Pro Lys Leu		Pro Ala Val Ser	
Gly Gly Val Trp		Phe Asn Leu Thr		Ala His Asp Tyr	
Thr Thr Arg Asn		Gly Val Arg Leu		Cys Leu Ser Gly	
Leu Asp Val Pro		Pro Pro Ala Gly		Pro Phe Trp Ile	
Val Phe Leu Gly		Thr Tyr Val Ala		Val Phe Asp Arg	
Lys Ser Ser Ala		Arg Val Gly Leu		Ala Arg Thr Arg	
Ala Asp Leu Gly		Trp Gly Glu Thr		Ala Gln Ala Gln	

<210> 5  
 <211> 200  
 <212> PRT

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 999322

&lt;400&gt; 5

Met	Cys	Glu	Leu	Met	Tyr	His	Leu	Gly	Glu	Pro	Ser	Leu	Ala	Gly
1				5					10					15
Gln	Arg	Leu	Ile	Gln	Asp	Asp	Met	Leu	Cys	Ala	Gly	Ser	Val	Gln
				20					25					30
Gly	Lys	Lys	Asp	Ser	Cys	Gln	Val	Thr	Ala	Ala	Pro	Gly	His	Pro
				35					40					45
Ile	Gln	Leu	Cys	Gly	Pro	Phe	Arg	Leu	Thr	Leu	Ser	Trp	Thr	Phe
				50					55					60
Ser	Pro	Cys	Pro	Thr	Pro	Gln	Gly	Leu	Gln	Arg	Asp	Gln	Ser	Pro
				65					70					75
Cys	Leu	Ala	Pro	Trp	Pro	Gln	Gln	Leu	Ile	Leu	Glu	Gly	Thr	Trp
				80					85					90
Gly	Pro	Gly	Val	Ser	Leu	Asn	Ala	Asp	Leu	Met	Gly	Pro	Ser	Leu
				95					100					105
Ser	Leu	Pro	Gln	Gly	Asp	Ser	Gly	Gly	Pro	Leu	Val	Cys	Pro	Ile
				110					115					120
Asn	Asp	Thr	Trp	Ile	Gln	Ala	Gly	Ile	Val	Ser	Trp	Gly	Phe	Gly
				125					130					135
Cys	Ala	Arg	Pro	Phe	Arg	Pro	Gly	Val	Tyr	Thr	Gln	Val	Leu	Ser
				140					145					150
Tyr	Thr	Asp	Trp	Ile	Gln	Arg	Thr	Leu	Ala	Glu	Ser	His	Ser	Gly
				155					160					165
Met	Ser	Gly	Ala	Arg	Pro	Gly	Ala	Pro	Gly	Ser	His	Ser	Gly	Thr
				170					175					180
Ser	Arg	Ser	His	Pro	Val	Leu	Leu	Leu	Glu	Leu	Leu	Thr	Val	Cys
				185					190					195
Leu	Leu	Gly	Ser	Leu										
				200										

&lt;210&gt; 6

&lt;211&gt; 435

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 1337018

&lt;400&gt; 6

Met	Asp	Pro	Asp	Ser	Asp	Gln	Pro	Leu	Asn	Ser	Leu	Asp	Val	Lys
1				5					10					15
Pro	Leu	Arg	Lys	Pro	Arg	Ile	Pro	Met	Glu	Thr	Phe	Arg	Lys	Val
				20					25					30
Gly	Ile	Pro	Ile	Ile	Ile	Ala	Leu	Leu	Ser	Leu	Ala	Ser	Ile	Ile
				35					40					45
Ile	Val	Val	Val	Leu	Ile	Lys	Val	Ile	Leu	Asp	Lys	Tyr	Tyr	Phe
				50					55					60
Leu	Cys	Gly	Gln	Pro	Leu	His	Phe	Ile	Pro	Arg	Lys	Gln	Leu	Cys

Asp Gly Glu Leu	65	Glu Asp Glu Glu His Cys	70	75
Val Lys Ser Phe	80	Val Ala Val Arg Leu Ser	85	90
Lys Asp Arg Ser	95	Leu Asp Ser Ala Thr Gly Asn	100	105
Trp Phe Ser Ala	110	Thr Glu Ala Leu Ala Glu	115	120
Thr Ala Cys Arg	125	Ser Lys Pro Thr Phe Arg	130	135
Ala Val Glu Ile	140	Leu Asp Val Val Glu Ile	145	150
Thr Glu Asn Ser	155	Arg Asn Ser Ser Gly Pro	160	165
Cys Leu Ser Gly	170	His Cys Leu Ala Cys Gly	175	180
Glu Ser Leu Lys	185	Gly Gly Glu Glu Ala Ser	190	195
Val Asp Ser Trp	200	Ile Gln Tyr Asp Lys Gln	205	210
His Val Cys Gly	215	Pro His Trp Val Leu Thr	220	225
Ala Ala His Cys	230	Asp Val Phe Asn Trp Lys	235	240
Val Arg Ala Gly	245	Ser Phe Pro Ser Leu Ala	250	255
Val Ala Lys Ile	260	Asn Pro Met Tyr Pro Lys	265	270
Asp Asn Asp Ile	275	Ala Gln Phe Pro Leu Thr Phe	280	285
Ser Gly Thr Val	290	Pro Phe Phe Asp Glu Glu	295	300
Leu Thr Pro Ala	305	Ile Gly Trp Gly Phe Thr	310	315
Lys Gln Asn Gly	320	Ile Leu Leu Gln Ala Ser	325	330
Val Gln Val Ile	335	Asn Ala Asp Asp Ala Tyr	340	345
Gln Gly Glu Val	350	Cys Ala Gly Ile Pro Glu	355	360
Gly Gly Val Asp	365	Ser Gly Gly Pro Leu Met	370	375
Tyr Gln Ser Asp	380	Gly Ile Val Ser Trp Gly	385	390
Tyr Gly Cys Gly	395	Gly Val Tyr Thr Lys Val	400	405
Ser Ala Tyr Leu	410	Val Trp Lys Ala Glu Leu	415	420
	425		430	435

&lt;210&gt; 7

&lt;211&gt; 260

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 1798496

&lt;400&gt; 7

Met	Gly	Arg	Pro	Arg	Pro	Arg	Ala	Ala	Lys	Thr	Trp	Met	Phe	Leu
1				5					10					15
Leu	Leu	Leu	Gly	Gly	Ala	Trp	Ala	Gly	His	Ser	Arg	Ala	Gln	Glu
				20					25					30
Asp	Lys	Val	Leu	Gly	Gly	His	Glu	Cys	Gln	Pro	His	Ser	Gln	Pro
				35					40					45
Trp	Gln	Ala	Ala	Leu	Ser	Gln	Gly	Gln	Gln	Leu	Leu	Cys	Gly	Gly
				50					55					60
Val	Leu	Val	Gly	Gly	Asn	Trp	Val	Leu	Thr	Ala	Ala	His	Cys	Lys
				65					70					75
Lys	Pro	Lys	Tyr	Thr	Val	Arg	Leu	Gly	Asp	His	Ser	Leu	Gln	Asn
				80					85					90
Lys	Asp	Gly	Pro	Glu	Gln	Glu	Ile	Pro	Val	Val	Gln	Ser	Ile	Pro
				95					100					105
His	Pro	Cys	Tyr	Asn	Ser	Ser	Asp	Val	Glu	Asp	His	Asn	His	Asp
				110					115					120
Leu	Met	Leu	Leu	Gln	Leu	Arg	Asp	Gln	Ala	Ser	Leu	Gly	Ser	Lys
				125					130					135
Val	Lys	Pro	Ile	Ser	Leu	Ala	Asp	His	Cys	Thr	Gln	Pro	Gly	Gln
				140					145					150
Lys	Cys	Thr	Val	Ser	Gly	Trp	Gly	Thr	Val	Thr	Ser	Pro	Arg	Glu
				155					160					165
Asn	Phe	Pro	Asp	Thr	Leu	Asn	Cys	Ala	Glu	Val	Lys	Ile	Phe	Pro
				170					175					180
Gln	Lys	Lys	Cys	Glu	Asp	Ala	Tyr	Pro	Gly	Gln	Ile	Thr	Asp	Gly
				185					190					195
Met	Val	Cys	Ala	Gly	Ser	Ser	Lys	Gly	Ala	Asp	Thr	Cys	Gln	Gly
				200					205					210
Asp	Ser	Gly	Gly	Pro	Leu	Val	Cys	Asp	Gly	Ala	Leu	Gln	Gly	Ile
				215					220					225
Thr	Ser	Trp	Gly	Ser	Asp	Pro	Cys	Gly	Arg	Ser	Asp	Lys	Pro	Gly
				230					235					240
Val	Tyr	Thr	Asn	Ile	Cys	Arg	Tyr	Leu	Asp	Trp	Ile	Lys	Lys	Ile
				245					250					255
Ile	Gly	Ser	Lys	Gly										
				260										

&lt;210&gt; 8

&lt;211&gt; 175

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 2082147

&lt;400&gt; 8

Met	Ala	Gln	Ser	Gln	Gly	Trp	Val	Lys	Arg	Tyr	Ile	Lys	Ala	Phe
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

1	5	10	15
Cys Lys Gly Phe Phe Val Ala Val Pro Val Ala Val Thr Phe Leu			
20	25	30	
Asp Arg Val Ala Cys Val Ala Arg Val Glu Gly Ala Ser Met Gln			
35	40	45	
Pro Ser Leu Asn Pro Gly Gly Ser Gln Ser Ser Asp Val Val Leu			
50	55	60	
Leu Asn His Trp Lys Val Arg Asn Phe Glu Val His Arg Gly Asp			
65	70	75	
Ile Val Ser Leu Val Ser Pro Lys Asn Pro Glu Gln Lys Ile Ile			
80	85	90	
Lys Arg Val Ile Ala Leu Glu Gly Asp Ile Val Arg Thr Ile Gly			
95	100	105	
His Lys Asn Arg Tyr Val Lys Val Pro Arg Gly His Ile Trp Val			
110	115	120	
Glu Gly Asp His His Gly His Ser Phe Asp Ser Asn Ser Phe Gly			
125	130	135	
Pro Val Ser Leu Gly Leu Leu His Ala His Ala Thr His Ile Leu			
140	145	150	
Trp Pro Pro Glu Arg Trp Gln Lys Leu Glu Ser Val Leu Pro Pro			
155	160	165	
Glu Arg Leu Pro Val Gln Arg Glu Glu Glu			
170	175		

&lt;210&gt; 9

&lt;211&gt; 519

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 2170967

&lt;400&gt; 9

Met Phe Leu Leu Pro Leu Pro Ala Ala Gly Arg Val Val Val Arg		
1	5	10
Arg Leu Ala Val Arg Arg Phe Gly Ser Arg Ser Leu Ser Thr Ala		
20	25	30
Asp Met Thr Lys Gly Leu Val Leu Gly Ile Tyr Ser Lys Glu Lys		
35	40	45
Glu Asp Asp Val Pro Gln Phe Thr Ser Ala Gly Glu Asn Phe Asp		
50	55	60
Lys Leu Leu Ala Gly Lys Leu Arg Glu Thr Leu Asn Ile Ser Gly		
65	70	75
Pro Pro Leu Lys Ala Gly Lys Thr Arg Thr Phe Tyr Gly Leu His		
80	85	90
Gln Asp Phe Pro Ser Val Val Leu Val Gly Leu Gly Lys Lys Ala		
95	100	105
Ala Gly Ile Asp Glu Gln Glu Asn Trp His Glu Gly Lys Glu Asn		
110	115	120
Ile Arg Ala Ala Val Ala Ala Gly Cys Arg Gln Ile Gln Asp Leu		
125	130	135
Glu Leu Ser Ser Val Glu Val Asp Pro Cys Gly Asp Ala Gln Ala		
140	145	150

Ala	Ala	Glu	Gly	Ala	Val	Leu	Gly	Leu	Tyr	Glu	Tyr	Asp	Asp	Leu	155	160	165
Lys	Gln	Lys	Lys	Lys	Met	Ala	Val	Ser	Ala	Lys	Leu	Tyr	Gly	Ser	170	175	180
Gly	Asp	Gln	Glu	Ala	Trp	Gln	Lys	Gly	Val	Leu	Phe	Ala	Ser	Gly	185	190	195
Gln	Asn	Leu	Ala	Arg	Gln	Leu	Met	Glu	Thr	Pro	Ala	Asn	Glu	Met	200	205	210
Thr	Pro	Thr	Arg	Phe	Ala	Glu	Ile	Ile	Glu	Lys	Asn	Leu	Lys	Ser	215	220	225
Ala	Ser	Ser	Lys	Thr	Glu	Val	His	Ile	Arg	Pro	Lys	Ser	Trp	Ile	230	235	240
Glu	Glu	Gln	Ala	Met	Gly	Ser	Phe	Leu	Ser	Val	Ala	Lys	Gly	Ser	245	250	255
Asp	Glu	Pro	Pro	Val	Phe	Leu	Glu	Ile	His	Tyr	Lys	Gly	Ser	Pro	260	265	270
Asn	Ala	Asn	Glu	Pro	Pro	Leu	Val	Phe	Val	Gly	Lys	Gly	Ile	Thr	275	280	285
Phe	Asp	Ser	Gly	Gly	Ile	Ser	Ile	Lys	Ala	Ser	Ala	Asn	Met	Asp	290	295	300
Leu	Met	Arg	Ala	Asp	Met	Gly	Gly	Ala	Ala	Thr	Ile	Cys	Ser	Ala	305	310	315
Ile	Val	Ser	Ala	Ala	Lys	Leu	Asn	Leu	Pro	Ile	Asn	Ile	Ile	Gly	320	325	330
Leu	Ala	Pro	Leu	Cys	Glu	Asn	Met	Pro	Ser	Gly	Lys	Ala	Asn	Lys	335	340	345
Pro	Gly	Asp	Val	Val	Arg	Ala	Lys	Asn	Gly	Lys	Thr	Ile	Gln	Val	350	355	360
Asp	Asn	Thr	Asp	Ala	Glu	Gly	Arg	Leu	Ile	Leu	Ala	Asp	Ala	Leu	365	370	375
Cys	Tyr	Ala	His	Thr	Phe	Asn	Pro	Lys	Val	Ile	Leu	Asn	Ala	Ala	380	385	390
Thr	Leu	Thr	Gly	Ala	Met	Asp	Val	Ala	Leu	Gly	Ser	Gly	Ala	Thr	395	400	405
Gly	Val	Phe	Thr	Asn	Ser	Ser	Trp	Leu	Trp	Asn	Lys	Leu	Phe	Glu	410	415	420
Ala	Ser	Ile	Glu	Thr	Gly	Asp	Arg	Val	Trp	Arg	Met	Pro	Leu	Phe	425	430	435
Glu	His	Tyr	Thr	Arg	Gln	Val	Val	Asp	Cys	Gln	Leu	Ala	Asp	Val	440	445	450
Asn	Asn	Ile	Gly	Lys	Tyr	Arg	Ser	Ala	Gly	Ala	Cys	Thr	Ala	Ala	455	460	465
Ala	Phe	Leu	Lys	Glu	Phe	Val	Thr	His	Pro	Lys	Trp	Ala	His	Leu	470	475	480
Asp	Ile	Ala	Gly	Val	Met	Thr	Asn	Lys	Asp	Glu	Val	Pro	Tyr	Leu	485	490	495
Arg	Lys	Gly	Met	Thr	Gly	Arg	Pro	Thr	Arg	Thr	Leu	Ile	Glu	Phe	500	505	510
Leu	Leu	Arg	Phe	Ser	Gln	Asp	Asn	Ala							515		

&lt;210&gt; 10

&lt;211&gt; 327

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 2484218

&lt;400&gt; 10

```

Met Ala Ala Ala Ala Ala Ala Ala Ala Ala Thr Asn Gly Thr Gly
  1          5          10          15
Gly Ser Ser Gly Met Glu Val Asp Ala Ala Val Val Pro Ser Val
          20          25          30
Met Ala Cys Gly Val Thr Gly Ser Val Ser Val Ala Leu His Pro
          35          40          45
Leu Val Ile Leu Asn Ile Ser Asp His Trp Ile Arg Met Arg Ser
          50          55          60
Gln Glu Gly Arg Pro Val Gln Val Ile Gly Ala Leu Ile Gly Lys
          65          70          75
Gln Glu Gly Arg Asn Ile Glu Val Met Asn Ser Phe Glu Leu Leu
          80          85          90
Ser His Thr Val Glu Glu Lys Ile Ile Ile Asp Lys Glu Tyr Tyr
          95          100          105
Tyr Thr Lys Glu Glu Gln Phe Lys Gln Val Phe Lys Glu Leu Glu
          110          115          120
Phe Leu Gly Trp Tyr Thr Thr Gly Gly Pro Pro Asp Pro Ser Asp
          125          130          135
Ile His Val His Lys Gln Val Cys Glu Ile Ile Glu Ser Pro Leu
          140          145          150
Phe Leu Lys Leu Asn Pro Met Thr Lys His Thr Asp Leu Pro Val
          155          160          165
Ser Val Phe Glu Ser Val Ile Asp Ile Ile Asn Gly Glu Ala Thr
          170          175          180
Met Leu Phe Ala Glu Leu Thr Tyr Thr Leu Ala Thr Glu Glu Ala
          185          190          195
Glu Arg Ile Gly Val Asp His Val Ala Arg Met Thr Ala Thr Gly
          200          205          210
Ser Gly Glu Asn Ser Thr Val Ala Glu His Leu Ile Ala Gln His
          215          220          225
Ser Ala Ile Lys Met Leu His Ser Arg Val Lys Leu Ile Leu Glu
          230          235          240
Tyr Val Lys Ala Ser Glu Ala Gly Glu Val Pro Phe Asn His Glu
          245          250          255
Ile Leu Arg Glu Ala Tyr Ala Leu Cys His Cys Leu Pro Val Leu
          260          265          270
Ser Thr Asp Lys Phe Lys Thr Asp Phe Tyr Asp Gln Cys Asn Asp
          275          280          285
Val Gly Leu Met Ala Tyr Leu Gly Thr Ile Thr Lys Thr Cys Asn
          290          295          300
Thr Met Asn Gln Phe Val Asn Lys Phe Asn Val Leu Tyr Asp Arg
          305          310          315
Gln Gly Ile Gly Arg Arg Met Arg Gly Leu Phe Phe
          320          325

```

&lt;210&gt; 11



&lt;211&gt; 458

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 2680548

&lt;400&gt; 11

Met	Ala	Ala	Pro	Arg	Ala	Gly	Arg	Gly	Ala	Gly	Trp	Ser	Leu	Arg	1	5	10	15
Ala	Trp	Arg	Ala	Leu	Gly	Gly	Ile	Arg	Trp	Gly	Arg	Arg	Pro	Arg	20	25	30	
Leu	Thr	Pro	Asp	Leu	Arg	Ala	Leu	Leu	Thr	Ser	Gly	Thr	Ser	Asp	35	40	45	
Pro	Arg	Ala	Arg	Val	Thr	Tyr	Gly	Thr	Pro	Ser	Leu	Trp	Ala	Arg	50	55	60	
Leu	Ser	Val	Gly	Val	Thr	Glu	Pro	Arg	Ala	Cys	Leu	Thr	Ser	Gly	65	70	75	
Thr	Pro	Gly	Pro	Arg	Ala	Gln	Leu	Thr	Ala	Val	Thr	Pro	Asp	Thr	80	85	90	
Arg	Thr	Arg	Glu	Ala	Ser	Glu	Asn	Ser	Gly	Thr	Arg	Ser	Arg	Ala	95	100	105	
Trp	Leu	Ala	Val	Ala	Leu	Gly	Ala	Gly	Gly	Ala	Val	Leu	Leu	Leu	110	115	120	
Leu	Trp	Gly	Gly	Gly	Arg	Gly	Pro	Pro	Ala	Val	Leu	Ala	Ala	Val	125	130	135	
Pro	Ser	Pro	Pro	Pro	Ala	Ser	Pro	Arg	Ser	Gln	Tyr	Asn	Phe	Ile	140	145	150	
Ala	Asp	Val	Val	Glu	Lys	Thr	Ala	Pro	Ala	Val	Val	Tyr	Ile	Glu	155	160	165	
Ile	Leu	Asp	Arg	His	Pro	Phe	Leu	Gly	Arg	Glu	Val	Pro	Ile	Ser	170	175	180	
Asn	Gly	Ser	Gly	Phe	Val	Val	Ala	Ala	Asp	Gly	Leu	Ile	Val	Thr	185	190	195	
Asn	Ala	His	Val	Val	Ala	Asp	Arg	Arg	Arg	Val	Arg	Val	Arg	Leu	200	205	210	
Leu	Ser	Gly	Asp	Thr	Tyr	Glu	Ala	Val	Val	Thr	Ala	Val	Asp	Pro	215	220	225	
Val	Ala	Asp	Ile	Ala	Thr	Leu	Arg	Ile	Gln	Thr	Lys	Glu	Pro	Leu	230	235	240	
Pro	Thr	Leu	Pro	Leu	Gly	Arg	Ser	Ala	Asp	Val	Arg	Gln	Gly	Glu	245	250	255	
Phe	Val	Val	Ala	Met	Gly	Ser	Pro	Phe	Ala	Leu	Gln	Asn	Thr	Ile	260	265	270	
Thr	Ser	Gly	Ile	Val	Ser	Ser	Ala	Gln	Arg	Pro	Ala	Arg	Asp	Leu	275	280	285	
Gly	Leu	Pro	Gln	Thr	Asn	Val	Glu	Tyr	Ile	Gln	Thr	Asp	Ala	Ala	290	295	300	
Ile	Asp	Phe	Gly	Asn	Ser	Gly	Gly	Pro	Leu	Val	Asn	Leu	Asp	Gly	305	310	315	
Glu	Val	Ile	Gly	Val	Asn	Thr	Met	Lys	Val	Thr	Ala	Gly	Ile	Ser	320	325	330	
Phe	Ala	Ile	Pro	Ser	Asp	Arg	Leu	Arg	Glu	Phe	Leu	His	Arg	Gly	335	340	345	
Glu	Lys	Lys	Asn	Ser	Ser	Ser	Gly	Ile	Ser	Gly	Ser	Gln	Arg	Arg	350	355	360	

```

Tyr Ile Gly Val Met Met Leu Thr Leu Ser Pro Ser Ile Leu Ala
      365                      370                      375
Glu Leu Gln Leu Arg Glu Pro Ser Phe Pro Asp Val Gln His Gly
      380                      385                      390
Val Leu Ile His Lys Val Ile Leu Gly Ser Pro Ala His Arg Ala
      395                      400                      405
Gly Leu Arg Pro Gly Asp Val Ile Leu Ala Ile Gly Glu Gln Met
      410                      415                      420
Val Gln Asn Ala Glu Asp Val Tyr Glu Ala Val Arg Thr Gln Ser
      425                      430                      435
Gln Leu Ala Val Gln Ile Arg Arg Gly Arg Glu Thr Leu Thr Leu
      440                      445                      450
Tyr Val Thr Pro Glu Val Thr Glu
      455

```

<210> 12  
 <211> 532  
 <212> PRT  
 <213> Homo sapiens

<220> -  
 <223> 2957969

```

<400> 12
Met Leu Gly Ala Trp Ala Gly Arg Lys Met Ala Asn Val Gly Leu
  1      5      10      15
Gln Phe Gln Ala Ser Ala Gly Asp Ser Asp Pro Gln Ser Arg Pro
      20      25      30
Leu Leu Leu Leu Gly Gln Leu His His Leu His Arg Val Pro Trp
      35      40      45
Ser His Val Arg Gly Lys Leu Gln Pro Arg Val Thr Glu Glu Leu
      50      55      60
Trp Gln Ala Ala Leu Ser Thr Leu Asn Pro Asn Pro Thr Asp Ser
      65      70      75
Cys Pro Leu Tyr Leu Asn Tyr Ala Thr Val Ala Ala Leu Pro Cys
      80      85      90
Arg Val Ser Arg His Asn Ser Pro Ser Ala Ala His Phe Ile Thr
      95     100     105
Arg Leu Val Arg Thr Cys Leu Pro Pro Gly Ala His Arg Cys Ile
      110     115     120
Val Met Val Cys Glu Gln Pro Glu Val Phe Ala Ser Ala Cys Ala
      125     130     135
Leu Ala Arg Ala Phe Pro Leu Phe Thr His Arg Ser Gly Ala Ser
      140     145     150
Arg Arg Leu Glu Lys Lys Thr Val Thr Val Glu Phe Phe Leu Val
      155     160     165
Gly Gln Asp Asn Gly Pro Val Glu Val Ser Thr Leu Gln Cys Leu
      170     175     180
Ala Asn Ala Thr Asp Gly Val Arg Leu Ala Ala Arg Ile Val Asp
      185     190     195
Thr Pro Cys Asn Glu Met Asn Thr Asp Thr Phe Leu Glu Glu Ile
      200     205     210
Asn Lys Val Gly Lys Glu Leu Gly Ile Ile Pro Thr Ile Ile Arg

```

	215		220		225
Asp Glu Glu Leu	Lys Thr Arg Gly Phe	Gly Gly Ile Tyr Gly	Val		
	230		235		240
Gly Lys Ala Ala	Leu His Pro Pro Ala	Leu Ala Val Leu Ser	His		
	245		250		255
Thr Pro Asp Gly	Ala Thr Gln Thr Ile	Ala Trp Val Gly Lys	Gly		
	260		265		270
Ile Val Tyr Asp	Thr Gly Gly Leu Ser	Ile Lys Gly Lys Thr	Thr		
	275		280		285
Met Pro Gly Met	Lys Arg Asp Cys Gly	Gly Ala Ala Ala Val	Leu		
	290		295		300
Gly Ala Phe Arg	Ala Ala Ile Lys Gln	Gly Phe Lys Asp Asn	Leu		
	305		310		315
His Ala Val Phe	Cys Leu Ala Glu Asn	Ser Val Gly Pro Asn	Ala		
	320		325		330
Thr Arg Pro Asp	Asp Ile His Leu Leu	Tyr Ser Gly Lys Thr	Val		
	335		340		345
Glu Ile Asn Asn	Thr Asp Ala Glu Gly	Arg Leu Val Leu Ala	Asp		
	350		355		360
Gly Val Ser Tyr	Ala Cys Lys Asp Leu	Gly Ala Asp Ile Ile	Leu		
	365		370		375
Asp Met Ala Thr	Leu Thr Gly Ala Gln	Gly Ile Ala Thr Gly	Lys		
	380		385		390
Tyr His Ala Ala	Val Leu Thr Asn Ser	Ala Glu Trp Glu Ala	Ala		
	395		400		405
Cys Val Lys Ala	Gly Arg Lys Cys Gly	Asp Leu Val His Pro	Leu		
	410		415		420
Val Tyr Cys Pro	Glu Leu His Phe Ser	Glu Phe Thr Ser Ala	Val		
	425		430		435
Ala Asp Met Lys	Asn Ser Val Ala Asp	Arg Asp Asn Ser Pro	Ser		
	440		445		450
Ser Cys Ala Gly	Leu Phe Ile Ala Ser	His Ile Gly Phe Asp	Trp		
	455		460		465
Pro Gly Val Trp	Val His Leu Asp Ile	Ala Ala Pro Val His	Ala		
	470		475		480
Gly Glu Arg Ala	Thr Gly Phe Gly Val	Ala Leu Leu Leu Ala	Leu		
	485		490		495
Phe Gly Arg Ala	Ser Glu Asp Pro Leu	Leu Asn Leu Val Ser	Pro		
	500		505		510
Leu Gly Cys Glu	Val Asp Val Glu Glu	Gly Asp Val Gly Arg	Asp		
	515		520		525
Ser Lys Arg Arg	Arg Leu Val				
	530				

&lt;210&gt; 13

&lt;211&gt; 1542

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 135360

&lt;400&gt; 13

```

atattctaaa agggcacagt taatgacgcc tcttcctagt gaatccgtgt tctttatgag 60
gtatctttta tagttgtatc tttttttttt tctgagatgg agtctcgtcc tactgtagcc 120
caggatggag tgcagtagtg tgatcttggc tcaactgcaac ccctgcctcc cgggttcaag 180
gaattctcct gccttagcct cctgagtagc tgagattaca ggcgccacc accacacctg 240
gctgattttt gtttcttagt agagacaggg tttcaccatg ttggccaggc tagtctcgaa 300
ctgacctcaa gtgatccatc cgccttgggc tcccaaagtg ttgggattac aggtgtgagc 360
cactgtgccc agccaagtta tatctctaaa gcaatgtgca aaaataaact gaacttgggt 420
tgattaggta tattcaacat ttgtcgggag agtagatgtt tcattttatt tcagtccttg 480
tgtaatttgt cttctctaact gttaaatact atgtagaatg tgtctgtgta attttataga 540
tactttttatt atggatggac attctaattt gtactgactt tgggtctgtg aactacttca 600
atgtttggag gttaccaaaa tcttaccttt cccttttcta ttctagaatt tacatagtac 660
atgacgaagt taaggataaaa gcttttgaac tagaactcag ctgggttggg gaatgtaagt 720
tattttttgta catttatttg ccttaggaat gatctgtacc acagctaatt tacaactgag 780
tgtcctttct aatataaatga aagctaaagc aaatttacta ggttgtctaa tgaagggaaa 840
gttctgctta ataattgact taagttgtga acacgttatt ttttgaaaca tccatttcat 900
ggttttaaga tactatgcta taaattaatg ctccaggatt ataaatagca taatttactt 960
tcatttccat aagaacttaa tatgtaggca catataatct catgtagaag cagcacacaa 1020
aaatattcga gtattactca tagtacaact ttgcaacctt aggtgagtca gatattgtgga 1080
ttgggtagat cctatgggat actgcaagtt acaatatggg actcaattta aaattcattt 1140
acacatgtgg cttaatttac agtaactaat ggaagacatg aaattgttcc aaaagatata 1200
agagaagaag cagagaaata tgctaaggta agccacagca caaaaacttc tcttgccag 1260
gtacagtcag ggaatctctt agcccaggag tttgagacca gcctgagcag cacagcaaga 1320
cccccatccc taatttaaaa aaaaaaaaaat tctctaacca aaattatgtg ttgaataata 1380
taaatagact ggggtggttt ctatgaaata aactgagag ttcagttgaa ctaaagatag 1440
aaattttcta gggtatctct agtgggtaaa gttgccttgg ttccaaaaaa aaaaaacttg 1500
ggaggttttag actgcaaaga gtttttttag acttctaata ct 1542

```

&lt;210&gt; 14

&lt;211&gt; 3043

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 447484

&lt;400&gt; 14

```

cccacgcgtc cggtaaatgg ctgtaataca ggaattttgc cacaaccagt tgggacagtc 60
ttgttgcaaa taccagaacc tcaagaatcg aacagtgcag caggaataaa tttaatagcc 120
cttcacagcat ttccacaggt ggaccttgag gtatttgctg cccttcctgc tgaacttcag 180
agggagctga aagcagcgta tgatcaaaaga caaaggcagg gcgagaacag cactcaccag 240
cagtcagcca gcgcactctgt gccaaagaat cctttacttc atctaaaggc agcagtgaag 300
gaaaagaaaa gaaacaagaa gaaaaaaacc attggttcac caaaaaggat tcagagtcct 360
ttgaataaca agctgcttaa cagtcctgca aaaactctgc caggggcctg tggcagtcct 420
cagaagttaa ttgatgggtt tctaaaacat gaaggacctc ctgcagagaa acccctggaa 480
gaactctctg cttctacttc aggtgtgcca ggcctttcta gtttgagtc tgacctgaa 540
ggctgtgtga gacctccagc acccaatcta gctggagctg ttgaattcaa tgatgtgaag 600
accttgctca gagaatggat aactacaatt tcagatccaa tgggaagaaga cattctccaa 660
gttggtgaaat actgtactga tctaataaga gaaaaagatt tggaaaaact ggatctagtt 720
ataaaataca tgaaaaggct gatgcagcaa tcggtggaat cggtttggaa tatggcattt 780
gactttattc ttgacaatgt ccagggtggt ttacaacaaa cttatggaag cacattaaaa 840
gttacataaa tattaccaga gagcctgatg ctctctgata gctgtgccat aagtgttgt 900
gaggtatttg caaagtgcag gatagtaatg ctcgagttt ttataatttt aaatttcttt 960
taaagcaagt gttttgtaca tttcttttca aaaagtgcc aatttgtcag tattgcatgt 1020
aaataattgt gttaattatt ttactgtagc atagattcta tttacaaaat gtttgtttat 1080
aaagttttat ggatttttac agtgaagtgt ttacagttgt ttaataaaga actgtatgta 1140

```

tattttgtac	aggctccttt	ttgtgaatcc	ttaaaaactc	aactctagga	agcaactact	1200
gtttattata	ctaaaaggct	gaaaaacctc	caggccagac	tgctaagctc	tgaaattcct	1260
gagaggtctc	agaccgggat	tctacttggt	ccaagaaagg	gtaaagcttc	taaaccatct	1320
tattcttgtc	tccaagcatg	aacacaggag	catgttaaga	aaatctttac	tacttcttcc	1380
atgcgagaaa	atctacatat	tttgaattag	aaacaccctc	acaccacctt	gaagattttt	1440
ttcctgggaa	cattatgtcc	cgtagatcag	aggtggtgtt	gtctttttgc	ttctactggc	1500
cattgagaaa	ctttgatgat	aaaaaagaac	ggtatagatt	tttcaaactg	atataaaaata	1560
tttttatggt	atatgttatg	ccataacttt	aaaataaaaa	tagtttaaaa	ttctatgcta	1620
gtggatattt	ggaacttttt	cctcaaacaa	acaccccaca	ctgacttcag	caaaacccta	1680
aaactactta	cagattactg	ctacgaatga	atcattaagt	tttgtgtctg	caacaattta	1740
gaagcactaa	gccccaatat	caggaaatgt	gtgtatgatg	gaatttttcta	ggacaaaaca	1800
gatcaagatt	aaaacagatc	aagattaatg	tataaaaaatg	tctactaaaa	cagatcaaga	1860
ttaaaacaga	tcaagattaa	tgtataaaaa	tctctactgt	taccaggtgc	tggcatacaa	1920
ggtagtgtga	tgatagttta	gtttgtaaga	taattcttgt	cctaggagga	caacttgtgg	1980
gagagaagct	acactaacat	ggaagccta	cagagcttgc	ttactgggtg	atgtctgttt	2040
tctttattgg	tagtttggtt	tagaattgtg	atgattacaa	tggactcgtg	actacacaag	2100
cagtaaaaag	cagccagctc	tatggctatc	ggagggcgag	tggaggggtc	cccagcatgg	2160
gcagagaaat	aaggtctgaa	gagccagagg	agtcagtacc	tttcagctgt	gactggcgga	2220
aggtggccgg	cgccatctca	cccatacagg	accagaaaaa	ctgcaactgc	tgctgggcca	2280
tggcagcggc	aggcaacata	gagaccctgt	ggcgcatcag	tttctgggat	tttgtggacg	2340
tctccgtgca	ggaactgctg	gactgtggcc	gctgtgggga	tggctgccac	ggtggcttcg	2400
tctgggacgc	gttcataact	gtcctcaaca	acagcggcct	ggccagtga	aaggactacc	2460
cgttccaggg	caaagtcaga	gcccacaggt	gccaccccaa	gaagtaccag	aaggtggcct	2520
ggatccagga	cttcacatg	ctgcagaaca	acgagcacag	aattgcgcag	tacctggcca	2580
cttatggccc	catcaccgtg	accatcaaca	tgaagccctt	tcagctatac	cggaaagggtg	2640
tgatcaaggc	cacaccacgc	acctgtgacc	cccagcttgt	ggaccactct	gtcctgtctg	2700
tgggttttgg	cagcgtcaag	tcagaggagg	ggatatgggc	agagacagtc	tcacgcagtc	2760
ctcagcctca	gcctccacac	cccaccccat	actggatcct	gaagaactcc	tggggggccc	2820
aatggggaga	gaagggttat	ttccggctgc	accgagggag	caatacctgt	ggcatcacca	2880
agttcccgtc	cactgcccgt	gtgcagaaac	cggatatgaa	gccccgagtc	tcctgccctc	2940
cctgaaccca	cctggccccc	tcagctctgt	cctgttaggc	caactgcctc	cttgccagcc	3000
ccacccccag	gtttttgccc	atcctcccaa	tctcaataca	ggg		3043

&lt;210&gt; 15

&lt;211&gt; 1081

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 789927

&lt;400&gt; 15

aggaggcaga	gggggcgtca	ggccgcggga	gaggaggcca	tgggcgcgcg	cggggcgctg	60
ctgctggcgc	tgctgctggc	tcgggctgga	ctcaggaagc	cggagtcgca	ggaggcggcg	120
cccttatcag	gaccatgcgg	ccgacgggtc	atcacgtcgc	gcatcgtggg	tggagaggac	180
gccgaactcg	ggcgttggcc	gtggcagggg	agcctgcgcc	tgtgggattc	ccacgtatgc	240
ggagtgaacc	tgctcagcca	ccgctgggca	ctcacggcgg	cgcactgctt	tgaaacctat	300
agtgaacctt	gtgatccctc	cgggtggatg	gtccagtttg	gccagctgac	ttccatgcca	360
tccttcttga	gcctgcagcg	ctactacacc	cgttactctg	tatcgaatat	ctatctgagc	420
cctcgctacc	tggggaattc	acctatgac	attgccttgg	tgaagcgtgc	tgcacctgtc	480
acctacacta	aacacatcca	gcccatctgt	ctccaggtcg	ccacatttga	gtttgagaac	540
cggacagact	gctgggtgac	tggctggggg	tacatcaaag	aggatgaggc	actgccatct	600
ccccacaccc	tccaggaagt	tcaggtcgcc	atcataaaca	actctatgtg	caaccacctc	660
ttcctcaagt	acagtttccg	caaggacatc	tttggagaca	tggtttgtgc	tggcaatgcc	720
caaggcggga	aggatgcctg	cttcgggtgac	tcaggtggac	ccttggcctg	taacaagaat	780

```

ggactgtggt atcagattgg agtcgtgagc tggggagtggt gctgtggtcg gccaatcgg 840
ccccgtgtct acaccaatat cagccaccac tttgagtgga tccagaagct gatggcccg 900
agtggcatgt cccagccaga cccctcctgg ccactactct tttccctct tctctgggct 960
ctcccactcc tggggccgggt ctgagcctac ctgagcccat gcagcctggg gccactgcca 1020
agtcaggccc tgggttctctt ctgtcttggt tggtaataaa cacattccag ttgatgctg 1080
c

```

&lt;210&gt; 16

&lt;211&gt; 2061

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 877617

&lt;400&gt; 16

```

cttgagagct ctcaaatact tggtcatgga tgaagccgac cgaataactga atatggattt 60
tgagacagag gttgacaagc ctcgagatcg gaaaacattc ctcttctctg ccaccatgac 120
caagaagggt caaaaacttc agcgagcagc tctgaagaat cctgtgaaat gtgccgtttc 180
ctctaaatac cagacagttg aaaaattaca gcaatattat atttttattc cctctaaatt 240
caaggatacc tacctgggtt atattctaaa tgaattggct ggaaactcct ttatgatatt 300
ctgcagcaoc tgaataataa cccagagAAC agctttgcta ctgcgaaatc ttggcttcac 360
tgccatcccc ctccatggac aaatgagtcA gagtaagcgc ctaggatccc ttaataagtt 420
taaggccaag gcccggtcca ttcttctagc aactgacgtt gccagccgag gtttggacat 480
acctcatgta gatgtggttg tcaactttga cattcctacc cattccaagg attacatcca 540
tcgagtaggt cgaacagcta gagctgggag ctccggaaag gctattactt ttgtcacaca 600
gtatgatgtg gaactcttcc agcgcataga acacttaatt gggaagaaac taccaggttt 660
tccaacacag gatgatgagg ttatgatgct gacagaacgc gtccccagcg atgtctccac 720
caccgtgct gcaacccctg ctgctgctgc tgcctctgct gaatgtggag ccttccgggg 780
ccacactgat ccgcattcct ctcatcgag tccaacctgg acgcaggacc ctgaacctac 840
tgaggggatg gagagaacca gcagagctcc ccaagttggg ggccccatcc ctgggggaca 900
agcccatctt cgtacctctc tgaactaca gggatgtgca gtattttggg gaaattgggc 960
tggaacgcc tccacaaaac ttactgttg cctttgacac tggctcctcc aatctctggg 1020
tcccgctccag gagatgccac ttcttcagtg tgcctgctg gttacaccac cgatttgatc 1080
ccaaagcctc tagctccttc caggccaatg ggaccaagt tgcattcaa tatggaactg 1140
ggcgggtaga tggaatcctg agcgaggaca agctgactat tgggtggaatc aagggtgcat 1200
cagtgatatt cggggagggt ctctgggagc ccagcctggg ctctgctttt gccattttg 1260
atgggatatt gggcctcggt tttccattc tgtctgtgga aggagtctcg ccccgatgg 1320
atgtactggt ggagcagggg ctattggata agcctgtctt ctctttttac ctcaacaggg 1380
accctgaaga gcctgatgga ggagagctgg tcctgggggg ctcggaaccg gcacactaca 1440
tcccaccctt cacttcctg ccagtcacgg tcctgccta ctggcagatc cacatggagc 1500
gtgtgaagggt gggcccaggg ctgactctct gtgccaaggg ctgtgctgcc atcctggata 1560
cgggcacgtc cctcatcaca ggaccactg aggagatccg ggccctgcat gcagccattg 1620
ggggaatccc cttgctgggt ggggagtaca tcatcctgtg ctcggaatc ccaaagctcc 1680
ccgcagtctc ctctcttctt ggggggtctt ggtttaacct cacggcccat gattacgtca 1740
tccagactac tcgaaatggc gtccgcctct gcttgctcgg tttccaggcc ctggatgtcc 1800
ctccgcctgc agggcccttc tggatcctcg gtgacgtctt cttggggacg tatgtggccg 1860
tcttcgaccg cggggacatg aagagcagcg cccgggtggg cctggcgcg gctcgactc 1920
gcggagcgga cctcggatgg ggagagactg cgcaggcgca gttccccggg tgacgccccaa 1980
gtgaagcgca tgcgcagcgg gtggtcgcg aggtcctgct acccagtaaa aatccactat 2040
ttccattgaa aaaaaaaaaa a

```

2061

&lt;210&gt; 17

&lt;211&gt; 1186

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 999322

&lt;400&gt; 17

taagcgtcgc	cagaccagcc	tgagtgggtct	cacagacgtt	ggctctgcgtg	tttatctcct	60
ctccccctccc	acccaccct	gaagctggga	acacttgggg	ccaggaccca	tgctgtccag	120
actgtgggac	tccccttggc	caaggtgacc	accatattgg	atdddgggga	tcttgagcca	180
gtgtccagga	ttgtgcccgt	gttgggatga	ataagccaag	gctaagaggt	catgagatta	240
gccagggtca	tgggagagga	tctgggcttg	agccctgctc	cctgacccca	ctgcctcctg	300
gtttgggagt	tgagaagagc	agggtgggtg	ggcagagaag	aggtaggagg	tgagggtgc	360
cgccatcaca	ggtgagaggg	cagaggctca	cctgatgggg	acgaggcttg	agggtgggctc	420
aggctggccc	ccacatcaca	tccagccctg	gagagtgtcc	ttcaggaggt	ggctgtgccc	480
ctcctggact	cgaacatgtg	tgagctgatg	taccacctag	gagagcccag	cctggctggc	540
cagcgcctca	tccaggacga	catgctctgt	gctggctctg	tccagggcaa	gaaagactcc	600
tgccagggtga	ctgcagctcc	tggtcacccc	atccagttgt	gtgggcccct	taggctcacc	660
ctgtcctgga	ctttctcccc	atgtcccaca	cctcagggtc	tccagaggga	ccagagtcct	720
tgccctagctc	cttggcctca	gcagctgatt	ctcgaaggca	cttggggccc	agggtgtctcc	780
ctcaatgcag	acctcatggg	gccctccctc	tctctccccc	agggtgactc	cggggggccg	840
ctggctctgcc	ccatcaatga	tacgtggatc	caggccggca	ttgtgagctg	gggattcggc	900
tgtgcccggc	ctttccggcc	tgggtgtctac	accaggtgc	taagctacac	agactggatt	960
cagagaaccc	tggctgaatc	tactcagge	atgtctgggg	cccggccagg	tgccccagga	1020
tcccactcag	gcacctccag	atcccaccca	gtgtgtctgc	ttgagctgtt	gaccgtatgc	1080
ttgcttgggt	ccctgtgaac	catgagccat	ggagtccggg	atccccttc	tggtaggatt	1140
gatggaatct	aataataaaa	actgtaggtt	ttttatgtgt	aaaaac		1186

&lt;210&gt; 18

&lt;211&gt; 2038

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 1337018

&lt;400&gt; 18

gcagcttgct	cagcggacaa	ggatgctggg	cgtgagggac	caaggcctgc	cctgcactcg	60
ggcctcctcc	agccagtgt	gaccaggga	ttctgacctg	ctggccagcc	aggacctgtg	120
tggggaggcc	ctcctgctgc	cttgggggtga	caatctcagc	tccaggctac	agggagaccg	180
ggaggatcac	agagccagca	tggatcctga	cagtgatcaa	cctctgaaca	gcctcgatgt	240
caaaccctg	cgcaaacc	gtatcccat	ggagaccttc	agaaagggtg	ggatcccat	300
catcatagca	ctactgagcc	tggcgagtat	catcattgtg	gttgtcctca	tcaaggatgat	360
tctggataaa	tactacttcc	tctgcgggca	gcctctccac	ttcatccga	ggaagcagct	420
gtgtgacgga	gagctggact	gtcccttggg	ggaggacgag	gagcactgtg	tcaagagctt	480
ccccgaagg	cctgcagtgg	cagtcgcct	ctccaaggac	cgatccacac	tgagggtgct	540
ggactcggcc	acagggaact	ggttctctgc	ctgtttcgac	aacttcacag	aagctctcgc	600
tgagacagcc	tgtaggcaga	tgggctacag	cagcaaacc	actttcagag	ctgtggagat	660
tggcccagac	caggatctgg	atgttgttga	aatcacagaa	aacagccagg	agcttcgcat	720
gcggaaactca	agtgggccc	gtctctcagg	ctccctgggtc	tccctgcact	gtcttgccctg	780
tggggagagc	ctgaagaccc	cccgtgtggg	gggtggggag	gaggcctctg	tggaattcttg	840
gccttggcag	gtcagcatcc	agtacgacaa	acagcacgtc	tgtggaggga	gcatcctgga	900
ccccactgg	gtcctcacgg	cagcccactg	cttcaggaaa	cataccgatg	tgttcaactg	960
gaagggtgcgg	gcaggctcag	acaaactggg	cagcttccca	tccctggctg	tggccaagat	1020
catcatcatt	gaattcaacc	ccatgtacc	caaagacaat	gacatcgccc	tcatgaagct	1080

```

gcagttccca ctcactttct caggcacagt caggcccatc tgtctgccct tctttgatga 1140
ggagctcact ccagccaccc cactctggat cattggatgg ggctttacga agcagaatgg 1200
aggggaagatg tctgacatac tgctgcaggc gtcagtccag gtcattgaca gcacacgggtg 1260
caatgcagac gatgcgtacc agggggaagt caccgagaag atgatgtgtg caggcatccc 1320
ggaagggggt gtggacacct gccaggggtga cagtgggtggg cccctgatgt accaatctga 1380
ccagtggcat gtggtgggca tctgttagctg gggctatggc tgcggggggc cgagcacccc 1440
aggagtatac accaaggtct cagcctatct caactggatc tacaatgtct ggaaggctga 1500
gctgtaatgc tgctgcccct ttgcagtgtt gggagccgct tccttcctgc cctgcccacc 1560
tggggatccc ccaaagtcag acacagagca agagtccctt tgggtacacc cctctgcccc 1620
cagcctcagc atttcttgga gcagcaaagg gcctcaattc ctataagaga ccctcgcagc 1680
ccagaggcgc ccagaggaag tcagcagccc tagctcggcc acacttggtg ctcccagcat 1740
cccagggaga gacacagccc actgaacaag gtctcagggg tattgctaag ccaagaagga 1800
actttcccac actactgaat ggaagcaggc tgtcttgtaa aagcccagat cactgtgggc 1860
tgagaggagg aaggaaaggg tctgcgccag ccctgtccgt ctaccccat cccaagcct 1920
actagagcaa gaaaccagtt gtaataataa atgcactgcc ctactgttgg tatgactacc 1980
gttacctact gttgtcattg ttattacagc tatggccact attattaaag agctgtga 2038

```

&lt;210&gt; 19

&lt;211&gt; 994

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 1798496

&lt;400&gt; 19

```

gtgcaggagg agaaggagga ggagcaggag gtggagattc ccagttaaaa ggctccagaa 60
tcgtgtacca ggcagagaac tgaagtactg gggcctcctc cactgggtcc gaatcagtag 120
gtgaccccg ccttggtattc tggaagacct caccatggga cgccccgac ctctgctggc 180
caagacgttg atgttcctgc tcttgctggg gggagcctgg gcaggacact ccagggcaca 240
ggaggacaag gtgctggggg gtcatgagtg ccaaccccat tcgcagcctt ggcaggcggc 300
cttggtcccag ggccagcaac tactctgtgg cgggtgtcctt gtaggtggca actgggtcct 360
tacagctgcc cactgtaaaa aaccgaaata cacagtacgc ctgggagacc acagcctaca 420
gaataaagat ggcccagagc aagaaatacc tgtggttcag tccatccac acccctgcta 480
caacagcagc gatgtggagg accacaacca tgatctgatg cttcttcaac tgcgtgacca 540
ggcatccctg ggggtccaaag tgaagcccat cagcctggca gatcattgca cccagcctgg 600
ccagaagtgc accgtctcag gctggggcac tgtcaccagt ccccgagaga attttcctga 660
cactctcaac tgtgcagaag taaaaatctt tccccagaag aagtgtgagg atgcttacct 720
ggggcagatc acagatggca tgggtctgtg aggcagcagc aaaggggctg acacgtgcca 780
gggcgattct ggaggccccc tgggtgtgtg tgggtgactc cagggcatca catcctgggg 840
ctcagacccc tgtgggaggt ccgacaaacc tggcgtctat accaacatct gccgctacct 900
ggactggatc aagaagatca taggcagcaa gggctgattc taggataagc actagatctc 960
ccttaataaa ctcaaacctc tctgaaaaaa aaaa 994

```

&lt;210&gt; 20

&lt;211&gt; 1318

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; 88

&lt;223&gt; a or g or c or t, unknown, or other



&lt;220&gt; -

&lt;223&gt; 2082147

&lt;400&gt; 20

```
tctgaggcgc gtgcgcggcc accccagcct agtcctcttc ttggtgccac tggctaacta 60
ggttgagaaa ccggcgccac aggcgcanca cctggccccg agctggcccc ctcctccccg 120
ccgagccgcc cccaacaacg cgccctctcc cagtcctcac aaaggggccc agtccggccc 180
ccggctcttg ccgtgaggga gcgctgtggg ggcgcgctgc cttctgcctg gaagtgttg 240
gcagggtggtg ggagagcgtc aggcctgaac aacatgattt taaagcacgt gtctgtctgt 300
cgttttttac ttttaggggt ttggccaaat tgggcgaggg cacaaaataa ccacttacct 360
cttctcaccg aggaagagcg ggagaaaggg tatggcacag tcacaagggt ggggtgaaaag 420
atacatcaag gccttttgta aaggcttctt tgtggcggtg cctgtggcag tgactttctt 480
ggatcgggtc gcctgtgttg caagagtaga aggagcatcg atgcagcctt ctttgaatcc 540
tgggggggagc cagtcacatg atgtggtgct tttgaaccac tggaaagtga ggaattttga 600
agtacaccgt ggtgacattg tatcattggt gtctcctaaa aaccagaac agaagatcat 660
taagagagtg attgctcttg aaggagatat tgtcagaacc ataggacaca aaaaccggtg 720
tgtcaaagtc ccccggtggt acatctgggt tgaagggtgat catcatggac acagttttga 780
cagtaattct tttgggcccgg tttccctagg acttctgcat gcccatgcc cacaatctct 840
gtggcccccga gagcgctggc agaaattgga atctgttctt cctccagagc gcttaccagt 900
acagagagaa gaggaatgac tgcataatc tacctgagtt gctggcattg ggaggccagt 960
tactggaaaag gaatggaaa aagaagcctc caaaggggaa aaacttctga caatatgatg 1020
ctgtgcgaga aatattttaca gcacattaaa acgatctgta ttattaaata aataattttc 1080
aaatgttaaa cagtattaaa tggcacctga ttttgtgta aattttagtt cctgtgtgtt 1140
taatgcccc aaatatgca gacctttggg aatataaaaa tattgcaccc acatgtctta 1200
atggggctga atttcagatt atttgttaca tatacttatt atattgattg ttgggttttg 1260
attttgggtgc ttgctgctga aataaattga aaattaatat tcaaaaaaaa aaaaaaag 1318
```

&lt;210&gt; 21

&lt;211&gt; 2136

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 2170967

&lt;400&gt; 21

```
ggctctttta aatgacccca ggcgtcgtgt attgaatcct agactcacgt ccgtctcgcc 60
ggcgcccgag ccagtcgcgc gcgaccgcgt ctgctcccc gaaagccccg cccgcaagg 120
ctgcccctgcc tacctggtct ccgacgtgct cgtctggagg gcggtgcgag gggccgagcc 180
gacaagatgt tcttgctgcc tcttccggct gcggggcgag tagtctgcc acgtctggcc 240
gtgagacgtt tcgggagccg gagtctctcc accgcagaca tgacgaagg ccttgtttta 300
ggaatctatt ccaaagaaaa agaagatgat gtgccacagt tcacaagtgc aggagagaat 360
tttgataaat tgttagcttg aaagctgaga gagactttga acatatctgg accacctctg 420
aaggcagggg agactcgaac cttttatggt ctgcatcagg acttccccag cgtggtgcta 480
gttggcctcg gcaaaaaggc agctggaatc gacgaacagg aaaactggca tgaaggcaaa 540
gaaaacatca gagctgctgt tgcagcgggg tgcaggcaga ttcaagacct ggagctctcg 600
tctgtggagg tggatccctg tggagacgct caggctgctg cggagggagc ggtgcttggt 660
ctctatgaat acgatgacct aaagcaaaaa aagaagatgg ctgtgtcgcc aaagctctat 720
ggaagtgggg atcaggaggc ctggcagaaa ggagtctgt ttgcttctgg gcagaacttg 780
gcacgccaat tgatggagac gccagccaat gagatgacgc caaccagatt tgctgaaatt 840
attgagaaga atctcaaaa tgctagtagt aaaaccgagg tccatatcag acccaagtct 900
tggattgagg aacaggcaat gggatcattc ctcagtgtgg ccaaaggatc tgacgagccc 960
ccagtcttct tggaaattca ctacaaaggc agccccaatg caaacgaacc acccctggtg 1020
tttgttggga aaggaattac ctttgacagt ggtggtatct ccatcaaggc ttctgcaaat 1080
atggacctca tgagggctga catgggagga gctgcaacta tatgctcagc catcgtgtct 1140
```

```

gctgcaaagc ttaatttgcc cattaatatt ataggtctgg cccctctttg tgaaaatatg 1200
cccagcggca aggccaaaca gecgggggat gttgttagag ccaaaaacgg gaagaccatc 1260
caggttgata aactgatgc tgaggggagg ctcatactgg ctgatgcgct ctgttacgca 1320
cacacgttta acccgaaggc catcctcaat gccgccacct taacagggtgc catggatgta 1380
gctttgggat caggtgccac tgggggtctt accaattcat cctggctctg gaacaaactc 1440
ttcgaggcca gcattgaaac aggggaccgt gtctggagga tgctctctct cgaacattat 1500
acaagacagg ttgtagattg ccagcttgct gatgttaaca acattggaaa atacagatct 1560
gcaggagcat gtacagctgc agcattcctg aaagaattcg taactcatcc taagtgggca 1620
catttagaca tagcaggcgt gatgaccaac aaagatgaag ttccctatct acggaaaggc 1680
atgactggga ggcccacaag gactctcatt gagttcttac ttcgtttcag tcaagacaat 1740
gcttagttca gatactcaa aatgtcttca ctctgtctta aattggacag ttgaacttaa 1800
aaggtttttg aataaatgga tgaaaatctt ttaacggaga caaaggatgg tatttaaaaa 1860
tgtagaacac aatgaaattt gtatgccttg atttttttt tcatttcaca caaagattta 1920
taaaggtaaa gttaatatct tacttgataa ggatttttaa gatactctat aaatgattaa 1980
aatttttaga acttcctaact cacttttcag agtatatgtt ttccattgag aagcaaaatt 2040
gtaactcaga tttgtgatgc taggaacatg agcaaaactga aaattactat gcacttgtca 2100
gaaacaataa atgcaacttg ttgtgaaaaa aaaaaa 2136

```

&lt;210&gt; 22

&lt;211&gt; 1388

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 2484218

&lt;400&gt; 22

```

ggaaaatggc ggcgggcgcg gcggcggtcg cagctacgaa cgggaccgga ggaagcagcg 60
ggatggaggt ggatgcagca gtagtcccca gcgtgatggc ctgaggagtg actgggagtg 120
tttccgtcgc tctccatccc cttgtcattc tcaacatctc agaccactgg atccgcatgc 180
gctcccagga ggggcggcct gtgcagggtga ttggggctct gattggcaag caggaggggc 240
gaaatatcga ggtgatgaac tcctttgagc tgctgtccca caccgtggaa gagaagatta 300
tcattgacaa ggaatattat tacaccaagg aggagcagtt taaacagggtg ttcaaggagc 360
tggagtttct gggttggtat accacagggg ggccacctga cccctcggac atccacgtcc 420
ataagcaggt gtgtgagatc atcgagagcc ccctctttct gaagttgaac cctatgacca 480
agcacacaga tcttcctgtc agcgtttttg agtctgtcat tgatataatc aatggagagg 540
ccacaatgct gtttgctgag ctgacctaca ctctggccac agaggaagcg gaacgcattg 600
gtgtagacca cgtagcccga atgacagcaa caggcagtggt agagaactcc actgtggctg 660
aacacctgat agcacagcac agcgccatca agatgctgca cagccgcgtc aagctcatct 720
tggagtacgt caaggcctct gaagcgggag aggtcccctt taatcatgag atcctgcggg 780
aggectatgc tctgtgtcac tgtctcccgg tgctcagcac agacaagttc aagacagatt 840
tttatgatca atgcaacgac gtggggctca tggcctacct cggcaccatc accaaaacgt 900
gcaacaccat gaaccagttt gtgaacaagt tcaatgtcct ctacgaccga caaggcatcg 960
gcaggagaat gcgcgggctc tttttctgat gaggtactt gaagggtga tggacagggg 1020
tcaggcaact atcccaaagg ggagggcact acacttcctt gagagaaacc gctgtcatta 1080
ataaaagggg agcagccctt gagcaccctt gctggtggct ctgtcctctg ttaggcacca 1140
cactggttgg tcaacttggg tgttcacga ggctcattct ggcttgctc agaagccctt 1200
ctgatgctct tcagtggagg aggcactacc atttgaagtg accccatgtc agtcacatgg 1260
actggtcttt agcaaagtc aaggctgect gcttccacct aagtggctct tgttctacac 1320
tttaatgtca ccctctacat catcttacct agcccaccca accttataaa catgataatt 1380
gactacta 1388

```

&lt;210&gt; 23

&lt;211&gt; 2476

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 2680548

&lt;400&gt; 23

```
ctcgcgtcct ggggtgccgc tctgagtagg gcgggcgagg aggcagccaa ggcggagctg 60
atggctgcgc cgagggcggg gcggggtgca ggctggagcc ttcgggcatg gcgggctttg 120
ggggggcattc gctgggggag gagaccccg ttagccctg acctccgggc cctgctgacg 180
tcaggaaactt ctgacccccg ggcccagtg acttatggga ccccgagtct ctgggcccgg 240
ttgtctgttg gggtcactga accccgagca tgctgacgt ctgggacccc ggggtccccg 300
gcacaactga ctgcggtgac ccagataacc aggacccggg aggcctcaga gaactctgga 360
acccgttcgc gcgcgtggct ggcggtggcg ctgggcgtg ggggggcagt gctgttgttg 420
ttgtggggcg ggggtcgggg tcctccggcc gtctcgcgc cgtccctag cccgccgccc 480
gcttctcccc ggagtcagta caacttcac gcagatgtgg tggagaagac agcacctgcc 540
gtggtctata tcgagatcct ggaccggcac cctttcttgg gccgcgaggt ccctatctcg 600
aacggctcag gattcgtggg ggctgccgat gggctcattg tcaccaacgc ccatgtggtg 660
gctgatcggc gcagagtccg tgtgagactg ctaagcgggc acacgtatga ggccgtgggc 720
acagctgtgg atcccgtggc agacatcgca acgctgagga ttcagactaa ggagcctctc 780
cccacgctgc ctctgggacg ctgagctgat gtccggcaag gggagtttgt tgttgccatg 840
ggaagtcctt ttgcactgca gaacacgac acatccggca ttgttagctc tgctcagcgt 900
ccagccagag acctgggact ccccaaacc aatgtggaat acattcaaac tgatgcagct 960
attgattttg gaaactctgg aggtccctg gttaacctgg atggggaggt gattggagtg 1020
aacaccatga aggtcacagc tggaatctcc tttgccatcc cttctgatcg tcttcgagag 1080
tttctgcac gtggggaaaa gaagaattcc tcctccgaa tcagtgggtc ccagcggcgc 1140
tacattgggg tgatgatgct gaccctgagt cccagcatcc ttgctgaact acagcttcga 1200
gaaccaagct ttcccgatgt tcagcatggt gtactcatcc ataaagtcac cctgggctcc 1260
cctgcacacc gggctggtct gcggcctggt gatgtgattt tggccattgg ggagcagatg 1320
gtacaaaatg ctgaagatgt ttatgaagct gttcgaaccc aatcccagtt ggcagtgcag 1380
atccggcggg gacgagaaac actgacctta tatgtgaccc ctgaggtcac agaatgaata 1440
gatcaccaag agtatgaggc tcctgctctg atttctcct tgctttctg gctgaggttc 1500
tgagggcacc gagacagagg gttaaatgaa ccagtggggg caggtccctc caaccaccag 1560
cactgactcc tgggctctga agaatacag aaacactttt tatataaaat aaaattatac 1620
ctagcaacat attatagtaa aaaatgaggt gggagggtg gatcttttcc cccacaaaaa 1680
ggctagaggt aaagctgtat cccctaacc ttaggggaga tactggagct gaccatcctg 1740
acctctatt aaagaaaatg agctgctgcc atcttttgtg ggcagttagt caggtgctgc 1800
tctttgtgg gtgggtgggt ctggtctgtt ctgctcgtg ctgggcctgg gagcaaagat 1860
tcccatgctt ggctacagat actgacagct ggcctctgaa ggagggtgaa aacttctgct 1920
tgacagttcc acatccatag tgcattggtc gatgagtgcg gttgctgaca tgggtttctt 1980
ggtaagctcc tgaggtaatg gcagcctcag acccctgcca ttaggggcca gtggtggttt 2040
gcagagggca gtggcactta gataatctgg ttgctggtct ggccagggtg gcgttcaaac 2100
ctcctgttgg cctcttcact gaaggcatca ccaatgtggc agttgtgcac ccagattcta 2160
tgtccatcat atttgcagtt acatttcatt gcattgttgg taaagtcact ctctgctact 2220
tcaaagtttg ggttgatgac aacctggaga atgtagtttc ctggcttcac atccgtgatg 2280
tcaatccact gacagtcaat gtcattgccg tagagatccc agcaaccac agtgatgctt 2340
tgctctccaa agttggcaca ctcataccgc ttggagacat cctcctgaca ctcagtgtct 2400
tcgagacaga aactagcttt gtggccctca gccaccttgg tgccatttgg ggtgaggata 2460
tcatagttag tgaaga 2476
```

&lt;210&gt; 24

&lt;211&gt; 2231

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 2957969

&lt;400&gt; 24

```

gtttgaaaca gcttcacaag gctgggttatg aagaagaaac tcaaaataac aggagtggct 60
tatggaacta catggaggta acagaggagg gtaccaacca aaggcccttg agcaatcagg 120
atgttggggg cgtgggcccg caggaagatg gcgaacgtgg ggctgcagtt ccaggcgagc 180
gcgggggact cggaccaca gagccggccc ctgctgctgc tcgggcagct gcaccacctg 240
caccgcgtgc cctggagcca cgtccgcccg aagctgcagc cccgggtcac cgaggagctc 300
tggcaggctg ccctgagcac gctcaacccc aaccccacgg acagctgtcc cctctacctg 360
aactacgcca ccgtggctgc cctgccctgc agggtagagc ggcacaacag cccctcggcc 420
gcccacttca tcacgaggct ggtgaggacc tgctgccc ccggagcgca tcgtgcatt 480
gtgatggtct gcgagcagcc ggaggtcttt gcttcgcct gtgccctggc ccgggccttc 540
ccgctgttca cccaccgctc aggtgcctct cggcgcttgg agaagaagac ggtcaccgtg 600
gagtttttcc tgggtgggaca agacaacggg ccggtggagg tgtccacatt gcagtgtcta 660
gcgaatgcc aagacggcgt gcggctagca gccgcctcgg tggacacacc ctgcaatgag 720
atgaacaccg acaccttcct cgaggagatt aacaaagtgg gaaaggagct ggggatcatc 780
ccaaccatca tccgggatga ggaactgaag acgagaggat ttggaggaat ctatggggtt 840
ggcaaagccg cctgcatcc cccagccctg gccgtcctca gccacacccc agatggagcc 900
acgcagacca tcgctgggt gggcaaaggc atcgtctatg acactggagg cctcagcatc 960
aaaggggaag ctaccatgcc ggggatgaag cgagactgcg ggggtgctgc ggcgctcctg 1020
ggggccttca gagccgcaat caagcagggt ttcaaagaca acctccacgc tgtgttctgc 1080
ttggctgaga actcgggtgg gccaatgag acaaggccag atgacatcca cctgctgtac 1140
tcaggggaag cgggtggaaat caacaacacg gatgccgagg gcaggctggt gctggcagat 1200
ggcgtgtcct atgcttgc aaacacacg ggacctgggg gccgacatca tctggacat ggccacctg 1260
accggggctc agggcattgc cacagggaag taccacgccg cgggtgctcac caacagcgtc 1320
gagtgaggag ccgcctgtgt gaaggcgggc aggaagtgtg gggacctggt gcaccgcgtg 1380
gtctactgcc ccgagctgca cttcagcgag ttcacctcag ctgtggcgga catgaagaac 1440
tcagtggcgg accgagacaa cagccccagc tcctgtgctg gcctcttcat cgcctcacac 1500
atcggtctcg actggcccgg agtctgggtc cacctggaca ttgctgcacc ggtgcatgct 1560
ggtgagcgag ccacaggctt cgggtgtggc ctctgctgg cgctcttcgg ccgtgcctct 1620
gaggacctc tgetgaacct ggtgtcccca ctgggctgtg aggtggatgt cgaggagggg 1680
gacgtgggga gggactccaa gagacgcagg cttgtgtgag cctcctgcct cggccctgac 1740
aaacggggat cttttacctc actttgcact gattaatttt aagcaattga aagattgcc 1800
ttcatatggg ttttggtttg tctttctggt cgtcagcgtg gtggtggaaa cagctgaagt 1860
tttaggagac agcttagggg ttggtgagg ccacggggag gggaccggga agcgtgggg 1920
cttgtttctg tttgttactt acaggactga gacatcttct gtaaaactgt acccctgggg 1980
ccttctgcac cccgggggtg ggcctcctgc ctgctgggtg cctgtccca gccccaggtc 2040
ctgtgcaggg cacctgcgtg gctgacagcc aggtctttac tccagccggg gctgccagcg 2100
catccagcca gccagccct gtgaaagatg gagctgactt gctgcagggg acctgattta 2160
tagggcaaga gaagtcacac tctggcctct cagaattcac ttgaggttca attaaataca 2220
gtcacaccgc c 2231

```

## SEQUENCE LISTING

<110> INCYTE PHARMACEUTICALS, INC.  
 BANDMAN, Olga  
 HILLMAN, Jennifer L.  
 YUE, Henry  
 GUEGLER, Karl J.  
 CORLEY, Neil C.  
 TANG, Y. Tom  
 SHAM, Purvi

<120> HUMAN PROTEASE MOLECULES

<130> PF-0458 PCT

<140> To Be Assigned

<141> Herewith

<150> 09/008,271

<151> 1998-01-16

<160> 24

<170> PERL PROGRAM

<210> 1

<211> 63

<212> PRT

<213> Homo sapiens

<220> -

<223> 135360

<400> 1

Met	Asp	Ile	Leu	Ile	Cys	Thr	Asp	Phe	Gly	Ser	Val	Asn	Tyr	Phe	
1				5					10					15	
Asn	Val	Trp	Arg	Leu	Pro	Lys	Ser	Tyr	Leu	Ser	Leu	Phe	Tyr	Ser	
				20					25					30	
Arg	Ile	Tyr	Ile	Val	His	Asp	Glu	Val	Lys	Asp	Lys	Ala	Phe	Glu	
				35					40					45	
Leu	Glu	Leu	Ser	Trp	Val	Gly	Glu	Cys	Lys	Leu	Phe	Leu	Tyr	Ile	
				50					55					60	
Tyr	Leu	Pro													

<210> 2

<211> 262

<212> PRT

<213> Homo sapiens

<220> -

<223> 447484

&lt;400&gt; 2

Met	Gly	Arg	Glu	Ile	Arg	Ser	Glu	Glu	Pro	Glu	Glu	Ser	Val	Pro
1				5					10					15
Phe	Ser	Cys	Asp	Trp	Arg	Lys	Val	Ala	Gly	Ala	Ile	Ser	Pro	Ile
			20						25					30
Lys	Asp	Gln	Lys	Asn	Cys	Asn	Cys	Cys	Trp	Ala	Met	Ala	Ala	Ala
			35						40					45
Gly	Asn	Ile	Glu	Thr	Leu	Trp	Arg	Ile	Ser	Phe	Trp	Asp	Phe	Val
			50						55					60
Asp	Val	Ser	Val	Gln	Glu	Leu	Leu	Asp	Cys	Gly	Arg	Cys	Gly	Asp
			65						70					75
Gly	Cys	His	Gly	Gly	Phe	Val	Trp	Asp	Ala	Phe	Ile	Thr	Val	Leu
			80						85					90
Asn	Asn	Ser	Gly	Leu	Ala	Ser	Glu	Lys	Asp	Tyr	Pro	Phe	Gln	Gly
			95						100					105
Lys	Val	Arg	Ala	His	Arg	Cys	His	Pro	Lys	Lys	Tyr	Gln	Lys	Val
			110						115					120
Ala	Trp	Ile	Gln	Asp	Phe	Ile	Met	Leu	Gln	Asn	Asn	Glu	His	Arg
			125						130					135
Ile	Ala	Gln	Tyr	Leu	Ala	Thr	Tyr	Gly	Pro	Ile	Thr	Val	Thr	Ile
			140						145					150
Asn	Met	Lys	Pro	Leu	Gln	Leu	Tyr	Arg	Lys	Gly	Val	Ile	Lys	Ala
			155						160					165
Thr	Pro	Thr	Thr	Cys	Asp	Pro	Gln	Leu	Val	Asp	His	Ser	Val	Leu
			170						175					180
Leu	Val	Gly	Phe	Gly	Ser	Val	Lys	Ser	Glu	Glu	Gly	Ile	Trp	Ala
			185						190					195
Glu	Thr	Val	Ser	Ser	Gln	Ser	Gln	Pro	Gln	Pro	Pro	His	Pro	Thr
			200						205					210
Pro	Tyr	Trp	Ile	Leu	Lys	Asn	Ser	Trp	Gly	Ala	Gln	Trp	Gly	Glu
			215						220					225
Lys	Gly	Tyr	Phe	Arg	Leu	His	Arg	Gly	Ser	Asn	Thr	Cys	Gly	Ile
			230						235					240
Thr	Lys	Phe	Pro	Leu	Thr	Ala	Arg	Val	Gln	Lys	Pro	Asp	Met	Lys
			245						250					255
Pro	Arg	Val	Ser	Cys	Pro	Pro								
			260											

&lt;210&gt; 3

&lt;211&gt; 314

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 789927

&lt;400&gt; 3

Met	Gly	Ala	Arg	Gly	Ala	Leu	Leu	Leu	Ala	Leu	Leu	Leu	Ala	Arg
1				5					10					15
Ala	Gly	Leu	Arg	Lys	Pro	Glu	Ser	Gln	Glu	Ala	Ala	Pro	Leu	Ser
			20						25					30
Gly	Pro	Cys	Gly	Arg	Arg	Val	Ile	Thr	Ser	Arg	Ile	Val	Gly	Gly
			35						40					45

Glu	Asp	Ala	Glu	Leu	Gly	Arg	Trp	Pro	Trp	Gln	Gly	Ser	Leu	Arg	50	55	60
Leu	Trp	Asp	Ser	His	Val	Cys	Gly	Val	Ser	Leu	Leu	Ser	His	Arg	65	70	75
Trp	Ala	Leu	Thr	Ala	Ala	His	Cys	Phe	Glu	Thr	Tyr	Ser	Asp	Leu	80	85	90
Ser	Asp	Pro	Ser	Gly	Trp	Met	Val	Gln	Phe	Gly	Gln	Leu	Thr	Ser	95	100	105
Met	Pro	Ser	Phe	Trp	Ser	Leu	Gln	Ala	Tyr	Tyr	Thr	Arg	Tyr	Phe	110	115	120
Val	Ser	Asn	Ile	Tyr	Leu	Ser	Pro	Arg	Tyr	Leu	Gly	Asn	Ser	Pro	125	130	135
Tyr	Asp	Ile	Ala	Leu	Val	Lys	Leu	Ser	Ala	Pro	Val	Thr	Tyr	Thr	140	145	150
Lys	His	Ile	Gln	Pro	Ile	Cys	Leu	Gln	Ala	Ser	Thr	Phe	Glu	Phe	155	160	165
Glu	Asn	Arg	Thr	Asp	Cys	Trp	Val	Thr	Gly	Trp	Gly	Tyr	Ile	Lys	170	175	180
Glu	Asp	Glu	Ala	Leu	Pro	Ser	Pro	His	Thr	Leu	Gln	Glu	Val	Gln	185	190	195
Val	Ala	Ile	Ile	Asn	Asn	Ser	Met	Cys	Asn	His	Leu	Phe	Leu	Lys	200	205	210
Tyr	Ser	Phe	Arg	Lys	Asp	Ile	Phe	Gly	Asp	Met	Val	Cys	Ala	Gly	215	220	225
Asn	Ala	Gln	Gly	Gly	Lys	Asp	Ala	Cys	Phe	Gly	Asp	Ser	Gly	Gly	230	235	240
Pro	Leu	Ala	Cys	Asn	Lys	Asn	Gly	Leu	Trp	Tyr	Gln	Ile	Gly	Val	245	250	255
Val	Ser	Trp	Gly	Val	Gly	Cys	Gly	Arg	Pro	Asn	Arg	Pro	Gly	Val	260	265	270
Tyr	Thr	Asn	Ile	Ser	His	His	Phe	Glu	Trp	Ile	Gln	Lys	Leu	Met	275	280	285
Ala	Gln	Ser	Gly	Met	Ser	Gln	Pro	Asp	Pro	Ser	Trp	Pro	Leu	Leu	290	295	300
Phe	Phe	Pro	Leu	Leu	Trp	Ala	Leu	Pro	Leu	Leu	Gly	Pro	Val		305	320	

&lt;210&gt; 4

&lt;211&gt; 420

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 877617

&lt;400&gt; 4

Met	Ser	Pro	Pro	Pro	Leu	Leu	Gln	Pro	Leu	Leu	Leu	Leu	Leu	Pro	1	5	10	15
Leu	Leu	Asn	Val	Glu	Pro	Ser	Gly	Ala	Thr	Leu	Ile	Arg	Ile	Pro	20	25	30	35
Leu	His	Arg	Val	Gln	Pro	Gly	Arg	Arg	Thr	Leu	Asn	Leu	Leu	Arg	40	45	50	55
Gly	Trp	Arg	Glu	Pro	Ala	Glu	Leu	Pro	Lys	Leu	Gly	Ala	Pro	Ser	60	65	70	75

50	55	60
Pro Gly Asp Lys	Pro Ile Phe Val	Pro Leu Ser Asn Tyr Arg Asp
65	70	75
Val Gln Tyr Phe	Gly Glu Ile Gly Leu	Gly Thr Pro Pro Gln Asn
80	85	90
Phe Thr Val Ala	Phe Asp Thr Gly Ser	Ser Asn Leu Trp Val Pro
95	100	105
Ser Arg Arg Cys	His Phe Phe Ser Val	Pro Cys Trp Leu His His
110	115	120
Arg Phe Asp Pro	Lys Ala Ser Ser Ser	Phe Gln Ala Asn Gly Thr
125	130	135
Lys Phe Ala Ile	Gln Tyr Gly Thr Gly	Arg Val Asp Gly Ile Leu
140	145	150
Ser Glu Asp Lys	Leu Thr Ile Gly Gly	Ile Lys Gly Ala Ser Val
155	160	165
Ile Phe Gly Glu	Ala Leu Trp Glu Pro	Ser Leu Val Phe Ala Phe
170	175	180
Ala His Phe Asp	Gly Ile Leu Gly Leu	Gly Phe Pro Ile Leu Ser
185	190	195
Val Glu Gly Val	Arg Pro Pro Met Asp	Val Leu Val Glu Gln Gly
200	205	210
Leu Leu Asp Lys	Pro Val Phe Ser Phe	Tyr Leu Asn Arg Asp Pro
215	220	225
Glu Glu Pro Asp	Gly Gly Glu Leu Val	Leu Gly Gly Ser Asp Pro
230	235	240
Ala His Tyr Ile	Pro Pro Leu Thr Phe	Val Pro Val Thr Val Pro
245	250	255
Ala Tyr Trp Gln	Ile His Met Glu Arg	Val Lys Val Gly Pro Gly
260	265	270
Leu Thr Leu Cys	Ala Lys Gly Cys Ala	Ala Ile Leu Asp Thr Gly
275	280	285
Thr Ser Leu Ile	Thr Gly Pro Thr Glu	Glu Ile Arg Ala Leu His
290	295	300
Ala Ala Ile Gly	Gly Ile Pro Leu Leu	Ala Gly Glu Tyr Ile Ile
305	310	315
Leu Cys Ser Glu	Ile Pro Lys Leu Pro	Ala Val Ser Phe Leu Leu
320	325	330
Gly Gly Val Trp	Phe Asn Leu Thr Ala	His Asp Tyr Val Ile Gln
335	340	345
Thr Thr Arg Asn	Gly Val Arg Leu Cys	Leu Ser Gly Phe Gln Ala
350	355	360
Leu Asp Val Pro	Pro Pro Ala Gly Pro	Phe Trp Ile Leu Gly Asp
365	370	375
Val Phe Leu Gly	Thr Tyr Val Ala Val	Phe Asp Arg Gly Asp Met
380	385	390
Lys Ser Ser Ala	Arg Val Gly Leu Ala	Arg Ala Arg Thr Arg Gly
395	400	405
Ala Asp Leu Gly	Trp Gly Glu Thr Ala	Gln Ala Gln Phe Pro Gly
410	415	420

<210> 5  
 <211> 200  
 <212> FRT



&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 999322

&lt;400&gt; 5

```

Met Cys Glu Leu Met Tyr His Leu Gly Glu Pro Ser Leu Ala Gly
 1          5          10          15
Gln Arg Leu Ile Gln Asp Asp Met Leu Cys Ala Gly Ser Val Gln
 20          25          30
Gly Lys Lys Asp Ser Cys Gln Val Thr Ala Ala Pro Gly His Pro
 35          40          45
Ile Gln Leu Cys Gly Pro Phe Arg Leu Thr Leu Ser Trp Thr Phe
 50          55          60
Ser Pro Cys Pro Thr Pro Gln Gly Leu Gln Arg Asp Gln Ser Pro
 65          70          75
Cys Leu Ala Pro Trp Pro Gln Gln Leu Ile Leu Glu Gly Thr Trp
 80          85          90
Gly Pro Gly Val Ser Leu Asn Ala Asp Leu Met Gly Pro Ser Leu
 95          100         105
Ser Leu Pro Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Pro Ile
 110         115         120
Asn Asp Thr Trp Ile Gln Ala Gly Ile Val Ser Trp Gly Phe Gly
 125         130         135
Cys Ala Arg Pro Phe Arg Pro Gly Val Tyr Thr Gln Val Leu Ser
 140         145         150
Tyr Thr Asp Trp Ile Gln Arg Thr Leu Ala Glu Ser His Ser Gly
 155         160         165
Met Ser Gly Ala Arg Pro Gly Ala Pro Gly Ser His Ser Gly Thr
 170         175         180
Ser Arg Ser His Pro Val Leu Leu Leu Glu Leu Leu Thr Val Cys
 185         190         195
Leu Leu Gly Ser Leu
 200

```

&lt;210&gt; 6

&lt;211&gt; 435

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 1337018

&lt;400&gt; 6

```

Met Asp Pro Asp Ser Asp Gln Pro Leu Asn Ser Leu Asp Val Lys
 1          5          10          15
Pro Leu Arg Lys Pro Arg Ile Pro Met Glu Thr Phe Arg Lys Val
 20          25          30
Gly Ile Pro Ile Ile Ile Ala Leu Leu Ser Leu Ala Ser Ile Ile
 35          40          45
Ile Val Val Val Ile Ile Lys Val Ile Leu Asp Lys Tyr Tyr Phe
 50          55          60
Leu Cys Gly Gln Pro Leu His Phe Ile Pro Arg Lys Gln Leu Cys

```

	65		70		75
Asp Gly Glu Leu Asp Cys Pro Leu Gly Glu Asp Glu Glu His Cys					
	80		85		90
Val Lys Ser Phe Pro Glu Gly Pro Ala Val Ala Val Arg Leu Ser					
	95		100		105
Lys Asp Arg Ser Thr Leu Gln Val Leu Asp Ser Ala Thr Gly Asn					
	110		115		120
Trp Phe Ser Ala Cys Phe Asp Asn Phe Thr Glu Ala Leu Ala Glu					
	125		130		135
Thr Ala Cys Arg Gln Met Gly Tyr Ser Ser Lys Pro Thr Phe Arg					
	140		145		150
Ala Val Glu Ile Gly Pro Asp Gln Asp Leu Asp Val Val Glu Ile					
	155		160		165
Thr Glu Asn Ser Gln Glu Leu Arg Met Arg Asn Ser Ser Gly Pro					
	170		175		180
Cys Leu Ser Gly Ser Leu Val Ser Leu His Cys Leu Ala Cys Gly					
	185		190		195
Glu Ser Leu Lys Thr Pro Arg Val Val Gly Gly Glu Glu Ala Ser					
	200		205		210
Val Asp Ser Trp Pro Trp Gln Val Ser Ile Gln Tyr Asp Lys Gln					
	215		220		225
His Val Cys Gly Gly Ser Ile Leu Asp Pro His Trp Val Leu Thr					
	230		235		240
Ala Ala His Cys Phe Arg Lys His Thr Asp Val Phe Asn Trp Lys					
	245		250		255
Val Arg Ala Gly Ser Asp Lys Leu Gly Ser Phe Pro Ser Leu Ala					
	260		265		270
Val Ala Lys Ile Ile Ile Ile Glu Phe Asn Pro Met Tyr Pro Lys					
	275		280		285
Asp Asn Asp Ile Ala Leu Met Lys Leu Gln Phe Pro Leu Thr Phe					
	290		295		300
Ser Gly Thr Val Arg Pro Ile Cys Leu Pro Phe Phe Asp Glu Glu					
	305		310		315
Leu Thr Pro Ala Thr Pro Leu Trp Ile Ile Gly Trp Gly Phe Thr					
	320		325		330
Lys Gln Asn Gly Gly Lys Met Ser Asp Ile Leu Leu Gln Ala Ser					
	335		340		345
Val Gln Val Ile Asp Ser Thr Arg Cys Asn Ala Asp Asp Ala Tyr					
	350		355		360
Gln Gly Glu Val Thr Glu Lys Met Met Cys Ala Gly Ile Pro Glu					
	365		370		375
Gly Gly Val Asp Thr Cys Gln Gly Asp Ser Gly Gly Pro Leu Met					
	380		385		390
Tyr Gln Ser Asp Gln Trp His Val Val Gly Ile Val Ser Trp Gly					
	395		400		405
Tyr Gly Cys Gly Gly Pro Ser Thr Pro Gly Val Tyr Thr Lys Val					
	410		415		420
Ser Ala Tyr Leu Asn Trp Ile Tyr Asn Val Trp Lys Ala Glu Leu					
	425		430		435

&lt;210&gt; 7

&lt;211&gt; 260

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 1798496

&lt;400&gt; 7

```

Met Gly Arg Pro Arg Pro Arg Ala Ala Lys Thr Trp Met Phe Leu
 1          5          10          15
Leu Leu Leu Gly Gly Ala Trp Ala Gly His Ser Arg Ala Gln Glu
 20          25          30
Asp Lys Val Leu Gly Gly His Glu Cys Gln Pro His Ser Gln Pro
 35          40          45
Trp Gln Ala Ala Leu Ser Gln Gly Gln Gln Leu Leu Cys Gly Gly
 50          55          60
Val Leu Val Gly Gly Asn Trp Val Leu Thr Ala Ala His Cys Lys
 65          70          75
Lys Pro Lys Tyr Thr Val Arg Leu Gly Asp His Ser Leu Gln Asn
 80          85          90
Lys Asp Gly Pro Glu Gln Glu Ile Pro Val Val Gln Ser Ile Pro
 95          100         105
His Pro Cys Tyr Asn Ser Ser Asp Val Glu Asp His Asn His Asp
 110         115         120
Leu Met Leu Leu Gln Leu Arg Asp Gln Ala Ser Leu Gly Ser Lys
 125         130         135
Val Lys Pro Ile Ser Leu Ala Asp His Cys Thr Gln Pro Gly Gln
 140         145         150
Lys Cys Thr Val Ser Gly Trp Gly Thr Val Thr Ser Pro Arg Glu
 155         160         165
Asn Phe Pro Asp Thr Leu Asn Cys Ala Glu Val Lys Ile Phe Pro
 170         175         180
Gln Lys Lys Cys Glu Asp Ala Tyr Pro Gly Gln Ile Thr Asp Gly
 185         190         195
Met Val Cys Ala Gly Ser Ser Lys Gly Ala Asp Thr Cys Gln Gly
 200         205         210
Asp Ser Gly Gly Pro Leu Val Cys Asp Gly Ala Leu Gln Gly Ile
 215         220         225
Thr Ser Trp Gly Ser Asp Pro Cys Gly Arg Ser Asp Lys Pro Gly
 230         235         240
Val Tyr Thr Asn Ile Cys Arg Tyr Leu Asp Trp Ile Lys Lys Ile
 245         250         255
Ile Gly Ser Lys Gly
 260

```

&lt;210&gt; 8

&lt;211&gt; 175

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 2082147

&lt;400&gt; 8

```

Met Ala Gln Ser Gln Gly Trp Val Lys Arg Tyr Ile Lys Ala Phe

```

1	5	10	15
Cys Lys Gly Phe Phe Val Ala Val Pro Val Ala Val Thr Phe Leu			
20	25	30	
Asp Arg Val Ala Cys Val Ala Arg Val Glu Gly Ala Ser Met Gln			
35	40	45	
Pro Ser Leu Asn Pro Gly Gly Ser Gln Ser Ser Asp Val Val Leu			
50	55	60	
Leu Asn His Trp Lys Val Arg Asn Phe Glu Val His Arg Gly Asp			
65	70	75	
Ile Val Ser Leu Val Ser Pro Lys Asn Pro Glu Gln Lys Ile Ile			
80	85	90	
Lys Arg Val Ile Ala Leu Glu Gly Asp Ile Val Arg Thr Ile Gly			
95	100	105	
His Lys Asn Arg Tyr Val Lys Val Pro Arg Gly His Ile Trp Val			
110	115	120	
Glu Gly Asp His His Gly His Ser Phe Asp Ser Asn Ser Phe Gly			
125	130	135	
Pro Val Ser Leu Gly Leu Leu His Ala His Ala Thr His Ile Leu			
140	145	150	
Trp Pro Pro Glu Arg Trp Gln Lys Leu Glu Ser Val Leu Pro Pro			
155	160	165	
Glu Arg Leu Pro Val Gln Arg Glu Glu Glu			
170	175		

&lt;210&gt; 9

&lt;211&gt; 519

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 2170967

&lt;400&gt; 9

Met Phe Leu Leu Pro Leu Pro Ala Ala Gly Arg Val Val Val Arg		
1	5	10
Arg Leu Ala Val Arg Arg Phe Gly Ser Arg Ser Leu Ser Thr Ala		
20	25	30
Asp Met Thr Lys Gly Leu Val Leu Gly Ile Tyr Ser Lys Glu Lys		
35	40	45
Glu Asp Asp Val Pro Gln Phe Thr Ser Ala Gly Glu Asn Phe Asp		
50	55	60
Lys Leu Leu Ala Gly Lys Leu Arg Glu Thr Leu Asn Ile Ser Gly		
65	70	75
Pro Pro Leu Lys Ala Gly Lys Thr Arg Thr Phe Tyr Gly Leu His		
80	85	90
Gln Asp Phe Pro Ser Val Val Leu Val Gly Leu Gly Lys Lys Ala		
95	100	105
Ala Gly Ile Asp Glu Gln Glu Asn Trp His Glu Gly Lys Glu Asn		
110	115	120
Ile Arg Ala Ala Val Ala Ala ly Cys Arg Gln Ile Gln Asp Leu		
125	130	135
Glu Leu Ser Ser Val Glu Val Asp Pro Cys Gly Asp Ala Gln Ala		
140	145	150

<210> 10  
<211> 327

&lt;212&gt; PRT

&lt;213&gt; H mo sapiens

&lt;220&gt; -

&lt;221&gt; 2484218

&lt;400&gt; 10

Met	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Thr	Asn	Gly	Thr	Gly
1				5					10					15
Gly	Ser	Ser	Gly	Met	Glu	Val	Asp	Ala	Ala	Val	Val	Pro	Ser	Val
				20					25					30
Met	Ala	Cys	Gly	Val	Thr	Gly	Ser	Val	Ser	Val	Ala	Leu	His	Pro
				35					40					45
Leu	Val	Ile	Leu	Asn	Ile	Ser	Asp	His	Trp	Ile	Arg	Met	Arg	Ser
				50					55					60
Gln	Glu	Gly	Arg	Pro	Val	Gln	Val	Ile	Gly	Ala	Leu	Ile	Gly	Lys
				65					70					75
Gln	Glu	Gly	Arg	Asn	Ile	Glu	Val	Met	Asn	Ser	Phe	Glu	Leu	Leu
				80					85					90
Ser	His	Thr	Val	Glu	Glu	Lys	Ile	Ile	Ile	Asp	Lys	Glu	Tyr	Tyr
				95					100					105
Tyr	Thr	Lys	Glu	Gln	Phe	Lys	Gln	Val	Phe	Lys	Glu	Leu	Glu	
				110					115					120
Phe	Leu	Gly	Trp	Tyr	Thr	Thr	Gly	Gly	Pro	Pro	Asp	Pro	Ser	Asp
				125					130					135
Ile	His	Val	His	Lys	Gln	Val	Cys	Glu	Ile	Ile	Glu	Ser	Pro	Leu
				140					145					150
Phe	Leu	Lys	Leu	Asn	Pro	Met	Thr	Lys	His	Thr	Asp	Leu	Pro	Val
				155					160					165
Ser	Val	Phe	Glu	Ser	Val	Ile	Asp	Ile	Ile	Asn	Gly	Glu	Ala	Thr
				170					175					180
Met	Leu	Phe	Ala	Glu	Leu	Thr	Tyr	Thr	Leu	Ala	Thr	Glu	Glu	Ala
				185					190					195
Glu	Arg	Ile	Gly	Val	Asp	His	Val	Ala	Arg	Met	Thr	Ala	Thr	Gly
				200					205					210
Ser	Gly	Glu	Asn	Ser	Thr	Val	Ala	Glu	His	Leu	Ile	Ala	Gln	His
				215					220					225
Ser	Ala	Ile	Lys	Met	Leu	His	Ser	Arg	Val	Lys	Leu	Ile	Leu	Glu
				230					235					240
Tyr	Val	Lys	Ala	Ser	Glu	Ala	Gly	Glu	Val	Pro	Phe	Asn	His	Glu
				245					250					255
Ile	Leu	Arg	Glu	Ala	Tyr	Ala	Leu	Cys	His	Cys	Leu	Pro	Val	Leu
				260					265					270
Ser	Thr	Asp	Lys	Phe	Lys	Thr	Asp	Phe	Tyr	Asp	Gln	Cys	Asn	Asp
				275					280					285
Val	Gly	Leu	Met	Ala	Tyr	Leu	Gly	Thr	Ile	Thr	Lys	Thr	Cys	Asn
				290					295					300
Thr	Met	Asn	Gln	Phe	Val	Asn	Lys	Phe	Asn	Val	Leu	Tyr	Asp	Arg
				305					310					315
Gln	Gly	Ile	Gly	Arg	Arg	Met	Arg	Gly	Leu	Phe	Phe			
				320					325					

&lt;210&gt; 11

&lt;211&gt; 458

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 2680548

&lt;400&gt; 11

Met	Ala	Ala	Pro	Arg	Ala	Gly	Arg	Gly	Ala	Gly	Trp	Ser	Leu	Arg	1	5	10	15
Ala	Trp	Arg	Ala	Leu	Gly	Gly	Ile	Arg	Trp	Gly	Arg	Arg	Pro	Arg	20	25	30	35
Leu	Thr	Pro	Asp	Leu	Arg	Ala	Leu	Leu	Thr	Ser	Gly	Thr	Ser	Asp	40	45	50	55
Pro	Arg	Ala	Arg	Val	Thr	Tyr	Gly	Thr	Pro	Ser	Leu	Trp	Ala	Arg	60	65	70	75
Leu	Ser	Val	Gly	Val	Thr	Glu	Pro	Arg	Ala	Cys	Leu	Thr	Ser	Gly	80	85	90	95
Thr	Pro	Gly	Pro	Arg	Ala	Gln	Leu	Thr	Ala	Val	Thr	Pro	Asp	Thr	100	105	110	115
Arg	Thr	Arg	Glu	Ala	Ser	Glu	Asn	Ser	Gly	Thr	Arg	Ser	Arg	Ala	120	125	130	135
Trp	Leu	Ala	Val	Ala	Leu	Gly	Ala	Gly	Gly	Ala	Val	Leu	Leu	Leu	140	145	150	155
Leu	Trp	Gly	Gly	Gly	Arg	Gly	Pro	Pro	Ala	Val	Leu	Ala	Ala	Val	160	165	170	175
Pro	Ser	Pro	Pro	Pro	Ala	Ser	Pro	Arg	Ser	Gln	Tyr	Asn	Phe	Ile	180	185	190	195
Ala	Asp	Val	Val	Glu	Lys	Thr	Ala	Pro	Ala	Val	Val	Tyr	Ile	Glu	200	205	210	215
Ile	Leu	Asp	Arg	His	Pro	Phe	Leu	Gly	Arg	Glu	Val	Pro	Ile	Ser	220	225	230	235
Asn	Gly	Ser	Gly	Phe	Val	Val	Ala	Ala	Asp	Gly	Leu	Ile	Val	Thr	240	245	250	255
Asn	Ala	His	Val	Val	Ala	Asp	Arg	Arg	Arg	Val	Arg	Val	Arg	Leu	260	265	270	275
Leu	Ser	Gly	Asp	Thr	Tyr	Glu	Ala	Val	Val	Thr	Ala	Val	Asp	Pro	280	285	290	295
Val	Ala	Asp	Ile	Ala	Thr	Leu	Arg	Ile	Gln	Thr	Lys	Glu	Pro	Leu	300	305	310	315
Pro	Thr	Leu	Pro	Leu	Gly	Arg	Ser	Ala	Asp	Val	Arg	Gln	Gly	Glu	320	325	330	335
Phe	Val	Val	Ala	Met	Gly	Ser	Pro	Phe	Ala	Leu	Gln	Asn	Thr	Ile	340	345	350	355
Thr	Ser	Gly	Ile	Val	Ser	Ser	Ala	Gln	Arg	Pro	Ala	Arg	Asp	Leu	360			

Tyr	Ile	Gly	Val	Met	Met	Leu	Thr	Leu	Ser	Pro	Ser	Ile	Leu	Ala	
				365					370					375	
Glu	Leu	Gln	Leu	Arg	Glu	Pro	Ser	Phe	Pro	Asp	Val	Gln	His	Gly	
				380					385					390	
Val	Leu	Ile	His	Lys	Val	Ile	Leu	Gly	Ser	Pro	Ala	His	Arg	Ala	
				395					400					405	
Gly	Leu	Arg	Pro	Gly	Asp	Val	Ile	Leu	Ala	Ile	Gly	Glu	Gln	Met	
				410					415					420	
Val	Gln	Asn	Ala	Glu	Asp	Val	Tyr	Glu	Ala	Val	Arg	Thr	Gln	Ser	
				425					430					435	
Gln	Leu	Ala	Val	Gln	Ile	Arg	Arg	Gly	Arg	Glu	Thr	Leu	Thr	Leu	
				440					445					450	
Tyr	Val	Thr	Pro	Glu	Val	Thr	Glu								
				455											

&lt;210&gt; 12

&lt;211&gt; 532

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 2957969

&lt;400&gt; 12

Met	Leu	Gly	Ala	Trp	Ala	Gly	Arg	Lys	Met	Ala	Asn	Val	Gly	Leu	
1				5					10					15	
Gln	Phe	Gln	Ala	Ser	Ala	Gly	Asp	Ser	Asp	Pro	Gln	Ser	Arg	Pro	
				20					25					30	
Leu	Leu	Leu	Leu	Gly	Gln	Leu	His	His	Leu	His	Arg	Val	Pro	Trp	
				35					40					45	
Ser	His	Val	Arg	Gly	Lys	Leu	Gln	Pro	Arg	Val	Thr	Glu	Glu	Leu	
				50					55					60	
Trp	Gln	Ala	Ala	Leu	Ser	Thr	Leu	Asn	Pro	Asn	Pro	Thr	Asp	Ser	
				65					70					75	
Cys	Pro	Leu	Tyr	Leu	Asn	Tyr	Ala	Thr	Val	Ala	Ala	Leu	Pro	Cys	
				80					85					90	
Arg	Val	Ser	Arg	His	Asn	Ser	Pro	Ser	Ala	Ala	His	Phe	Ile	Thr	
				95					100					105	
Arg	Leu	Val	Arg	Thr	Cys	Leu	Pro	Pro	Gly	Ala	His	Arg	Cys	Ile	
				110					115					120	
Val	Met	Val	Cys	Glu	Gln	Pro	Glu	Val	Phe	Ala	Ser	Ala	Cys	Ala	
				125					130					135	
Leu	Ala	Arg	Ala	Phe	Pro	Leu	Phe	Thr	His	Arg	Ser	Gly	Ala	Ser	
				140					145					150	
Arg	Arg	Leu	Glu	Lys	Lys	Thr	Val	Thr	Val	Glu	Phe	Phe	Leu	Val	
				155					160					165	
Gly	Gln	Asp	Asn	Gly	Pro	Val	Glu	Val	Ser	Thr	Leu	Gln	Cys	Leu	
				170					175					180	
Ala	Asn	Ala	Thr	Asp	Gly	Val	Arg	Leu	Ala	Ala	Arg	Ile	Val	Asp	
				185					190					195	
Thr	Pro	Cys	Asn	Glu	Met	Asn	Thr	Asp	Thr	Phe	Leu	Glu	Glu	Ile	
				200					205					210	
Asn	Lys	Val	Gly	Lys	Glu	Leu	Gly	Ile	Ile	Pro	Thr	Ile	Ile	Arg	



215	220	225
Asp Glu Glu Leu Lys Thr Arg Gly Phe	Gly Gly Ile Tyr Gly Val	
230	235	240
Gly Lys Ala Ala Leu His Pro Pro Ala	Leu Ala Val Leu Ser His	
245	250	255
Thr Pro Asp Gly Ala Thr Gln Thr Ile	Ala Trp Val Gly Lys Gly	
260	265	270
Ile Val Tyr Asp Thr Gly Gly Leu Ser	Ile Lys Gly Lys Thr Thr	
275	280	285
Met Pro Gly Met Lys Arg Asp Cys Gly	Gly Ala Ala Ala Val Leu	
290	295	300
Gly Ala Phe Arg Ala Ala Ile Lys Gln	Gly Phe Lys Asp Asn Leu	
305	310	315
His Ala Val Phe Cys Leu Ala Glu Asn	Ser Val Gly Pro Asn Ala	
320	325	330
Thr Arg Pro Asp Asp Ile His Leu Leu	Tyr Ser Gly Lys Thr Val	
335	340	345
Glu Ile Asn Asn Thr Asp Ala Glu Gly	Arg Leu Val Leu Ala Asp	
350	355	360
Gly Val Ser Tyr Ala Cys Lys Asp Leu	Gly Ala Asp Ile Ile Leu	
365	370	375
Asp Met Ala Thr Leu Thr Gly Ala Gln	Gly Ile Ala Thr Gly Lys	
380	385	390
Tyr His Ala Ala Val Leu Thr Asn Ser	Ala Glu Trp Glu Ala Ala	
395	400	405
Cys Val Lys Ala Gly Arg Lys Cys Gly	Asp Leu Val His Pro Leu	
410	415	420
Val Tyr Cys Pro Glu Leu His Phe Ser	Glu Phe Thr Ser Ala Val	
425	430	435
Ala Asp Met Lys Asn Ser Val Ala Asp	Arg Asp Asn Ser Pro Ser	
440	445	450
Ser Cys Ala Gly Leu Phe Ile Ala Ser	His Ile Gly Phe Asp Trp	
455	460	465
Pro Gly Val Trp Val His Leu Asp Ile	Ala Ala Pro Val His Ala	
470	475	480
Gly Glu Arg Ala Thr Gly Phe Gly Val	Ala Leu Leu Leu Ala Leu	
485	490	495
Phe Gly Arg Ala Ser Glu Asp Pro Leu	Leu Asn Leu Val Ser Pro	
500	505	510
Leu Gly Cys Glu Val Asp Val Glu Glu	Gly Asp Val Gly Arg Asp	
515	520	525
Ser Lys Arg Arg Arg Leu Val		
530		

&lt;210&gt; 13

&lt;211&gt; 1542

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 135360

&lt;400&gt; 13

```

atattctttaa agggcacagc taatgacgcc tcttccctagt gaatcogtgt tcttctatgag 60
gtatcttttta tagttgtatc tttttttttt tctgagatgg agtctcgtct tactgtagcc 120
caggatggag tgcagttagt tgatcttggc tctctgcaac ccttgcctcc cgggttcaag 180
gaattctctt gccttagcct cctgagtagc tgagattaca ggcgcccccc accacacctg 240
gctgattttc gtctcttagt agagacaggg tttcaccaag ttggccaggc tagtctcgaa 300
ctgacctcaa gtgatccatc cgccttgggt tcccaazgtg ttgggattac aggtgtgagc 360
cactgtgccc agccaagtta tatctctaaa gcaatgtgca aaataaaact gaacttgggt 420
tgattaggta tattcaacat ttgtcgggag agtagatgtt tcattttatt tcagtccctg 480
tgaattttgt ctctctaat gttaaaact ctctagactt tggtctgtgta atttctataga 540
tacttttatt atggatggac attctaattt gctactgact ttgggtctgtg aactacttca 600
atgtctggag gttaccaaaa tcttaccttt cctttttcta tcttagaatt taccatagta 660
atgacgaagt taaggataaa gcttttgaac tagaactcag ctgggttgggt gaatgtcagt 720
tattctttgt calttatttg cctttaggaat gatctgtacc acagctaatt tacaactgag 780
tgtrctttct aatataatga aagctaaagc aaatttacta ggttgtctaa tgaagggaaa 840
gttctgtctta ataattgact taagtctgta acacgttatt ttttgaacaa tccatttcat 900
ggcttttaaga tactatgcta taatttaatt ctccaggatt ataaatagca taatttactt 960
tcatttccat aagaaacttae tatgtaggca catataatct catgtagaag cagcacacaa 1020
aaatattcga gtattactca tagtacaact ttgcaacctt aggtgagtc aatcaattta aaattcattt 1080
ttgggtagat cctatgggtat actgcaagtt acaatatgggt actcaattta aaattcattt 1140
acacatgttg cttaatttac agtaactaat ggaagacatg aaattgttcc aaaagatata 1200
agagaagaag cagagaacta tgctaaggta agccacagca caaaaacttc tcttggccag 1260
gtacagtcag ggaatctctt agcccaggag tttagagcca gnetgagcag caccagcaaga 1320
ccccctatcc taatttaaaa aaaaaaaat tctctaacca aaattatgtg ttgaataata 1380
taaatagact ggggttggtt ctatgaata acactgagag ttcaagtgaa ctaaagatag 1440
aaattttcta ggttatctct agtgggtaaa gttgccttgg ttccaaaaaa aaaaaacttg 1500
ggaggttttag actgcacaaga gtttttttag acttctaata ct 1542

```

&lt;210&gt; 14

&lt;211&gt; 3043

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 447484

&lt;400&gt; 14

```

cccacgcgtc oggtaaaatgg ctgtaataca ggaattttgc cacaaccagt tgggacagtc 60
ttgtttgcaaa taccagaacc tcaagaatcg aacagtgcag caggaataaa ttttaatagcc 120
cttccagcat tttcacaggt ggacctgag gtatttgcgt ccttctctgc tgaacttcag 180
agggagctga aagcagcgtg tgatcaaaga caaaggcagg gcgagaacog cactcaaccg 240
cagtcagcca ggcacatctg gccaaagaat cetttacttc atctaaaggc agcagtgaan 300
gaaaagaaaa gaaacaagaa gaaaaaaacc atttggttcac caaaaaggat tcagagtcct 360
ttgaataaaca agctgcttaa cagtccctgca aaaactctgc caggggcectg tggcagtcct 420
cagaagttaa ttgatgggtt tctaaaacat gaaggacctc ctgcagagaa acccctggaa 480
gaactctctg ctteacttct aggtgtgcca ggcctttcta gtttgcagtc ttgaattcaa tgatgtgaag 600
ggctgtgtga gacctccagc acccaatcta gctggagctg ttgaattcaa tgatgtgaag 660
accttgcctc gagaatggat aactacaatt tcagatccaa tggagaaga catcttccaa 660
gttgtgaaat actgtactga tctaactgaa gnaaaagatt tggaaaaact ggtcttagtt 720
ataaaataca tgaaaaaggct gatgcagcaa tccgttggat cggtttggaa tatggcattt 780
gaatttattc ttgacaatgt ccaggttggt ttcaacana cttaaggaa cacttataaa 840
gttacataaa tattaccaga gagcctgagt ctctctgata gctgtgccat aagtgtctgt 900
gaggtatttg caaagtgcac gatagtaatg ctccgagttt ttataatttt aaatttcttt 960
taaaagcaagt gttttgtaca tttcttttca aaaagtgcac aatttgtcag tatfgcatgt 1020
aaataaattgt gtttaattat ttaactgtagc atagattcta ttacaaaat gtttgtttat 1080
aaagctttat ggatttttac agtgaagtgt ttacagttgt tcaataaaga actgtatgta 1140

```

tattttgtac	agggtccctt	ttgtgaetcc	ttaaaaactc	aactctagga	agcaactact	1200
gtttattkta	ctaaaagggt	gaaa acctc	caggccagac	tgtatagctc	tgaatttcc	1250
gagaggtctc	agaccgggat	tctacttgtt	ccaagaaagg	gtatagcttc	ttaaccatct	1320
cattcttctc	tccaagcatg	aacacaggag	catgttaaga	aaatcttlac	tacttcttcc	1380
atgcggagaa	atctacatnt	tttgaattag	aaacacccct	acacccactt	gaagattctt	1440
ttcctgggaa	cattatgtcc	cgtagatcag	agggtgggtg	gtctttttgc	ttctactggc	1500
cattgagaaa	ctttgatgat	aaaaaagAAC	ggatagatt	tttcaaacgt	atataaaata	1560
tttttatgtt	atctgttatg	ccataacttt	aaaataaaaa	tagtttataa	ttctatgcta	1620
gtggatattt	ggaacttttt	cctcaaacaa	acaccccaaa	ctgacttcag	caaaacccta	1680
aaactagcta	cagattactg	ctacgaatga	atcattaagt	tttgtgtctg	caacaattta	1740
gaagcactaa	gcccacatnt	caggaaatgt	gtgtatgatg	gaatttttca	ggacaaaaaa	1800
gatcaagatt	aaaacagatc	aagattaatg	tataaaaatg	tctactaaaa	cagatcaaga	1860
ctaaacagaa	tcaagattaa	tgtataaaaa	tctctactgt	taccagggtg	tggcatacaa	1920
ggtagtgtga	tgtatgkta	gtttgttaaga	taattcttgt	cctaggaggga	caacttgttg	1980
gagagaagct	acactaacat	ggaagcctaa	cagagcttgc	ttactgggtg	atgtctgttt	2040
tctttatttg	tagtttggtt	tagaatttgt	atgattacaa	tggactcgtg	actacacaa	2100
cagtaaaaaa	cagccagctc	tatggctatc	ggaggggcag	tggagggggt	cccagcatgg	2160
gcagagaaat	aagggtctgaa	gagccagagg	agtcagtacc	tttcagctgt	gactggcgga	2220
aggtagggcg	cgccatctca	cccatcaagg	accagaaaaa	ctgcaactgc	tgtggggcca	2280
tggcagcgcc	aggcaacata	gagacccctgt	ggcgcacag	ttcttgggat	tttgtggacg	2340
tctccgtgca	ggaactgctg	gactgtggcc	gctgtgggga	tggctgcrac	ggtaggcttc	2400
cttgggacgc	gttcataact	gtcctcaaca	acagcggcct	ggccagtga	aaggactacc	2460
cgttccaggg	caaagtraga	gcccacaggt	gccaccccaa	gaagtaccag	aagggtggct	2520
ggatccaggg	cttcatctat	ctgcagaaca	acgagcacag	aattgcgrag	tacctggcca	2580
cttatggccc	catcacctgt	accatcaaca	tgaagccctt	ttagctatct	cggaagggtg	2640
tgatcaaggc	cacacccacc	acctgtgacc	cccagcttgt	ggaccactct	gtcctgctgg	2700
tgggttttgg	cagcgtcaag	tcagaggagg	ggatatgggc	agagacagtc	tcatcgagct	2760
ctcagcctca	gcttccacac	cccaccccat	actggatcct	gaagaactcc	tggggggccc	2820
aatggggaga	gaagggttat	ttccggctgc	accgagggag	caatacctgt	ggcatcacca	2880
agttcccgct	cactgcccgt	gtgcagaaac	cggatatgaa	gcccagagtc	tcttgccctc	2940
cctgaaccca	cctggccccc	tcagctctgt	cctgttaggc	caactgcctc	cttgccagcc	3000
ccaccccccag	gtttttggccc	atcctcccaa	tctcaataca	ggg		3063

&lt;210&gt; 15

&lt;211&gt; 1081

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 789927

&lt;400&gt; 15

aggaggcaga	gggggcgta	ggccgcggga	gaggaggcca	tgggcgcgcg	cggggcgctg	60
ctgctggcgc	tgtctgctgg	tcgggctgga	ctcaggaagc	cggagtcgca	ggaggcggcg	120
cccttatcag	gaccatgcgg	ccgacgggtc	atcacgtcgc	gcctcgtggg	tggagaggac	180
gcgaactcgc	ggcgttggcc	gtggcagggg	agcctgcgcc	tgtgggattc	ccacgtatgc	240
ggagtgaagc	tgtctagcca	ccgctgggca	ctcacggcgg	cgcactgctt	tgaaacctat	300
agtgacctta	gtgatccctc	cggttggatg	gtccagtitt	gncagctgac	ttccatgcca	360
tccttcttga	gcctgcaggc	ctactacacc	cgttacttgc	tatcgaata	ctacttgagc	420
cctcgtctac	tggggaattc	acccatagac	attgccttgg	tgaagctgtc	tgcacctgtc	480
acctacacta	aacacatcca	gcccattctgt	ctccaggcct	ccacatttga	gtttgagAAC	540
cggacagact	gctgggtgac	tggctggggg	tacatcaaa	aggatgaggr	actgccatct	600
ccccacccc	tccagggaagt	tcaggctcgc	atcataaaca	actctatgtg	caaccacctc	660
ttcctcaagt	acagtttctc	caaggac tc	tttggagaca	tggtttgtgc	tggcaatgac	720
caaggcgsga	aggatgcctg	cttcgggtgac	tcagggtggac	ccttggcctg	taacaagaat	780

```

ggactgttgg atcagattgg agtcgtgagc tggggagtg gctgtggtcg gccaatcgg 840
cccggtgtct acaccaatat cagccaccac tttgagtggg tccagaagct gatggccag 900
agtggcatgt cccagccaga cccctctctg ccactactct tttccctct tctctgggt 960
ctccactcc tggggccggg ctgagcctac ctgagcccat gcagcctggg gccactgcca 1020
agtcaaggcc tggttctctt ctgtcttctt tggtaataaa cacattccag ttgatgcctg 1080
c

```

1081

&lt;210&gt; 16

&lt;211&gt; 2061

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 877617

&lt;400&gt; 16

```

cttgagagct ctcaataact tggtcatgga tgaagccgac ogaatactga atatggattt 60
tgagacagag gttganaago ntogagatcg gaaaacattc ctcttctctg ccacatgac 120
caagaagggt caaaaacttc agcgagcagc tctgaageat cctgtgaat gtgccgtttc 180
ctctaaatcc cagacagttg aaaaattaca gcaatattat atttttatto cctctaaatt 240
caaggatacc taccctggtt atattctaaa tgaacttggt ggaaactcct ttatgatatt 300
ctgcagcacc tgaataaata cccagagAAC agctttgcta ctgcgaaatc ttggttccac 360
tgccatcccc ctccatggac gcccgttcca tcttcttagc aactgacgtt gccagccgag gtttggacat 420
taaggccaag gcccgttcca tcttcttagc aactgacgtt gccagccgag gtttggacat 480
acctcatgta gatgtggttg tcaacttga cattcctacc cattccaagg attacatcca 540
tcgagtaggt cgaacagcta gagctgggcs ctccggaag gctattaact ttgtcacaca 600
gtatgatgtg gaactcttcc agcgcataga acacttaatt gggaaagaac taccaggttt 660
tccaacacag gatgatgagg ttatgatgct gacagaaagc gtcccagag atgtctccac 720
caccgtgtgt gcaacccctg ctgctgtctg tgcctctgct gaatgtggag ccttcggggg 780
ccacactgat ccgcattcct ctccatcgag tccaacctgg acgcaggacc ctgaacctac 840
tgaggggatg gagagaacca gcagagctcc ccaagttggg ggcgccatcc cctggggaca 900
agcccatctt cgtacctctc tcgaactaca gggatgtgca gtattttggg gaaattgggc 960
tgggaacgac tccacaaaac ttcaactgtt cctttgacac tggctcctcc aatctctggg 1020
tcccgctccag gagatgccac ttcttcagtg tgcctgtctg gttacaccac cgatttgatc 1080
ccaaagcctc tagctccttc caggccaatg ggaaccaagt tggcatcca tatggaactg 1140
ggcgggtaga tggaaatcct agcgaggaca agctgactat tggtggaatc aagggtgcat 1200
cagtgaattt cggggaggct ctctgggagc ccagcctggg cttegtttt gccattttg 1260
atgggatatt gggcctcggc ttcccatc tctctgtgga aggagtctcg ccccgatgg 1320
atgtantggt ggagcagggg ctaltggata agcctgtctt ctcttttac ctcaacaggg 1380
acctgaaga gcttgatgga ggagagctgg tccctggggg ctccgaccgg gcacactaca 1440
tcccacccct caccctcgtg ccagtcacgg tccctgccta ctggcagatc cacatggagc 1500
gtgtgaagggt gggcccagggt ctgaactctt gtgccaagggt ctgtgtgtcc atcctggata 1560
cgggcacgto cctcatcaca ggacccactg aggagatccg ggccttgcat gcagccattg 1620
ggggaatccc ctctgtgggt ggggagtaca tcatcctgtg ctgggaaatc ccaaagctcc 1680
ccgcagtctc ctctccttctt gggggggtct ggttttaacct caccggccat gattacgtca 1740
tcagaaactac tcgaastggc gtccgcctct gcttgctcgg tttccaggcc ctggatgtcc 1800
ctccgcctac agggcccttc tggatcctcg gtgaogtctt ctgggggacg tatgtggcgg 1860
tcttcgaccy cggggacatg aagagcagcg cccgggtggg cctggcgcg cctcgactc 1920
gcggagcggg cctcggatgg ggagagactg cgcaggcgca gttccccggg tgacgcccac 1980
gtgaagcgca tgcgcagcgg gtggtcgcgg aggtcctgct acccagtaaa aatccactat 2040
ttccattgaa aaaaaaaaaa a

```

2061

&lt;210&gt; 17

&lt;211&gt; 1186

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 999322

&lt;400&gt; 17

```

taagcgtcgc cagaccagcc tgagtggctc cacagacgtt ggtctgcgtg tttatctcct 60
ctccctccc accccaccct gaagctggga acacttgggg ccaggaccra tgctgtccag 120
actgtgggac tccccttggc caaggtgarc aacatacttg attttgggga tcttgagcca 180
gtgtccagga ttgtgcccgt gttgggatga ataagccaag gctaagaggt catgagatta 240
gccagggtca tgggagagga tctgggcttg agccctgtct cctgaccca ctgctcctg 300
gttctgggag tgagaagagc aggttgggtg ggcagagaa ggttaggagg tgagggtgc 360
cgccatcaca ggtgagaggg cagaggctca cctgatgggg acgaggcttg aggtgggctc 420
aggttggccc ccacatcaca tccagccctg gcagtggtcc ttcaggaggt ggtgtgccc 480
ctcctggact cgaacatgtg tgagctgatg taccacctag gagagcccag cctggctggc 540
caggccctca tccaggacga catgctctgt gctggctctg tccagggcaa gaaagactcc 600
tgccaggtag ctgcagctcc tggtcacccc atccagtgt gtgggcccct taggtcacc 660
ctgtcctgga ctttctcccc atgtccaca cctcagggtc tccagaggga ccagagtcct 720
tgcttagctc cttggcctca gcagctgatt ctcaaggca ctggggccc aggtgtctcc 780
ctcaatgcag acctcatggg gccctccctc tctctcccc aggtgactc cggggggccc 840
ctggtctgcc ccacatga taagtggatc caggccggca ttgtgagctg gggattcggc 900
tgtgcccgcc ctttccggcc tgggtgttac acccaggtgc taagctacac agactggatt 960
cagagaaacc tggctgaatc tcactraggc atgtctgggg cccgcccagg tgcgccagga 1020
tcccactcag gcacctccag atccaccca gtgtgtctgc ttgagctgtt gacctatgc 1080
tcgtctgggt cctgtgaaac catgagccat ggagtcggg atccccctt tggtaggatt 1140
gatggaatct aataataaaz actgtaggtt ttttatgtgt aaaaac 1186

```

&lt;210&gt; 18

&lt;211&gt; 2038

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 1337018

&lt;400&gt; 18

```

gcagcttgc cagcggacaa ggtatgctggg cgtgaggagc caaggcctgc cctgcactcg 60
ggcctcctcc agccagtgtc gaccagggac tctgacctg ctggccagcc aggaactgtg 120
tggggaggcc ctctgtgtg cttggggtga caatctcagc tccaggctac agggagaccg 180
ggaggatcac agagccagca tggatcctga cagtgatcaa cctctgaaca gcttcgatgt 240
caaacccctg cgcacacccc gtatccccc atggaccttc agaaagggtg ggtaccccat 300
catcatagca ctactgagcc tggcgagtat catcattgtg gttgtcrtca tcaaggtgat 360
tctggataaa tactacttcc tctgcgggca gacctccac ttcacccga ggaagcagct 420
gtgtgacgga gagctggact gtcccttggg ggaggacag gagcactgtg tcaagagctt 480
ccccgaaggg cctgcagtgg cagtccgccc ctccaaggac cgatccacac tgcagggtgt 540
ggactcggcc acagggaart ggttctctgc ctgtttcgac aacttcacag aagctctcgc 600
tgagacagcc tgtaggcaga tgggctacag cagcaaaccc actttcagag ctgtggagat 660
tggcccagac caggatctgg atgttgttga aatcacagaa aacagccagg agcttgcct 720
gcccgaactca agtgggccc gtctctcagg ctccctggtc tccctgcact gtcttgctg 780
tggggagagc ctgaagaccc ccgtgtggg ggggtggggg gaggcctctg tggattcttg 840
gccttggcag gtacgacccc agtacgacaa acagcacgtc tgtggaggga gcacccctga 900
ccccactgg gtcccaagg cagcccactg ctccaggaaa cataccgatg tgttcaactg 960
gaaggtgagg gcaggctcag acaaacctgg cagcttccca tccctggctg tggcraagat 1020
catcatcatt gaattcaacc ccatgtaccc caaagacaat gacatcgccc tcatgaagct 1080

```

```

gcagttccca ctcactttct caggcacagt caggcccatc tgtctgceet tctttgatga 1140
ggagctcact ccagccaccc cactctggat cattggatgg ggctttaoga agcagaatgg 1200
aggggaagatg tctgacatac tgcctgcaggc gtcagtccag gtcattgaca gcararggtg 1260
caatgcagac gatgcgtacc aggggggaagt caccgagaag atgatgtgtg caggcatccc 1320
ggaagggggt gtggacacct gccaggstga cagtgggtggg cccctgatgt accaatctga 1380
ccagtggcat gctggtgggca tctttagctg gggctatggc kgcggggggc cgagcaccce 1440
aggagtatac accaaggctct cagcctatct caactggatc tacaatgtct ggaaggctga 1500
gctgtaatgc tgcctgcccc ktgcagtgtc gggagcogct tcttctctgc cctgcccacc 1560
tggggatccc ccnaagtcag acacagagca agagtccctc tgggtacacc cctctgcccc 1620
cagcctcagc atttcttggg gcagcaaaag gctcgaatc ctataagaga cctcgagcgc 1680
ccagaggcgcc ccagagggaag tcagcagccc tagctogggc acacttggty ctcccagcat 1740
cccaggggaga gacacagccc actgaacaag gtctcagggg tattgctaag ccaagaagga 1800
actttccnac actactgaat ggaagcaggg tctcttgcga aagcccgat cactgtgggc 1860
tggagaggga aagggaaggg tctgcgccag cctgtccgt cttcacccat ccccaagcct 1920
actagagcaa gaaaccagt tttaataaaa atgcactgcc ctactgttgg tatgactacc 1980
gttaccctact gttgtcattg ttattacagc tatggccact attattaaag agctgtga 2038

```

&lt;210&gt; 19

&lt;211&gt; 994

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 1798496

&lt;400&gt; 19

```

gtgcaggagg agaaggagga ggagcaggag gtggagattc ccagttaaaa ggctccagaa 60
tcgtgtacca ggcagagAAC tgaagtactg gggcctcttc cactgggtcc gaatcagtag 120
gtgacccccg ccttggattc tggaaagacct caccatggga cgtccccgac ctctgctggc 180
csagacgtgg atgttcctgc tcttgcctgg gggagcctgg gcaggacact ccagggcaca 240
ggaggaacaag gtgctggggg gtcatgagtg ccaacccccat tgcagcctt ggagggcggc 300
cttgtcccaag ggcagcaaac tactctgttg cgggtgtcctt gtagggtggca actgggtcct 360
tacagctgcc cactgtaaaa aaccgaataa caccgtacgc ctgggagacc acagcctaca 420
gaatcaagat ggcccagagc aagaaatacc tgtggttcag tccatccac acccctgcta 480
caacagcagc gatgtggagg accacaacca tgaatctgat ctctctcaac tgggtgacca 540
ggcatccctg gggtcacaag tgaagcccat cagcctggga gatcattgca cccagccttg 600
ccagaagtgc accgtctcag gctggggcac tgtcaccagt ccccgagaga attttcctga 660
cactctcaac tgtgcagaag taaaaatctt tccccagaag aagtgtgagg atgcttacc 720
ggggcagatc acagatggca tggctgtgtg aggcagcagc aaaggggctg acacgtgcca 780
gggcgattct ggaaggcccc tggctgtgtg tggctgactc cagggcatac catcctgggg 840
ctcagacccc tgtgggaggt ccgacaaacc tggcgtctat accaacatct gccgctacct 900
ggactggatc aagaagatca taggcagcaa gggctgattc taggataagc actagatctc 960
ccttaataaaa ctacacactc tctgaaaaaa aaaa 994

```

&lt;210&gt; 20

&lt;211&gt; 1318

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; 88

&lt;223&gt; a or g or c or t, unknown, or other

&lt;220&gt; -

&lt;223&gt; 2082147

&lt;400&gt; 20

```

tctgaggcgc gtgcgcggcc acccagcct agtcctcttc ttggtgccac tggcfaacta 60
ggctgagaaa cggcgccac aggcgcandc cctggcccg agctggcccg ctctccccc 120
ccgagccgcc cccaacacg cgcctctcc cagtcctcac aaaggggccc agtcggccc 180
cgggtctggt ccgtgagggg gcgctgtggg ggogcgctgc ctctgcctg gaagtgttg 240
gcaggtgggt ggagagcgtc aggcctgaac aacatgattt taagcagct gtctgtctgt 300
cgtcttttac ttttagggct ttggcraaat tgggcgaggg cacaaaataa ccacttacc 360
cttctcaccg aggaagagcg ggagaaaggg tatggcacag tcacaagggt ggggtgaaaag 420
atacatcaag gccttttcta aaggcttctt tgtggcgggt cctgtggcag tgactctct 480
ggatcggggt gcctgtgtgg caagagttaga agggagcatc atgcagcctt ctttgaatcc 540
tgggggggag cagtcactct atgtgtgtct ttgaaccac tggaaagtga ggaattttga 600
agtacaccgt ggtgacattg tatcattggt gtctcctaaa aaccagaac agaagatcat 660
taagagagtg attgctcttg aaggagatat tgtcagaacc ataggacaca aaaccggta 720
tgcacaagtc ccccggtggt acatctgggt tgaagggtgac catcatggac acagtttga 780
cagtaattct tttggccgg tttcctagg acttctgcat gccatgccn cacatattct 840
gtggccccc aagcgtctgg agaaattgga atctgtctt cctccagagc gcttaccagt 900
acagagagaa gaggaattga tgcattgaat tacctgagtt gctggcattg ggaaggccagt 960
tactggaaag gaatggaaaa aagaagcctc caaaaggga aaactctga caatatgat 1020
ctgtgcgaga aatatttaca gcacattaaa acgatctgta ttattaaata aataattttc 1080
aatgtttaa cagtattaaa tggcacctga ctttgtgtta aattttagtt cctgttgttt 1140
taatgcccc aaaatatgca gacrtttggg aatataaaaa tatggcacc acatgtctta 1200
atggggctga atttcagatt attgttaca tatacttatt atattgattg ttgggttttg 1260
attttggtgc tgcctgntga antaaattga aaattaatat tcaaaaaaaa aaaaaaag 1318

```

&lt;210&gt; 21

&lt;211&gt; 2136

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 2170567

&lt;400&gt; 21

```

ggctctttta aatgacccca ggctcgtgt attgaatcct agactcacgt ccgtctcggc 60
ggcgcccgag ccagtcggcg cgcaccgct ctgctctccc gaaagcccg ccgcgaagg 120
ctgcccctgc tacctggtct ccgacgtgct cgtctggag ggglgagag gggccgagcc 180
gacaagatgt tcttgcctgc tcttccggct gcggggcgag tagtcgtccg acgtctggcc 240
gtgagacgtc tcgggagccg gagtctctcc accgcagaca tgadgaagg cctgtttta 300
ggaatctatt ccaagaaaa agaagatgat gtgccacagt tcacaagtgc aggagagaat 360
tttgataaat tgttagcttg aaagctgaga gagacttga acatatctgg accacctctg 420
aaggcaggga agactcgaac cttttatggt ctgcacagg acttccccag cgtggtgcta 480
gttggcctcg gcaaaaaggc agctggaat gacgaacag aaactggca tgaaggcaaa 540
gaaaacatca gagctgctgt tgcagcgggg tgcaggcaga tcaagacct ggaactctcg 600
tctgtggagg tggatccctg tggagacgtc caggctgctg cggaggagc ggtgcttgg 660
ctctatgaat acgatgacct aaagcaaaaa aagaagctg ctgtgtcgg aaagctctat 720
ggaagtgggg atcaggaggc ctggcagaaa ggaagtcctg ttgcttcttg gcagaacttg 780
gcacgccaat tgatggagac gccagccaat gagatgaog caaccagatt tgcgaaatt 840
attgagaaga atctcaaaag tgcctagtag aaaaccgagg tccatatcag acccaagctc 900
tggattgagg aacaggcaat gggatcattc ctacgtgtgg ccaagggatc tgacgagccc 960
ccagtcctct tggaaattca ctacaaaggc agccccaatg caaacgaacc accctgggtg 1020
tttgttggga aaggaattac ctttgacagt ggtggtatct ccatcaaggc ttctgcacat 1080
atggacctca tgaaggctga catgggagga gctgcaacta tatgctcagc catcgtgtct 1140

```

```

getgcaaaagc ttaatttgcc cattaatatt ataggctctgg cccctctttg tgaaaatattg 1200
cccagcgggca aggcccaacaa gccggggggat gttgttagag ccaaaaacggg gaagaccatcc 1260
caggttgata acactgatgc tgagggggagg ctcatactgg ctgatgcgct ctgttarcga 1320
cacacgttta acccgaaaggc catcctcaat gcggccacct taacagggtgc catggatgta 1380
gctttgggat caggtgccac tgggggtcttt accaattcat cctggctctg gaacaaactc 1440
ttcgagggccg gcattgaaac agggggaccgt gtctggagga tgcctctctt cgaacattat 1500
acaagacagg ttgtagattg ccagcttgct gatgtaaca acattggaaa atacagatct 1560
gcaggagcat gtacagctgc agcattcctg aaagaattcg taactcatcc taagtgggca 1620
catttagaca tagcaggcgt gatgaccaac aaagatgaag ttccctatct acggaaaggc 1680
atgactggga ggcacacaag gactctcatt gacttcttac ttcgtttcag tcaagacaa 1740
gcttagttca gatactcaa aatgtcttca ctctgtctta aattggacag ttgaacttaa 1800
aagggttttcg aataaatgga tgaaaatctt ttaacggaga caaggatgg ttttaaaaa 1860
tgtagaacac aatgaattt gtatgccttg atttttttt tcatttcaca caaagattta 1920
taaaggtaaa gttaatatct tacttgataa ggatttttaa gatctctat amatgattaa 1980
aatttttaga acttctaat cacttttcag agtatatgtt ttccattgag aagcaaaatt 2040
gtaactcaga ttctgatgc taggaacatg agcaaaactg aaattactat gcaattgtca 2100
gaacaataa atgcaacttg ttgtgaaaaa aaaaaa 2136

```

&lt;210&gt; 22

&lt;211&gt; 1388

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 2484210

&lt;400&gt; 22

```

ggaaaatggc ggccggcggcg gcggcgggctg cagctacgaa cgggaccgga ggaagcagcg 60
ggatggagggt ggatgcagca gtatcccca gctgatggc ctgcggagtg actgggagtg 120
ttccgctcgc tctccatccc ctgtcattc tcaacatctc agaccactgg atccgcattg 180
gtccccagga gggcgggcct gtgcaggctga ttggggctct gattggcaag caggagggcc 240
gaaatatcga ggtgatgaac tcttttgagc tgcgtgacca caccgtggaa gagaagatta 300
tcattgacaa ggaatatbat tacaccaagg aggagcagtt taacagggtg ttcaaggagc 360
tggagtttct gggttgggtat accacagggg ggccacctga cccctcggac atccacgtcc 420
ataagcaggt gtgtgagatc atcgagagcc cctctcttct gaagtgaac cctatgacca 480
agcacacaga tcttctctgc agcgtttttg agtctgtcat tgatataatc aatggagagg 540
ccacaatgct gtttgcctgag ctgacctaca ctctggccac agagggaagc gaacgcattg 600
gtgtagacca cgtagcccca atgacagcaa caggcagtg agagaactcc actgtggctg 660
aacacctgat agcacagcac agcgcctaca agatgctgca cagcccgctc aagctcatct 720
tggagtacgt caaggccctt gaagcgggag aggtccctt taatcatgag atcctgcggg 780
aggcctatgc tctgtgtcac tgtctcccgg tgctcagcac agacaagttc aagacagatt 840
tttatgatca atgcaacgac gtggggctca tggcctacct cggcaccatc accaaaactg 900
gcaacacccat gaaccagttt gtgaacaaagt tcaatgtcct ctacgaccga caaggcatcg 960
gcaggagaaat gcgcgggctc tcttctctgat gaggtactt gaagggtgga tggacagggg 1020
tcaggcaact atcccaagg ggagggcact acacttctt gagagaaacc gctgtcatta 1080
ataaaagggg agcagccctt gagcaccctt gctggtygct ctgtcctctg ttaggcacca 1140
cactggttgg tcaacttggg tgttcacoga ggctcattt ggcttgcctc agaagccctt 1200
ctgatgctct tcagtggagg aggcactacc atttgaagtg accccatgtc agtcacatgg 1260
actggcttll agcaaatcc aaggctgctt gcttccacct aagtgtctc tgttctacac 1320
tttaactgtca cctctacat catcttacct agccaccca acctataaa catgataatt 1380
gactacta 1388

```

&lt;210&gt; 23

&lt;211&gt; 2476



&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 2680548

&lt;400&gt; 23

```

ctcgctgctt gggtgcccgc tctgagtagg gggggcgagg aggcagccaa ggcgagagctg 60
atggctgccc cgagggcggg gcggggtgca ggcctggagcc ttggggcatg gcgggctttg 120
gggggcattc gctgggggag gagaccccggt ttgacccctg acctccgggc cctgctgacg 180
tcaggaaact ctgacccccg ggcccgagtg acctatggga cccccagtcct ctgggccccg 240
ttgtctgttg gggtcactga accccgagca tgcctgacgt ctgggacccc ggggtccccg 300
gcacaaactga ctgcgggtgac cccagatacc aggcacccggg aggcctcaga gaactctgga 360
accggttcgc gcgctggtct ggccgttgcc cctggcgctg ggggggcagt gctgttgttg 420
ttgtggggcg ggggtcgggg tccctccggc gtccctcgccg ccgtccctag ccgcccgcgc 480
gctctctccc ggagtcagta caacttcac gcagatgttg tggagaagac agracctgcc 540
gtggtctata tcgagatcct ggaccggcac cttttcttgg gccgcgaggt cctatctctg 600
aacggctcag gattcgtggt ggctgcccgt gggctcattg tcaccaacgc ccatgtggtg 660
gctgatcggg gcagagtcctg tctgagactg ctaagcggcg acacgtatga ggccgtggtc 720
acagctgtgg atcccgctgg agacatcgca acgctgagga ttcagactaa ggagcctctc 780
cccacgctgc ctctgggagc ctccagctgat gtccggcagg gggagtctgt tgtctgccatg 840
ggaagtccct ttgcactgca gaacacgac acatccggca ttgttagctc tgctcagcgt 900
ccagccagag acctgggact cccccaacc aatgtggaat acattcaaac tgatgcagct 960
attgattttg gaaactctgg aggtcccttg gttaacctgg atggggaggt gatggagtg 1020
aacaccatga aggtcacagc tgggaatctc ttggccatcc cttctgatcg tcttcgagag 1080
tttctgcac gtggggaaaa gaagaattcc tccctcggaa tcagtgggtc ccagcggcgc 1140
tacattgggg tgatgatgct gacccctgag cccagcatcc ttgctgaact acagcttcca 1200
gaaccaagct ttcccgatgt tcagcatggt gtactcatcc ataaagtcat cctgggctcc 1260
cctgcacacc gggctggtct gcggcctggg gatgtgattt tggccatttg gggagagatg 1320
gtacaaaatg ctgaagatgt ttatgaagct gttcgaaccc aatcccagt ttggcagtgag 1380
atccggcggg gacgagaaac actgacctta tatgtgaccc ctgaggtcac agaattgaata 1440
gatcaccaag agtatgaggc tccctgctctg atttccctcc tgcctttctg gctgaggttc 1500
tgagggcacc tgggctctga agaatacacg aaacactttt tatataaaat azaattatac 1560
cactgactcc tgggctctga agaatacacg aaacactttt tatataaaat azaattatac 1620
ctagcaacat attatagtaa aaatgaggt gggagggctg gatcttttcc cccaccaaaa 1680
ggctagaggt aaagctgtat cccctaacac ttaggggaga tactggagct gaccatcctg 1740
acctcctatt aaagaaaaat agctgctgct atcttttctg ggcagttagt cagytgctgc 1800
tctttgtggt gtggtgggct ctggtctgtt ctgctcgggt ctgggcctgg gagcaaatat 1860
tcccatgctt ggctacagat actgacagct ggccctctga ggagggtgaa aacttctgct 1920
tgacagtcc acatccatag tgcattggtc agccctgcca ttaggggcca gtggtggttt 2040
ggaagtctcc tgaggtaatg gcagcctcag gataatctgg ttgctggtct ggccagggtg ggttcaaac 2100
gcagagggca gtggcaacta gaaggcatca ccaatgtggc agttgtgac ccagattcta 2160
ctcctgttgg cctcttcaat acatttcact gcattgttgg taaagtcact ctctgctacc 2220
tcaaagtctg ggttgatgac aacctggaga atgtagtttc ctggctcac atccgtgatg 2280
tcaatccact gacagtcatt gtcattgccg tagagatccc agcaaacccac agtgatgctt 2340
tgctctccaa agttggcaca ctataccgc ttggagacat cctcctgaca ctcatgtctt 2400
tcgagacaga aactagcttt gtggccctca gccaccttgg tgccatttgg ggtgaggata 2460
tcatagtgag tgaaga

```

2476

&lt;210&gt; 24

&lt;211&gt; 2231

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; -

&lt;223&gt; 2957969

&lt;400&gt; 24

```

gtttgaaaca gcttcacaa gctgggttatg aagaagaaac tcaaaataac aggagtggtct 60
tatggaaacta catggaggtta acagagggagg gtaccaacca aaggccctctg agcaatcagg 120
atgttggggg cgtggggcggg caggaagatg gctgaacgttg ggctgcagt.t ccaggcgagg 180
gggggggact cggacccaca gagccggccc ctgctgctgc tcgggtagct gcaccacctg 240
caccgcgtgc cctggagcca cgtccgcggg aagctgcagc cccgggtcac ctaggagctc 300
tggcaggtctg cctgtagcac gctcaacccc aaccccacgg acagctgtcc cctctacctg 360
aactacgcca cctggtctgc cctgocctgc aggtgagcc tgccctgcgc ccggagcgca tcgctgcatt 480
gcccacttca tcaagcgggt ggtgaggtctt gcttccgcct gtgccctggc ccgggacctc 540
gtgatgggtct ggcagcagcc ggaggtctt gcttccgcct gtgccctggc ccgggacctc 540
ccgctgttca cccaccgtc aggtgcctct cggcgcttgg agaaagaaac ggtcacctg 600
gagtttttcc tgggtgggaca agacaacggg ccggtggagg tgtccacatt gcagtgttta 660
gcgaatgcra cagacggcgt ggggttagca gcccgcctcg tggacacacc ctgcaatgag 720
atgaacaccc acaccttcc ctaggagatt aacaaagttg gaaaggagct ggggatcctc 780
cccaccatca tccgggatga ggaactgaag acgagaggtt ttggaggaa ctatggggtt 840
ggcaaaagccg ccttgcatcc cccagccctg gcccgcctca gccacacccc agatggagcc 900
acgcagacca tcgcctgggt gggcaaggcc atcgtctatg acactggagg cctcagcatc 960
aaagggaaga ctaccatgcc ggggatgaag ctagactgcg ggggtgctgc ggccgtcctg 1020
ggggccctca gagccgcaat caagcagggt ttcaaaaga acctccacc tggtttctgc 1080
ttggctgaga actcgggtggg gcccacatgc acaaaggccag atgacatcca cctgctgtac 1140
tcagggaaga cgggtggaat caacaacacg gatgcagag gcaggctggt gctggcagat 1200
ggcgtgtcct atgcttgcaa ggaacctggg gccgacatca tctgggcat ggccaccctg 1260
accggggctc agggcattgc cacagggaag taccacgccg cgtgtctcac caacagcct 1320
gagtgggagg ccgcctgtgt gaaggcgggc aggaagtgtg gggacctggt gcaccgctg 1380
gtctactgcc ccgagctgca cttcagcgag ttcacctcag ctgtggcgg catgaagaac 1440
tcagtggcgg accgagacaa cagccccagc tctgtgtctg gctcttctat cgcctcacac 1500
atcggcttgc actggcccg agtctgggtc cacttggaca ttgctgcacc ggtgcctgct 1560
ggtagcggag ccacaggctt cgggtgtggc ctcctgtctg cgtctctcgg ccgtgcctct 1620
gaggacccctc tgcggaacct ggtgtcccca ctgggctgtg aggtggatgt ctagggggg 1680
gacgtgggga gggactccaa gagacgcagg ctgtgttgag cctcctgcct cggccctgac 1740
aaacggggat ctcttaacct actttgcact gattaaatctt aaacaaattg aagattgccc 1800
ttcatatggg ttttggtttg tctttctggt cgtcagcgtg gtggtggaaa cagctgaagt 1860
tttagggag acgttagggg ttggtgcggg ccacggggag gggaccggga agcgtcggg 1920
cctgtttctg tttgttactt acaggactga gacatcttct gtaaaactgt acccctggg 1980
ccttctgcac ccgggggtga ggcctcctgc ctgctgggtg cctgtccca gccccaggtc 2040
ctgtgcaggg cactgcgtg gctgacagcc aggtctttac tccagccggg gctgcagcg 2100
catccagcca gccagccct gtgaaagatg gagctgactt gctgcagggg acctgattta 2160
tagggcaaga gaagtcacac tctggcctct cagaattcac ttgaggttca attaaataca 2220
gtcacaccgc c 2231

```

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification:</b> C12N 15/57, 9/64, 9/48, 1/19, 5/10, 1/21, A61K 38/48, C07K 16/40	<b>A3</b>	<b>(11) International Publication Number:</b> WO 99/36550 <b>(43) International Publication Date:</b> 22 July 1999 (22.07.99)
<b>(21) International Application Number:</b> PCT/US99/00655 <b>(22) International Filing Date:</b> 12 January 1999 (12.01.99) <b>(30) Priority Data:</b> 09/008,271 16 January 1998 (16.01.98) US <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b> US 09/008,271 (CIP) Filed on 16 January 1998 (16.01.98) <b>(71) Applicant (for all designated States except US):</b> INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive, #12, Mountain View, CA 94040 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, Ca 94025 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US).	<b>(74) Agents:</b> BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US). <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> <b>(88) Date of publication of the international search report:</b> 18 November 1999 (18.11.99)	

**(54) Title:** HUMAN PROTEASE MOLECULES**(57) Abstract**

The invention provides human protease molecules (HUPM) and polynucleotides which identify and encode HUPM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HUPM.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

International Application No

PC1/US 99/00655

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/57 C12N9/64 C12N9/48 C12N1/19 C12N5/10  
C12N1/21 A61K38/48 C07K16/40

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EMBL/GENBANK DATABASES Accession no T29740, Sequence reference HS74011 9 January 1995 ADAMS M ET AL: "Initial assessment of human gene diversity and expression patterns based upon 52 million basepairs of cDNA sequence" XP002103800 the whole document	1-13,15, 22,23
A	TAMURA T ET AL: "Molecular cloning and sequence analysis of cDNAs for five major subunits of human proteasomes (multi-catalytic proteinase complexes)" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1089, 1991, pages 95-102, XP002103799 figures 1D,2	

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*A\* document member of the same patent family

Date of the actual completion of the international search

26 May 1999

Date of mailing of the international search report

20.09.99

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

VAN DER SCHAAL C.A.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT, US 99/00655

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>EMBL/GENBANK DATABASES Accession no  P56202, Sequence reference LYMP_HUMAN  1 November 1997  BROWN J ET AL: "Lymphopain precursor"  XP002103801  the whole document  -----</p>	

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 00655

### Box I Observation where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 18-21  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-23 partially

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: Invention 1: claims 1-23 partially

Human protease molecule with amino acid sequence SEQ ID NO 1, nucleotides encoding the protease, antibodies against the enzyme, antagonists or agonists of the enzyme and their use

2. Claims: Inventions 2-12, claims 1-23 partially

Invention 2 being a human protease molecule with amino acid sequence SEQ ID NO 2, nucleotides encoding the protease, antibodies against the enzyme, antagonists or agonists of the enzyme and their use; Invention 3 being a human protease molecule with amino acid sequence SEQ ID NO 3, nucleotides encoding the protease, antibodies against the enzyme, antagonists or agonists of the enzyme and their use etc... Invention 12 being a human protease molecule with amino acid sequence SEQ ID NO 12, nucleotides encoding the protease, antibodies against the enzyme, antagonists or agonists of the enzyme and their use etc...